Human secreted proteins

[0001] This Application claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/277,340 (filed on Mar. 12, 2001); this Application also claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/306,171 (filed on Jul. 19, 2001); this Application also claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/331,287 (filed on Nov. 13, 2001); this Application is also a Continuation-in-part of Ser. No. 09/981,876 (filed on Oct. 19, 2001), which is a Divisional of Ser. No. 09/621,011 (filed on Jul. 20, 2000), which is a Continuation of Ser. No. 09/148,545 (filed on Sep. 04, 1998; issued as U.S. Pat. No. 6,590,075), which is a Continuation-in-part of PCT/US98/04482 (filed on Mar. 06, 1998); this Application is also a Continuation-in-part of Ser. No. 09/621,011 (filed on Jul. 07, 20, 2000), which is a Continuation of Ser. No. 09/148,545 (filed on Sep. 04, 1998; issued as U.S. Pat. No. 6,590,075), which is a Continuation-in-part of PCT/US98/04482 (filed on Mar. 06, 1998); this Application is also a Continuation-in-part of Ser. No. 09/148,545 (filed on Sep. 04, 1998; issued as U.S. Pat. No. 6,590,075), which is a Continuation-in-part of PCT/US98/04482 (filed on Mar. 06, 1998); this Applicattion is also a Continuation-in-part of PCT/US98/04482(filed on Mar. 06, 1998), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/040,162 (filed on Mar. 07, 1997), 60/040,333 (filed on Mar. 07, 1997), 60/038,621 (filed on Mar. 07, 1997), 60/040,161 (filed on Mar. 07, 1997), 60/040,626 (filed on Mar. 07, 1997), 60/040,334 (filed on Mar. 07, 1997), 60/040,336 (filed on Mar. 07, 1997), 60/040,163 (filed on Mar. 07, 1997), 60/047,615 (filed on May 23, 1997), 60/047,600 (filed on May 23, 1997), 60/047,597 (filed on May 23, 1997), 60/047,502 (filed on May 23, 1997), 60/047,633 (filed on May 23, 1997), 60/047,583 (filed on May 23, 1997), 60/047,617 (filed on May 23, 1997), 60/047,618 (filed on May 23, 1997), 60/047,503 (filed on May 23, 1997), 60/047,592 (filed on May 23, 1997), 60/047,581 (filed on May 23, 1997), 60/047,584 (filed on May 23, 1997), 60/047,500 (filed on May 23, 1997), 60/047,587 (filed on May 23, 1997), 60/047,492 (filed on May 23, 1997), 60/047,598 (filed on May 23, 1997), 60/047,613 (filed on May 23, 1997), 60/047,582 (filed on May 23, 1997), 60/047,596 (filed on May 23, 1997), 60/047,612 (filed on May 23, 1997), 60/047,632 (filed on May 23, 1997), 60/047,601 (filed on May 23, 1997), 60/043,580 (filed on Apr. 11, 1997), 60/043,568 (filed on Apr. 11, 1997), 60/043,314 (filed on Apr. 11, 1997), 60/043,569 (filed on Apr. 11, 1997), 60/043,311 (filed on Apr. 11, 1997), 60/043,671 (filed on Apr. 11, 1997), 60/043,674 (filed on Apr. 11, 1997), 60/043,669 (filed on Apr. 11, 1997), 60/043,312 (filed on Apr. 11, 1997), 60/043,313 (filed on Apr. 11, 1997), 60/043,672 (filed on Apr. 11, 1997), 60/043,315 (filed on Apr. 11, 1997), 60/048,974 (filed on Jun 06, 1997), 60/056,886 (filed on Aug. 22, 1997), 60/056,877 (filed on Aug. 22, 1997), 60/056,889 (filed on Aug. 22, 1997), 60/056,893 (filed on Aug. 22, 1997), 60/056,630 (filed on Aug. 22, 1997), 60/056,878 (filed on Aug. 22, 1997), 60/056,662 (filed on Aug. 22, 1997), 60/056,872 (filed on Aug. 22, 1997), 60/056,882 (filed on Aug. 22, 1997), 60/056,637 (filed on Aug. 22, 1997), 60/056,903 (filed on Aug. 22, 1997), 60/056,888 (filed on Aug. 22, 1997), 60/056,879 (filed on Aug. 22, 1997), 60/056,880 (filed on Aug. 22, 1997), 60/056,894 (filed on Aug. 22, 1997), 60/056,911 (filed on Aug. 22, 1997), 60/056,636 (filed on Aug. 22, 1997), 60/056,874 (filed on Aug. 22, 1997), 60/056,910 (filed on Aug. 22, 1997), 60/056,864 (filed on Aug. 22, 1997), 60/056,631 (filed on Aug. 22, 1997), 60/056,845 (filed on Aug. 22, 1997), 60/056,892 (filed on Aug. 22, 1997), 60/047,595 (filed on May 23, 1997), 60/057,761 (filed on Sep. 05, 1997), 60/047,599 (filed on May 23, 1997), 60/047,588 (filed on May 23, 1997), 60/047,585 (filed on May 23, 1997), 60/047,586 (filed on May 23, 1997), 60/047,590 (filed on May 23, 1997), 60/047,594 (filed on May 23, 1997), 60/047,589 (filed on May 23, 1997), 60/047,593 (filed on May 23, 1997), 60/047,614 (filed on May 23, 1997), 60/043,578 (filed on Apr. 11, 1997), 60/043,576 (filed on Apr. 11, 1997), 60/047,501 (filed on May 23, 1997), 60/043,670 (filed on Apr. 11, 1997), 60/056,632 (filed on Aug. 22, 1997), 60/056,664 (filed on Aug. 22, 1997), 60/056,876 (filed on Aug. 22, 1997), 60/056,881 (filed on Aug. 22, 1997), 60/056,909 (filed on Aug. 22, 1997), 60/056,875 (filed on Aug. 22, 1997), 60/056,862 (filed on Aug. 22, 1997), 60/056,887 (filed on Aug. 22, 1997), 60/056,908 (filed on Aug. 22, 1997), 60/048,964 (filed on Jun. 06, 1997), 60/057,650 (filed on Sep. 05, 1997), and, 60/056,884 (filed on Aug. 22, 1997); this Application is also a Continuation-in-part of Ser. No. 09/882,171 (filed on Jun. 18, 2001), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/190,068 (filed on Mar. 17, 2000); 09/882,171 is also a Continuation of Ser. No. 09/809,391 (filed on Mar. 16, 2001; now abandoned), which is a Continuation-in-part of 09/149,476 (filed on Sep. 08, 1998; issued as U.S. Pat. No. 6,420,526), which is a Continuation-in-part of PCT/US98/04493 (filed on Mar. 06, 1998); this Application is also a Continuation-in-part of Ser. No. 09/809,391 (filed on Mar. 16, 2001; now abandoned), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/190,068 (filed on Mar. 17, 2000); 09/809,391 is also a Continuation-in-part of Ser. No. 09/149,476 (filed on Sep. 08, 1998; issued as U.S. Pat. No. 6,420,526), which is a Continuation-in-part of PCT/US98/04493 (filed on Mar. 06, 1998); this Application is also a Continuation-in-part of 09/149,476 (filed on Sep. 08, 1998; issued as U.S. Pat. No. 6,420,526), which is a Continuation-in-part of PCT/US98/04493 (filed on Mar. 06, 1998); this Application is also a Continuation-in-part of PCT/US98/04493 (filed on Mar. 06, 1998), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/040,161 (filed on Mar. 07, 1997), 60/040,162 (filed on Mar. 07, 1997), 60/040,333 (filed on Mar. 07, 1997), 60/038,621 (filed on Mar. 07, 1997), 60/040,626 (filed on Mar. 07, 1997), 60/040,334 (filed on Mar. 07, 1997), 60/040,336 (filed on Mar. 07, 1997), 60/040,163 (filed on Mar. 07, 1997), 60/047,600 (filed on May 23, 1997), 60/047,615 (filed on May 23, 1997), 60/047,597 (filed on May 23, 1997), 60/047,502 (filed on May 23, 1997), 60/047,633 (filed on May 23, 1997), 60/047,583 (filed on May 23, 1997), 60/047,617 (filed on May 23, 1997), 60/047,618 (filed on May 23, 1997), 60/047,503 (filed on May 23, 1997), 60/047,592 (filed on May 23, 1997), 60/047,581 (filed on May 23, 1997), 60/047,584 (filed on May 23, 1997), 60/047,500 (filed on May 23, 1997), 60/047,587 (filed on May 23, 1997), 60/047,492 (filed on May 23, 1997), 60/047,598 (filed on May 23, 1997), 60/047,613 (filed on May 23, 1997), 60/047,582 (filed on May 23, 1997), 60/047,596 (filed on May 23, 1997), 60/047,612 (filed on May 23, 1997), 60/047,632 (filed on May 23, 1997), 60/047,601 (filed on May 23, 1997), 60/043,580 (filed on Apr. 11, 1997), 60/043,568 (filed on Apr. 11, 1997), 60/043,314 (filed on Apr. 11, 1997), 60/043,569 (filed on Apr. 11, 1997), 60/043,311 (filed on Apr. 11, 1997), 60/043,671 (filed on Apr. 11, 1997), 60/043,674 (filed on Apr. 11, 1997), 60/043,669 (filed on Apr. 11, 1997), 60/043,312 (filed on Apr. 11, 1997), 60/043,313 (filed on Apr. 11, 1997), 60/043,672 (filed on Apr. 11, 1997), 60/043,315 (filed on Apr. 11, 1997), 60/048,974 (filed on Jun. 06, 1997), 60/056,886 (filed on Aug. 22, 1997), 60/056,877 (filed on Aug. 22, 1997), 60/056,889 (filed on Aug. 22, 1997), 60/056,893 (filed on Aug. 22, 1997), 60/056,630 (filed on Aug. 22, 1997), 60/056,878 (filed on Aug. 22, 1997), 60/056,662 (filed on Aug. 22, 1997), 60/056,872 (filed on Aug. 22, 1997), 60/056,882 (filed on Aug. 22, 1997), 60/056,637 (filed on Aug. 22, 1997), 60/056,903 (filed on Aug. 22, 1997), 60/056,888 (filed on Aug. 22, 1997), 60/056,879 (filed on Aug. 22, 1997), 60/056,880 (filed on Aug. 22, 1997), 60/056,894 (filed on Aug. 22, 1997), 60/056,911 (filed on Aug. 22, 1997), 60/056,636 (filed on Aug. 22, 1997), 60/056,874 (filed on Aug. 22, 1997), 60/056,910 (filed on Aug. 22, 1997), 60/056,864 (filed on Aug. 22, 1997), 60/056,631 (filed on Aug. 22, 1997), 60/056,845 (filed on Aug. 22, 1997), 60/056,892 (filed on Aug. 22, 1997), 60/057,761 (filed on Sep. 05, 1997), 60/047,595 (filed on May 23, 1997), 60/047,599 (filed on May 23, 1997), 60/047,588 (filed on May 23, 1997), 60/047,585 (filed on May 23, 1997), 60/047,586 (filed on May 23, 1997), 60/047,590 (filed on May 23, 1997), 60/047,594 (filed on May 23, 1997), 60/047,589 (filed on May 23, 1997), 60/047,593 (filed on May 05, 1997), 60/047,614 (filed on May 23, 1997), 60/043,578 (filed on Apr. 11, 1997), 60/043,576 (filed on Apr. 11, 1997), 60/047,501 (filed on May 23, 1997), 60/043,670 (filed on Apr. 11, 1997), 60/056,632 (filed on Aug. 22, 1997), 60/056,664 (filed on Aug. 22, 1997), 60/056,876 (filed on Aug. 22, 1997), 60/056,881 (filed on Aug. 22, 1997), 60/056,909 (filed on Aug. 22, 1997), 60/056,875 (filed on Aug. 22, 1997), 60/056,862 (filed on Aug. 22, 1997), 60/056,887 (filed on Aug. 22, 1997), 60/056,908 (filed on Aug. 22, 1997), 60/048,964 (filed on Jun. 06, 1997), 60/057,650 (filed on Sept. 05, 1997), 60/056,884 (filed on Aug. 22, 1997), 60/057,669 (filed on Sep. 05, 1997), 60/049,610 (filed on Jun. 13, 1997), 60/061,060 (filed on Oct. 02, 1997), 60/051,926 (filed on Jul. 08, 1997), 60/052,874 (filed on Jul. 16, 1997), 60/058,785 (filed on Sep. 12, 1997), and, 60/055,724 (filed on Aug. 18, 1997); this Application is also a Continuation-in-part of Ser. No. 10/058,993 (filed on Jan. 30, 2002), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/265,583 (filed on Feb. 02, 2001); 10/058,993 is also a Continuation-in-part of Ser. No. 09/852,659 (filed on May. 11, 2001), which is a Continuation-in-part of Ser. No. 09/152,060 (filed on Sep. 11, 1998; issued as U.S. Pat. No. 6,448,230), which is a Continuation-in-part of PCT/US98/04858 (filed on Mar. 12, 1998); Ser. No. 10/058,993 is also a Continuation-in-part of Ser. No. 09/853,161 (filed on May. 11, 2001), which is a Continuation-in-part of Ser. No. 09/152,060 (filed on Sep. 11, 1998; issued as U.S. Pat. No. 6,448,230), which is a Continuation-in-part of PCT/US98/04858 (filed on Mar. 12, 1998); Ser. No. 10/058,993 is also a Continuation-in-part of Ser. No. 09/852,797 (filed on May 11, 2001), which is a Continuation-in-part of Ser. No. 09/152,060 (filed on Sep. 11, 1998; issued as U.S. Pat. No. 6,448,230), which is a Continuation-in-part of PCT/US98/04858 (filed on Mar. 12, 1998); this Application is also a Continuation-in-part of Ser. No. 09/852,659 (filed on May 11, 2001), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/265,583 (filed on Feb. 02, 2001); 09/852,659 is also a Continuation-in-part of Ser. No. 09/152,060 (filed on Sep. 11, 1998; issued as U.S. Pat. No. 6,448,230), which is a Continuation-in-part of PCT/US98/04858 (filed on Mar. 12, 1998); this Application is also a Continuation-in-part of Ser. No. 09/853,161 (filed on May 11 11, 2001), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/265,583 (filed on Feb. 02, 2001); 09/853,161 is also a Continuation-in-part of Ser. No. 09/152,060 (filed on Sep. 11, 1998; issued as U.S. Pat. No. 6,448,230), which is a Continuation-in-part of PCT/US98/04858 (filed on Mar. 12, 1998); this Application is also a Continuation-in-part of Ser. No. 09/852,797 (filed on May 11, 2001), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/265,583 (filed on Feb. 02, 2001); 09/852,797 is also a Continuation-in-part of Ser. No. 09/152,060 (filed on Sep. 11, 1998; issued as U.S. Pat. No. 6,448,230), which is a Continuation-in-part of PCT/US98/04858 (filed on Mar. 12, 1998); this Application is also a Continuation-in-part of Ser. No. 09/152,060 (filed on Sep. 11, 1998; issued as U.S. Pat. No. 6,448,230), which is a Continuation-in-part of PCT/US98/04858 (filed on Mar. 12, 1998); this Application is also a Continuation-in-part of PCT/US98/04858 (filed on Mar. 12, 1998), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/040,762 (filed on Mar. 14, 1997), 60/040,710 (filed on Mar. 14, 1997), 60/050,934 (filed on May 30, 1997), 60/048,100 (filed on May 30, 1997), 60/048,357 (filed on May 30, 1997), 60/048,189 (filed on May 30, 1997), 60/057,765 (filed on Sep. 05, 1997), 60/048,970 (filed on Jun. 06, 1997), and, 60/068,368 (filed on Dec. 19, 1997); this Application is also a Continuation-in-part of Ser. No. 10/059,395 (filed on Jan. 31, 2002; now abandoned), which is a Divisional of Ser. No. 09/966,262 (filed on Oct. 01, 2001; now abandoned), which is a Continuation of Ser. No. 09/154,707 (filed on Sep. 17, 1998; now abandoned), which is a Continuation-in-part of PCT/US98/05311 (filed on Mar. 19, 1998); this Application is also a Continuation-in-part of Ser. No. 09/984,245 (filed on Oct. 29, 2001; now abandoned), which is a Divisional of Ser. No. 09/154,707 (filed on Sep. 17, 1998; now abandoned), which is a Continuation-in-part of PCT/US98/05311 (filed on Mar. 19, 1998); this Application is also a Continuation-in-part of Ser. No. 09/983,966 (filed on Oct. 26, 2001; now abandoned), which is a Divisional of Ser. No. 09/154,707 (filed on Sep. 17, 1998; now abandoned), which is a Continuation-in-part of PCT/US98/05311 (filed on Mar. 19, 1998); this Application is also a Continuation-in-part of Ser. No. 09/966,262 (filed on Oct. 01, 2001; now abandoned), which is a Continuation of Ser. No. 09/154,707 (filed on Sep. 17, 1998; now abandoned), which is a Continuation-in-part of PCT/US98/05311 (filed on Mar. 19, 1998); this Application is also a Continuation-in-part of Ser. No. 09/154,707 (filed on Sep. 17, 1998; now abandoned), which is a Continuation-in-part of PCT/US98/05311 (filed on Mar. 19, 1998); this Application is also a Continuation-in-part of PCT/US98/05311 (filed on Mar. 03, 1998), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/041,277 (filed on Mar. 21, 1997), 60/042,344 (filed on Mar. 21, 1997), 60/041,276 (filed on Mar. 21, 1997), 60/041,281 (filed on Mar. 21, 1997), 60/048,094 (filed on May 30, 1997), 60/048,350 (filed on May 30, 1997), 60/048,188 (filed on May 30, 1997), 60/048,135 (filed on May 30, 1997), 60/050,937 (filed on May 30, 1997), 60/048,187 (filed on May 30, 1997), 60/048,099 (filed on May 30, 1997), 60/048,352 (filed on May 30, 1997), 60/048,186 (filed on May 30, 1997), 60/048,069 (filed on May 30, 1997), 60/048,095 (filed on May 30, 1997), 60/048,131 (filed on May 30, 1997), 60/048,096 (filed on May 30, 1997), 60/048,355 (filed on May 30, 1997), 60/048,160 (filed on May 30, 1997), 60/048,351 (filed on May 30, 1997), 60/048,154 (filed on May 30, 1997), 60/054,804 (filed on Aug. 05, 1997), 60/056,370 (filed on Aug. 19, 1997), and, 60/060,862 (filed on Oct. 02, 1997); this Application is also a Continuation-in-part of Ser. No. 09/814,122 (filed on Mar. 22, 2001; now abandoned), which is a Continuation of Ser. No. 09/577,145 (filed on May 24, 2000; now abandoned), which is a Continuation of 09/166,780 (filed on Oct. 06, 1998; now abandoned), which is a Continuation-in-part of PCT/US98/06801 (filed on Apr. 07, 1998); this Application is also a Continuation-in-part of PCT/US98/06801 (filed on Apr. 07, 1998), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/042,726 (filed on Apr. 08, 1997), 60/042,727 (filed on Apr. 08, 1997), 60/042,728 (filed on Apr. 08, 1997), 60/042,754 (filed on Apr. 08, 1997), 60/042,825 (filed on Apr. 08, 1997), 60/048,068 (filed on May 30, 1997), 60/048,070 (filed on May 30, 1997), and, 60/048,184 (filed on May 30, 1997); this Application is also a Continuation-in-part of PCT/US98/06801 (filed on Apr. 07, 1997), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/042,726 (filed on Apr. 08, 1997), 60/042,727 (filed on Apr. 08, 1997), 60/042,728 (filed on Apr. 08, 1997), 60/042,754 (filed on Apr. 08, 1997), 60/042,825 (filed on Apr. 08, 1997), 60/048,068 (filed on May 30, 1997), 60/048,070 (filed on May 30, 1997), and, 60/048,184 (filed on May 30, 1997); this Application is also a Continuation-in-part of PCT/US98/10868 (filed on May 28, 1998), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/044,039 (filed on May 30, 1997), 60/048,093 (filed on May 30, 1997), 60/048,190 (filed on May 30, 1997), 60/050,935 (filed on May 30, 1997), 60/048,101 (filed on May 30, 1997), 60/048,356 (filed on May 30, 1997), 60/056,250 (filed on Aug. 29, 1997), 60/056,296 (filed on Aug. 29, 1997), and, 60/056,293 (filed on Aug. 29, 1997); this Application is also a Continuation-in-part of PCT/US98/11422 (filed on Jun. 04, 1998), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/048,885 (filed on Jun. 06, 1997), 60/049,375 (filed on Jun. 06, 1997), 60/048,881 (filed on Jun. 06, 1997), 60/048,880 (filed on Jun. 06, 1997), 60/048,896 (filed on Jun. 06, 1997), 60/049,020 (filed on Jun. 06, 1997), 60/048,876 (filed on Jun. 06, 1997), 60/048,895 (filed on Jun. 06, 1997), 60/048,884 (filed on Jun. 06, 1997), 60/048,894 (filed on Jun. 06, 1997), 60/048,971 (filed on Jun. 06, 1997), 60/048,964 (filed on Jun. 06, 1997), 60/048,882 (filed on Jun. 06, 1997), 60/048,899 (filed on Jun. 06, 1997), 60/048,893 (filed on Jun. 06, 1997), 60/048,900 (filed on Jun. 06, 1997), 60/048,901 (filed on Jun. 06, 1997), 60/048,892 (filed on Jun. 06, 1997), 60/048,915 (filed on Jun. 06, 1997), 60/049,019 (filed on Jun. 06, 1997), 60/048,970 (filed on Jun. 06, 1997), 60/048,972 (filed on Jun. 06, 1997), 60/048,916 (filed on Jun. 06, 1997), 60/049,373 (filed on Jun. 06, 1997), 60/048,875 (filed on Jun. 06, 1997), 60/049,374 (filed on Jun. 06, 1997), 60/048,917 (filed on Jun. 06, 1997), 60/048,949 (filed on Jun. 06, 1997), 60/048,974 (filed on Jun. 06, 1997), 60/048,883 (filed on Jun. 06, 1997), 60/048,897 (filed on Jun. 06, 1997), 60/048,898 (filed on Jun. 06, 1997), 60/048,962 (filed on Jun. 06, 1997), 60/048,963 (filed on Jun. 06, 1997), 60/048,877 (filed on Jun. 06, 1997), 60/048,878 (filed on Jun. 06, 1997), 60/057,645 (filed on Sep. 05, 1997), 60/057,642 (filed on Sep. 05, 1997), 60/057,668 (filed on Sep. 05, 1997), 60/057,635 (filed on Sep. 05, 1997), 60/057,627 (filed on Sep. 05, 1997), 60/057,667 (filed on Sep. 05, 1997), 60/057,666 (filed on Sep. 05, 1997), 60/057,764 (filed on Sep. 05, 1997), 60/057,643 (filed on Sep. 05, 1997), 60/057,769 (filed on Sep. 05, 1997), 60/057,763 (filed on Sep. 05, 1997), 60/057,650 (filed on Sep. 05, 1997), 60/057,584 (filed on Sep. 05, 1997), 60/057,647 (filed on Sep. 05, 1997), 60/057,661 (filed on Sep. 05, 1997), 60/057,662 (filed on Sep. 05, 1997), 60/057,646 (filed on Sep. 05, 1997), 60/057,654 (filed on Sep. 05, 1997), 60/057,651 (filed on Sep. 05, 1997), 60/057,644 (filed on Sep. 05, 1997), 60/057,765 (filed on Sep. 05, 1997), 60/057,762 (filed on Sep. 05, 1997), 60/057,775 (filed on Sep. 05, 1997), 60/057,648 (filed on Sep. 05, 1997), 60/057,774 (filed on Sep. 05, 1997), 60/057,649 (filed on Sep. 05, 1997), 60/057,770 (filed on Sep. 05, 1997), 60/057,771 (filed on Sep. 05, 1997), 60/057,761 (filed on Sep. 05, 1997), 60/057,760 (filed on Sep. 05, 1997), 60/057,776 (filed on Sep. 05, 1997), 60/057,778 (filed on Sep. 05, 1997), 60/057,629 (filed on Sep. 05, 1997), 60/057,628 (filed on Sep. 05, 1997), 60/057,777 (filed on Sep. 05, 1997), 60/057,634 (filed on Sep. 05, 1997), and, 60/070,923 (filed on Dec. 18, 1997); this Application is also a Continuation-in-part of PCT/US01/05614 (filed on Feb. 21, 2001), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/184,836 (filed on Feb. 24, 2000), and, 60/193,170 (filed on Mar. 29, 2000); this Application is also a Continuation-in-part of PCT/US98/12125 (filed on Jun. 11, 1998), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/049,547 (filed on Jun. 13, 1997), 60/049,548 (filed on Jun. 13, 1997), 60/049,549 (filed on Jun. 13, 1997), 60/049,550 (filed on Jun. 13, 1997), Jun. 60/049,566 (filed on Jun. 13, 1997), 60/049,606 (filed on Jun. 13, 1997), 60/049,607 (filed on 06/13197), 60/049,608 (filed on Jun. 13, 1997), 60/049,609 (filed on Jun. 13, 1997), 60/049,610 (filed on Jun. 13, 1997), 60/049,611 (filed on Jun. 13, 1997), 60/050,901 (filed on Jun. 13, 1997), 60/052,989 (filed on Jun. 13, 1997), 60/051,919 (filed on Jul. 08, 1997), 60/055,984 (filed on Aug. 18, 1997), 60/058,665 (filed on Sep. 12, 1997), 60/058,668 (filed on Sep. 12, 1997), 60/058,669 (filed on Sep. 12, 1997), 60/058,750 (filed on Sep. 12, 1997), 60/058,971 (filed on Sep. 12, 1997), 60/058,972 (filed on Sep. 12, 1997), 60/058,975 (filed on Sep. 12, 1997), 60/060,834 (filed on Oct. 02, 1997), 60/060,841 (filed on Oct. 02, 1997), 60/060,844 (filed on Oct. 02, 1997), 60/060,865 (filed on Oct. 02, 1997), 60/061,059 (filed on Oct. 02, 1997), and, 60/061,060 (filed on Oct. 02, 1997); this Application is also a Continuation-in-part of Ser. No. 09/627,081 (filed on July. 27, 2000; now abandoned), which is a Continuation of Ser. No. 09/213,365 (filed on Dec. 17, 1998; now abandoned), which is a Continuation-in-part of PCT/US98/13608 (filed on Jun. 30, 1998); this Application is also a Continuation-in-part of PCT/US98/13608 (filed on Jun. 30, 1998), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/051,480 (filed on Jul. 01, 1997), 60/051,381 (filed on Jul. 01, 1997), 60/058,663 (filed on Sep. 12, 1997), and, 60/058,598 (filed on Sep. 12, 1997); this Application is also a Continuation-in-part of Ser. No. 09/984,490 (filed on Oct. 30, 2001), which is a Divisional of Ser. No. 09/227,357 (filed on Jan. 08, 1999; issued as U.S. Pat. No. 6,342,581), which is a Continuation-in-part of PCT/US98/13684 (filed on Jul. 07, 1998); this Application is also a Continuation-in-part of Ser. No. 09/983,802 (filed on Oct. 25, 2001), which is a Continuation of Ser. No. 09/227,357 (filed on Oct. 10, 2001; issued as U.S. Pat. No. 6,342,581), which is a Continuation-in-part of PCT/US98/13684 (filed on Jul. 07, 1998); this Application is also a Continuation-in-part of Ser. No. 09/973,278 (filed on Oct. 10, 2001), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/239,899 (filed on Oct. 13, 2000); 09/973,278 is also a Continuation-in-part of Ser. No. 09/227,357 (filed on Jan. 08, 1999; issued as U.S. Pat. No. 6,342,581), which is a Continuation-in-part of PCT/US98/13684 (filed on Jul. 07, 1998); this Application is also a Continuation-in-part of PCT/US98/13684 (filed on Jul. 07, 1998), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/051,926 (filed on Jul. 08, 1997), 60/052,793 (filed on Jul. 08, 1997), 60/051,925 (filed on Jul. 08, 1997), 60/051,929 (filed on Jul. 08, 1997), 60/052,803 (filed on Jul. 08, 1997), 60/052,732 (filed on Jul. 08, 1997), 60/051,931 (filed on Jul. 08, 1997), 60/051,932 (filed on Jul. 08, 1997), 60/051,916 (filed on Jul. 08, 1997), 60/051,930 (filed on Jul. 08, 1997), 60/051,918 (filed on Jul. 08, 1997), 60/051,920 (filed on Jul. 08, 1997), 60/052,733 (filed on Jul. 08, 1997), 60/052,795 (filed on Jul. 08, 1997), 60/051,919 (filed on Jul. 08, 1997), 60/051,928 (filed on Jul. 08, 1997), 60/055,722 (filed on Aug. 18, 1997), 60/055,723 (filed on Aug. 18, 1997), 60/055,948 (filed on Aug. 18, 1997), 60/055,949 (filed on Aug. 18, 1997), 60/055,953 (filed on Aug. 18, 1997), 60/055,950 (filed on Aug. 18, 1997), 60/055,947 (filed on Aug. 18, 1997), 60/055,964 (filed on Aug. 18, 1997), 60/056,360 (filed on Aug. 18, 1997), 60/055,684 (filed on Aug. 18, 1997), 60/055,984 (filed on Aug. 18, 1997), 60/055,954 (filed on Aug. 18, 1997), 60/058,785 (filed on Sep. 12, 1997), 60/058,664 (filed on Sep. 12, 1997), 60/058,660 (filed on Sep. 12, 1997), and, 60/058,661 (filed on Sep. 12, 1997); this Application is also a Continuation-in-part of Ser. No. 09/776,724 (filed on Feb. 06, 2001; now abandoned), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/180,909 (filed on Feb. 08, 2000); 09/776,724 is also a Continuation-in-part of Ser. No. 09/669,688 (filed on Sep. 26, 2000; now abandoned), which is a Continuation of Ser. No. 09/229,982 (filed on Jan. 14, 1999; now abandoned), which is a Continuation-in-part of PCT/US98/14613 (filed on Jul. 15, 1998); this Application is also a Continuation-in-part of Ser. No. 09/669,688 (filed on Sep. 26, 2000; now abandoned), which is a Continuation of Ser. No. 09/229,982 (filed on Jan. 14, 1999; now abandoned), which is a Continuation-in-part of PCT/US98/14613 (filed on Jul. 15, 1998); this Application is also a Continuation-in-part of Ser. No. 09/229,982 (filed on Jan. 14, 1999; now abandoned), which is a Continuation-in-part of PCT/US98/14613 (filed on Jul. 15, 1998); this Application is also a Continuation-in-part of PCT/US98/14613 (filed on Jul. 15, 1998), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/052,661 (filed on Jul. 16, 1997), 60/052,872 (filed on Jul. 16, 1997), 60/052,871 (filed on Jul. 16, 1997), 60/052,874 (filed on Jul. 16, 1997), 60/052,873 (filed on Jul. 16, 1997), 60/052,870 (filed on Jul. 16, 1997), 60/052,875 (filed on Jul. 16, 1997), 60/053,440 (filed on Jul. 22, 1997), 60/053,441 (filed on Jul. 22, 1997), 60/053,442 (filed on Jul. 22, 1997), 60/056,359 (filed on Aug. 18, 1997), 60/055,725 (filed on Aug. 18, 1997), 60/055,985 (filed on Aug. 18, 1997), 60/055,952 (filed on Aug. 18, 1997), 60/055,989 (filed on Aug. 18, 1997), 60/056,361 (filed on Aug. 18, 1997), 60/055,726 (filed on Aug. 18, 1997), 60/055,724 (filed on Aug. 18, 1997), 60/055,946 (filed on Aug. 18, 1997), and, 60/055,683 (filed on Aug. 18, 1997); this Application also claims benefit under 35 U.S.C. §119(e) of U.S. Provisional Ser. No. 60/295,558 (filed on Jun. 05, 2001); this Application is also a Continuation-in-part of Ser. No. 09/820,649 (filed on Mar. 30, 2001), which is a Continuation of Ser. No. 09/666,984 (filed on Sep. 21, 2000; now abandoned), which is a Continuation of Ser. No. 09/236,557 (filed on Jan. 26, 1999; now abandoned), which is a Continuation-in-part of PCT/US98/15949 (filed on Jul. 29, 1998); this Application is also a Continuation-in-part of PCT/US98/15949 (filed on Jul. 29, 1998), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/054,212 (filed on Jul. 30, 1997), 60/054,209 (filed on Jul. 30, 1997), 60/054,234 (filed on Sep. 30, 1997), 60/054,218 (filed on Jul. 30, 1997), 60/054,214 (filed on Jul. 30, 1997), 60/054,236 (filed on Jul. 30, 1997), 60/054,215 (filed on Jul. 30, 1997), 60/054,211 (filed on Jul. 30, 1997), 60/054,217 (filed on Jul. 30, 1997), 60/054,213 (filed on Jul. 30, 1997), 60/055,968 (filed on Aug. 18, 1997), 60/055,969 (filed on Aug. 18, 1997), 60/055,972 (filed on Aug. 18, 1997), 60/056,561 (filed on Aug. 19, 1997), 60/056,534 (filed on Aug. 19, 1997), 60/056,729 (filed on Aug. 19, 1997), 60/056,543 (filed on Aug. 19, 1997), 60/056,727 (filed on Aug. 19, 1997), 60/056,554 (filed on Aug. 19, 1997), and, 60/056,730 (filed on Aug. 19, 1997); this Application is also a Continuation-in-part of Ser. No. 09/969,730 (filed on Oct. 04, 2001; now abandoned), which is a Continuation-in-part of Ser. No. 09/774,639 (filed on Feb. 01, 2001; issued as U.S. Pat. No. 6,806,351), which is a Continuation of Ser. No. 09/244,112 (filed on Feb. 04, 1999; now abandoned), which is a Continuation-in-part of PCT/US98/16235 (filed on Aug. 04, 1998); this Application is also a Continuation-in-part of Ser. No. 09/774,639 (filed on Feb. 01, 2001; issued as U.S. Pat. No. 6,806,351), which is a Continuation of Ser. No. 09/244,112 (filed on Feb. 04, 1999; now abandoned), which is a Continuation-in-part of PCT/US98/16235 (filed on Aug. 04, 1998); this Application is also a Continuation-in-part of Ser. No. 09/969,730 (filed on Oct. 04, 2001; now abandoned), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/238,291 (filed on Oct. 06, 2000); this Application is also a Continuation-in-part of PCT/US98/16235 (filed on Aug. 04, 1998), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/055,386 (filed on Aug. 05, 1997), 60/054,807 (filed on Aug. 05, 1997), 60/055,312 (filed on Aug. 05, 1997), 60/055,309 (filed on Aug. 05, 1997), 60/054,798 (filed on Aug. 05, 1997), 60/055,310 (filed on Aug. 05, 1997), 60/054,806 (filed on Aug. 05, 1997), 60/054,809 (filed on Aug. 05, 1997), 60/054,804 (filed on Aug. 05, 1997), 60/054,803 (filed on Aug. 05, 1997), 60/054,808 (filed on Aug. 05, 1997), 60/055,311 (filed on Aug. 05, 1997), 60/055,986 (filed on Aug. 18, 1997), 60/055,970 (filed on Aug. 18, 1997), 60/056,563 (filed on Aug. 19, 1997), 60/056,557 (filed on Aug. 19, 1997), 60/056,731 (filed on Aug. 19, 1997), 60/056,365 (filed on Aug. 19, 1997), 60/056,367 (filed on Aug. 19, 1997), 60/056,370 (filed on Aug. 19, 1997), 60/056,364 (filed on Aug. 19, 1997), 60/056,366 (filed on Aug. 19, 1997), 60/056,732 (filed on Aug. 19, 1997), and, 60/056,371 (filed on Aug. 19, 1997); this Application is also a Continuation-in-part of Ser. No. 09/716,128 (filed on Nov. 17, 2000; now abandoned), which is a Continuation of Ser. No. 09/251,329 (filed on Feb. 17, 1999; now abandoned), which is a Continuation-in-part of PCT/US98/17044 (filed on Aug. 18, 1998); this Application is also a Continuation-in-part of PCT/US98/17044 (filed on Aug. 18, 1998), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/056,555 (filed on Aug. 19, 1997), 60/056,556 (filed on Aug. 19, 1997), 60/056,535 (filed on Aug. 19, 1997), 60/056,629 (filed on Aug. 19, 1997), 60/056,369 (filed on Aug. 19, 1997), 60/056,628 (filed on Aug. 19, 1997), 60/056,728 (filed on Aug. 19, 1997), 60/056,368 (filed on Aug. 19, 1997), 60/056,726 (filed on Aug. 19, 1997), 60/089,510 (filed on Jun. 16, 1998), and, 60/092,956 (filed on Jul. 15, 1998); this Application is also a Continuation-in-part of Ser. No. 09/729,835 (filed on Dec. 06, 2000; now abandoned), which is a Divisional of Ser. No. 09/257,179 (filed on Feb. 25, 1999; issued as U.S. Pat. No. 6,410,709), which is a Continuation-in-part of PCT/US98/17709 (filed on Aug. 27, 1998); this Application is also a Continuation-in-part of Ser. No. 09/257,179 (filed on Feb. 25, 1999; issued as U.S. Pat. No. 6,410,709), which is a Continuation-in-part of PCT/US98/17709 (filed on Aug. 27, 1998); this Application is also a Continuation-in-part of PCT/US98/17709 (filed on Aug. 27, 1998), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/056,270 (filed on Aug. 29, 1997), 60/056,271 (filed on Aug. 29, 1997), 60/056,247 (filed on Aug. 29, 1997), and, 60/056,073 (filed on Aug. 29, 1997); this Application is also a Continuation-in-part of Ser. No. 10/047,021 (filed on Jan. 17, 2002; now abandoned), which is a Continuation-in-part of Ser. No. 09/722,329 (filed on Nov. 28, 2000; now abandoned), which is a Continuation of Ser. No. 09/262,109 (filed on Mar. 04, 1999; now abandoned), which is a Continuation-in-part of PCT/US98/18360 (filed on Sep. 03, 1998); this Application is also a Continuation-in-part of Ser. No. 09/722,329 (filed on Nov. 28, 2000; now abandoned), which is a Continuation of Ser. No. 09/262,109 (filed on Mar. 04, 1999), which is a Continuation-in-part of PCT/US98/18360 (filed on Sep. 03, 1998); this Application is also a Continuation-in-part of Ser. No. 10/047,021 (filed on Jan. 17, 2002; now abandoned), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/262,066 (filed on Jan. 18, 2001); this Applicabon is also a Continuation-in-part of PCT/US98/18360 (filed on Sep. 03, 1998), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/057,626 (filed on Sep. 05, 1997), 60/057,663 (filed on Sep. 05, 1997), 60/057,669 (filed on Sep. 05, 1997), 60/058,667 (filed on Sep. 12, 1997), 60/058,974 (filed on Sep. 12, 1997), 60/058,973 (filed on Sep. 12, 1997), 60/058,666 (filed on Sep. 12, 1997), and, 60/090,112 (filed on Jun. 22, 1998); this Application is also a Continuation-in-part of Ser. No. 09/281,976 (filed on Mar. 31, 1999; now abandoned), which is a Continuation-in-part of PCT/US98/20775 (filed on Oct. 01, 1998); this Application is also a Continuation-in-part of PCT/US98/20775 (filed on Oct. 01, 1998), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/060,837 (filed on Oct. 02, 1997), 60/060,862 (filed on Oct. 02, 1997), 60/060,839 (filed on Oct. 02, 1997), 60/060,866 (filed on Oct. 02, 1997), 60/060,843 (filed on Oct. 02, 1997), 60/060,836 (filed on Oct. 02, 1997), 60/060,838 (filed on Oct. 02, 1997), 60/060,874 (filed on Oct. 02, 1997), 60/060,833 (filed on Oct. 02, 1997), 60/060,884 (filed on Oct. 02, 1997), and, 60/060,880 (filed on Oct. 02, 1997); this Application is also a Continuation-in-part of Ser. No. 09/984,429 (filed on Oct. 30, 2001), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/244,591 (filed on Nov. 01, 2000); 09/984,429 is also a Continuation-in-part of Ser. No. 09/288,143 (filed on Apr. 08, 1999; issued as U.S. Pat. No. 6,433,139), which is a Continuation-in-part of PCT/US98/21142 (filed on Oct. 08, 1998); this Application also claims benefit under 35 U.S.C § 119(e) of U.S. Provisional Ser. No. 60/244,591 (filed on Nov. 01, 2000); this Application is also a Continuation-in-part of Ser. No. 09/288,143 (filed on Apr. 08, 1999; issued as U.S. Pat. No. 6,433,139), which is a Continuation-in-part of PCT/US98/21142 (filed on Oct. 08, 1998); this Application is also a Continuation-in-part of PCT/US98/21142 (filed on Oct. 08, 1998), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/061,463 (filed on Oct. 09, 1997), 60/061,529 (filed on Oct. 09, 1997), 60/071,498 (filed on Oct. 09, 1997), 60/061,527 (filed on Oct. 09, 1997), 60/061,536 (filed on Oct. 09, 1997), and, 60/061,532 (filed on Oct. 09, 1997); this Application is also a Continuation-in-part of Ser. No. 09/296,622 (filed on Apr. 23, 1999; now abandoned), which is a Continuation-in-part of PCT/US98/22376 (filed on Oct. 23, 1998); this Applicabon is also a Continuation-in-part of PCT/US98/22376 (filed on Oct. 23, 1998), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/063,099 (filed on Oct. 24, 1997), 60/063,088 (filed on Oct. 24, 1997), 60/063,100 (filed on Oct. 24, 1997), 60/063,387 (filed on Oct. 24, 1997), 60/063,148 (filed on Oct. 24, 1997), 60/063,386 (filed on Oct. 24, 1997), 60/062,784 (filed on Oct. 24, 1997), 60/063,091 (filed on Oct. 24, 1997), 60/063,090 (filed on Oct. 24, 1997), 60/063,089 (filed on Oct. 24, 1997), 60/063,092 (filed on Oct. 24, 1997), 60/063,111 (filed on Oct. 24, 1997), 60/063,101 (filed on Oct. 24, 1997), 60/063,109 (filed on Oct. 24, 1997), 60/063,110 (filed on Oct. 24, 1997), 60/063,098 (filed on Oct. 24, 1997), and, 60/063,097 (filed on Oct. 24, 1997); this Application is also a Continuation-in-part of Ser. No. 09/974,879 (filed on Oct. 12, 2001; now abandoned), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/239,893 (filed on Oct. 13, 2000); 09/974,879 is also a Continuation-in-part of Ser. No. 09/818,683 (filed on Mar. 28, 2001; now abandoned), which is a Continuation of Ser. No. 09/305,736 (filed on May 05, 1999; now abandoned), which is a Continuation-in-part of PCT/US98/23435 (filed on Nov. 04, 1998); this Application is also a Continuation-in-part of Ser. No. 09/818,683 (filed on Mar. 28, 2001; now abandoned), which is a Continuation of Ser. No. 09/305,736 (filed on May 05, 1999; now abandoned), which is a Continuation-in-part of PCT/US98/23435 (filed on Nov. 04, 1998); this Application is also a Continuation-in-part of Ser. No. 09/305,736 (filed on May 05, 1999; now abandoned), which is a Continuation-in-part of PCT/US98/23435 (filed on Nov. 04, 1998); this Application is also a Continuation-in-part of PCT/US98/23435 (filed on Nov. 04, 1998), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/064,911 (filed on Nov. 07, 1997), 60/064,912 (filed on Nov. 07, 1997), 60/064,983 (filed on Nov. 07, 1997), 60/064,900 (filed on Nov. 07, 1997), 60/064,988 (filed on Nov. 07, 1997), 60/064,987 (filed on Nov. 07, 1997), 60/064,908 (filed on Nov. 07, 1997), 60/064,984 (filed on Nov. 07, 1997), 60/064,985 (filed on Nov. 07, 1997), 60/066,094 (filed on Nov. 17, 1997), 60/066,100 (filed on Nov. 17, 1997), 60/066,089 (filed on Nov. 17, 1997), 60/066,095 (filed on Nov. 17, 1997), and, 60/066,090 (filed on Nov. 17, 1997); this Application is also a Continuation-in-part of Ser. No. 09/334,595 (filed on Jun. 17, 1999; now abandoned), which is a Continuation-in-part of PCT/US98/27059 (filed on Dec. 17, 1998); this Application is also a Continuation-in-part of PCT/US98/27059 (filed on Dec. 17, 1998), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/070,923 (filed on Dec. 18, 1997), 60/068,007 (filed on Dec. 18, 1997), 60/068,057 (filed on Dec. 18, 1997), 60/068,006 (filed on Dec. 18, 1997), 60/068,369 (filed on Dec. 19, 1997), 60/068,367 (filed on Dec. 19, 1997), 60/068,368 (filed on Dec. 19, 1997), 60/068,169 (filed on Dec. 19, 1997), 60/068,053 (filed on Dec. 18, 1997), 60/068,064 (filed on Dec. 18, 1997), 60/068,054 (filed on Dec. 18, 1997), 60/068,008 (filed on Dec. 18, 1997), and, 60/068,365 (filed on Dec. 19, 1997); this Application is also a Continuation-in-part of Ser. No. 09/938,671 (filed on Aug. 27, 2001; now abandoned), which is a Continuation of Ser. No. 09/739,907 (filed on Dec. 20, 2000; now abandoned), which is a Continuation of Ser. No. 09/348,457 (filed on Jul. 07, 1999; now abandoned), which is a Continuation-in-part of PCT/US99/00108 (filed on Jan. 06, 1999); this Application is also a Continuation-in-part of Ser. No. 09/739,907 (filed on Dec. 20, 2000; now abandoned), which is a Continuation of Ser. No. 09/348,457 (filed on Jul. 07, 1999; now abandoned), which is a Continuation-in-part of PCT/US99/00108 (filed on Jan. 06, 1999); this Application is also a Continuation-in-part of Ser. No. 09/348,457 (filed on Jul. 07, 1999; now abandoned), which is a Continuation-in-part of PCT/US99/00108 (filed on Jan. 06, 1999); this Application is also a Continuation-in-part of PCT/US99/00108 (filed on Jan. 06, 1999), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/070,704 (filed on Jan. 07, 1998), 60/070,658 (filed on Jan. 07, 1998), 60/070,692 (filed on Jan. 07, 1998), and, 60/070,657 (filed on Jan. 07, 1998); this Application is also a Continuation-in-part of Ser. No. 09/949,925 (filed on Sep. 12, 2001), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos.60/232,150 (filed on Sep. 12, 2000); 09/949,925 is also a Continuation-in-part of PCT/US99/01621 (filed on Jan. 27, 1999); Ser. No. 09/949,925 is also a Continuation-in-part of Ser. No. 09/363,044 (filed on Jul. 29, 1999; now abandoned), which is a Continuation-in-part of PCT/US99/01621 (filed on Jan. 27, 1999); this Application is also a Continuation-in-part of Ser. No. 09/813,153 (filed on Mar. 21, 2001; now abandoned), which is a Continuation of Ser. No. 09/363,044 (filed on Jul. 29, 1999; now abandoned), which is a Continuation-in-part of PCT/US99/01621 (filed on Jan. 27, 1999); this Application is also a Continuation-in-part of Ser. No. 09/363,044 (filed on Jul. 29, 1999; now abandoned), which is a Continuation-in-part of PCT/US99/01621 (filed on Jan. 27, 1999); this Application is also a Continuation-in-part of PCT/US99/01621 (filed on Jan. 27, 1999), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/073,170 (filed on Jan. 30, 1998), 60/073,167 (filed on Jan. 30, 1998), 60/073,165 (filed on Jan. 30, 1998), 60/073,164 (filed on Jan. 30, 1998), 60/073,162 (filed on Jan. 30, 1998), 60/073,161 (filed on Jan. 30, 1998), 60/073,160 (filed on Jan. 30, 1998), and, 60/073,159 (filed on Jan. 30, 1998), this Application is also a Continuation-in-part of Ser. No. 10/062,548 (filed on Feb. 05, 2002), which is a Continuation of Ser. No. 09/369,247 (filed on Aug. 05, 1999; issued as U.S. Pat. No. 6,569,992), which is a Continuation-in-part of PCT/US99/02293 (filed on Feb. 04, 1999); this Application is also a Continuation-in-part of Ser. No. 09/369,247 (filed on Aug. 05, 1999; issued as U.S. Pat. No. 6,569,992), which is a Continuation-in-part of PCT/US99/02293 (filed on Feb. 04, 1999); this Application is also a Continuation-in-part of PCT/US99/02293 (filed on Feb. 04, 1999), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/074,118 (filed on Feb. 09, 1998), 60/074,157 (filed on Feb. 09, 1998), 60/074,037 (filed on Feb. 09, 1998), 60/074,141 (filed on Feb. 09, 1998), and, 60/074,341 (filed on Feb. 09, 1998); this Application is also a Continuation-in-part of Ser. No. 09/716,129 (filed on Nov. 17, 2000; issued as U.S. Pat. No. 6,632,920), which is a Continuation-in-part of PCT/US99/03939 (filed on Feb. 24, 1999); Ser. No. 09/716,129 is also a Continuation of Ser. No. 09/382,572 (filed on Aug. 25, 1999; now abandoned), which is a Continuation-in-part of PCT/US99/03939 (filed on Feb. 24, 1999); this Application is also a Continuation-in-part of PCT/US99/03939 (filed on Feb. 24, 1999), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/076,053 (filed on Feb. 26, 1998), 60/076,051 (filed on Feb. 26, 1998), 60/076,054 (filed on Feb. 26, 1998), 60/076,052 (filed on Feb. 26, 1998), and, 60/076,057 (filed on Feb. 26, 1998); this Application is also a Continuation-in-part of Ser. No. 09/798,889 (filed on Mar. 06, 2001; now abandoned), which is a Continuation of Ser. No. 09/393,022 (filed on Sep. 09, 1999; now abandoned), which is a Continuation-in-part of PCT/US99/05721 (filed on Mar. 11, 1999); this Application is also a Continuation-in-part of PCT/US99/05721 (filed on 03/11/99), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/077,714 (filed on Mar. 12, 1998), 60/077,686 (filed on Mar. 12, 1998), 60/077,687 (filed on Mar. 12, 1998), and, 60/077,696 (filed on Mar. 12, 1998); this Application is also a Continuation-in-part of Ser. No. 09/397,945 (filed on Sep. 17, 1999; now abandoned), which is a Continuation-in-part of PCT/US99/05804 (filed on Mar. 18, 1999); this Application is also a Continuation-in-part of PCT/US99/05804 (filed on Mar. 18, 1999), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/078,566 (filed on Mar. 19, 1998), 60/078,576 (filed on Mar. 19, 1998), 60/078,573 (filed on Mar. 19, 1998), 60/078,574 (filed on Mar. 19, 1998), 60/078,579 (filed on Mar. 19, 1998), 60/080,314 (filed on Apr. 01, 1998), 60/080,312 (filed on Apr. 01, 1998), 60/078,578 (filed on Mar. 19, 1998), 60/078,581 (filed on Mar. 19, 1998), 60/078,577 (filed on Mar. 19, 1998), 60/078,563 (filed on Mar. 19, 1998), and, 60/080,313 (filed on Apr. 01, 1998); this Application is also a Continuation-in-part of Ser. No. 09/948,783 (filed on Sep. 10, 2001; now abandoned), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/231,846 (filed on Sep. 11, 2000); 09/948,783 is also a Continuation-in-part of Ser. No. 09/892,877 (filed on Jun. 28, 2001; now abandoned), which is a Continuation of Ser. No. 09/437,658 (filed on Nov. 10, 1999; now abandoned), which is a Continuation-in-part of PCT/US99/09847 (filed on May 06, 1999); this Application is also a Continuation-in-part of Ser. No. 09/892,877 (filed on Jun. 28, 2001; now abandoned), which is a Continuation of Ser. No. 09/437,658 (filed on Nov. 10, 1999; now abandoned), which is a Continuation-in-part of PCT/US99/09847 (filed on May 06, 1999); this Application is also a Continuation-in-part of PCT/US99/09847 (filed on May 06, 1999), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/085,093 (filed on May 12, 1998), 60/085,094 (filed on May 12, 1998), 60/085,105 (filed on May 12, 1998), 60/085,180 (filed on May 12, 1998), 60/085,927 (filed on May 18, 1998), 60/085,906 (filed on May 18, 1998), 60/085,920 (filed on May 18, 1998), 60/085,924 (filed on May 18, 1998), 60/085,922 (filed on May 18, 1998), 60/085,923 (filed on May 18, 1998), 60/085,921 (filed on May 18, 1998), 60/085,925 (filed on May 18, 1998), and, 60/085,928 (filed on May 18, 1998); this Application is also a Continuation-in-part of Ser. No. 10/050,873 (filed on Jan. 18, 2002; now abandoned), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/263,681 (filed on Jan. 24, 2001), and, 60/263,230 (filed on Jan. 23, 2001); 10/050,873 is also a Continuation-in-part of Ser. No. 09/461,325 (filed on Dec. 14, 1999; issued as U.S. Pat. No. 6,475,753), which is a Continuation-in-part of PCT/US99/13418 (filed on Jun. 15, 1999); this Application is also a Continuation-in-part of Ser. No. 10/012,542 (filed on Dec. 12, 2001; issued as U.S. Pat. No. 6,627,741), which is a Divisional of Ser. No. 09/461,325 (filed on Dec. 14, 1999; issued as U.S. Pat. No. 6,475,753), which is a Continuation-in-part of PCT/US99/13418 (filed on Jun. 15, 1999); this Application is also a Continuation-in-part of Ser. No. 09/461,325 (filed on Dec. 14, 1999; issued as U.S. Pat. No. 6,475,753), which is a Continuation-in-part of PCT/US99/13418 (filed on Jun. 15, 1999); this Application is also a Continuation-in-part of PCT/US99/13418 (filed on Jun. 15, 1999), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/089,507 (filed on Jun. 16, 1998), 60/089,508 (filed on Jun. 16, 1998), 60/089,509 (filed on Jun. 16, 1998), 60/089,510 (filed on Jun. 16, 1998), 60/090,112 (filed on Jun. 22, 1998), and, 60/090,113 (filed on Jun. 22, 1998); this Application is also a Continuation-in-part of Ser. No. 09/984,271 (filed on Oct. 29, 2001), which is a Divisional of Ser. No. 09/482,273 (filed on Jan. 13, 2000; issued as U.S. Pat. No. 6,534,631), which is a Continuation-in-part of PCT/US99/15849 (filed on Jul. 14, 1999); this Application is also a Continuation-in-part of Ser. No. 09/984,276 (filed on Oct. 29, 2001), which is a Divisional of Ser. No. 09/482,273 (filed on Jan. 13, 2000; issued as U.S. Pat. No. 6,534,631), which is a Continuation-in-part of PCT/US99/15849 (filed on Jul. 14, 1999); this Application is also a Continuation-in-part of Ser. No. 09/482,273 (filed on Jan. 13, 2000; issued as U.S. Pat. No. 6,534,631), which is a Continuation-in-part of PCT/US99/15849 (filed on Jul. 14, 1999); this Application is also a Continuation-in-part of PCT/US99/15849 (filed on Jul. 14, 1999), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/092,921 (filed on Jul. 15, 1998), 60/092,922 (filed on Jul. 15, 1998), and, 60/092,956 (filed on Jul. 15, 1998); this Application is also a Continuation-in-part of PCT/US01/29871 (filed on Sep. 24, 2001), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/234,925 (filed on Sep. 25, 2000); this Application is also a Continuation-in-part of PCT/US01/00911 (filed on Jan. 12, 2001), which is a Continuation-in-part of Ser. No. 09/482,273 (filed on Jan. 13, 2000; issued as U.S. Pat. No. 6,534,631); this Application also claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/350,898 (filed on Jan. 25, 2002); this Application is also a Continuation-in-part of Ser. No. 09/489,847 (filed on Jan. 24, 2000; issued as U.S. Pat. No. 6,476,195), which is a Continuation-in-part of PCT/US99/17130 (filed on Jul. 29, 1999); this Application is also a Continuation-in-part of PCT/US99/17130 (filed on Jul. 29, 1999), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/094,657 (filed on Jul. 30, 1998), 60/095,486 (filed on Aug. 05, 1998), 60/096,319 (filed on Aug. 12, 1998), 60/095,454 (filed on Aug. 06, 1998), and, 60/095,455 (filed on Aug. 06, 1998); this Application is also a Continuation-in-part of Ser. No. 10/054,988 (filed on Jan. 25, 2002), which is a Continuation of Ser. No. 09/904,615 (filed on Jul. 16, 2001; issued as U.S. Pat. No. 6,566,325), which is a Continuation of Ser. No. 09/739,254 (filed on Dec. 19, 2000; now abandoned), which is a Continuation of Ser. No. 09/511,554 (filed on Feb. 23, 2000; now abandoned), which is a Continuation-in-part of PCT/US99/19330 (filed on Aug. 24, 1999); this Application is also a Continuation-in-part of Ser. No. 09/904,615 (filed on Jul. 16, 2001; issued as U.S. Pat. No. 6,566,325), which is a Continuation of Ser. No. 09/739,254 (filed on Dec. 19, 2000; now abandoned), which is a Continuation of Ser. No. 09/511,554 (filed on Feb. 23, 2000; now abandoned), which is a Continuation-in-part of PCT/US99/19330 (filed on Aug. 24, 1999); this Application is also a Continuation-in-part of PCT/US99/19330 (filed on Aug. 24, 1999), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/097,917 (filed on Aug. 25, 1998), and, 60/098,634 (filed on Aug. 31, 1998); this Application is also a Continuation-in-part of Ser. No. 09/820,893 (filed on Mar. 30, 2001; now abandoned), which is a Continuation of Ser. No. 09/531,119 (filed on Mar. 20, 2000; now abandoned), which is a Continuation-in-part of PCT/US99/22012 (filed on Sep. 22, 1999); this Application is also a Continuation-in-part of PCT/US99/22012 (filed on Sep. 22, 1999), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/101,546 (filed on Sep. 23, 1998), and, 60/102,895 (filed on Oct. 02, 1998); this Application is also a Continuation-in-part of Ser. No. 09/948,820 (filed on Sep. 10, 2001; now abandoned), which is a Continuation of Ser. No. 09/565,391 (filed on May 05, 2000; now abandoned), which is a Continuation-in-part of PCT/US99/26409 (filed on Nov. 09, 1999); this Application is also a Continuation-in-part of Ser. No. 09/565,391 (filed on May 05, 2000; now abandoned), which is a Continuation-in-part of PCT/US99/26409 (filed on Nov. 09, 1999); this Application is also a Continuation-in-part of PCT/US99/26409 (filed on Nov. 09, 1999), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/108,207 (filed on Nov. 12, 1998); this Application is also a Continuation-in-part of Ser. No. 09/895,298 (filed on Jul. 02, 2001; now abandoned), which is a Continuation of 09/591,316 (filed on Jun. 09, 2000; now abandoned), which is a Continuation-in-part of PCT/US99/29950 (filed on Dec. 16, 1999); this Application is also a Continuation-in-part of PCT/US99/29950 (filed on Dec. 16, 1999), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/113,006 (filed on Dec. 18, 1998), and, 60/112,809 (filed on Dec. 17, 1998); this Application is also a Continuation-in-part of Ser. No. 09/985,153 (filed on Nov. 01, 2001), which is a Continuation of Ser. No. 09/618,150 (filed on Jul. 17, 2000; now abandoned), which is a Continuation-in-part of PCT/US00/00903 (filed on Jan. 18, 2000); this Application is also a Continuation-in-part of PCT/US00/00903 (filed on Jan. 18, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/116,330 (filed on Jan. 19, 1999); this Application is also a Continuation-in-part of Ser. No. 09/997,131 (filed on Nov. 30, 2001), which is a Continuation of Ser. No. 09/628,508 (filed on Jul. 28, 2000; now abandoned), which is a Continuation-in-part of PCT/US00/03062 (filed on Feb. 08, 2000); this Application is also a Continuation-in-part of PCT/US00/03062 (filed on Feb. 08, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/119,468 (filed on Feb. 10, 1999); this Application is also a Continuation-in-part of Ser. No. 10/050,882 (filed on Jan. 18, 2002; now abandoned), which is a Continuation of Ser. No. 09/661,453 (filed on Sep. 13, 2000; now abandoned), which is a Continuation-in-part of PCT/US00/06783 (filed on Mar. 16, 2000); this Application is also a Continuation-in-part of Ser. No. 09/661,453 (filed on Sep. 13, 2000; now abandoned), which is a Continuation-in-part of PCT/US00/06783 (filed on Mar. 16, 2000); this Application is also a Continuation-in-part of PCT/US00/06783 (filed on Mar. 16, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/125,055 (filed on Mar. 18, 1999); this Application is also a Continuation-in-part of Ser. No. 10/050,704 (filed on Jan. 18, 2002; now abandoned), which is a Continuation of Ser. No. 09/684,524 (filed on Nov. 10, 2000; now abandoned), which is a Continuation-in-part of PCT/US00/08979 (filed on Apr. 06, 2000); this Application is also a Continuation-in-part of Ser. No. 09/684,524 (filed on Nov. 10, 2000; now abandoned), which is a Continuation-in-part of PCT/US00/08979 (filed on Apr. 06, 2000); this Application is also a Continuation-in-part of PCT/US00/08979 (filed on Apr. 06, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/128,693 (filed on Apr. 09, 1999), and, 60/130,991 (filed on Apr. 26, 1999); this Application is also a Continuation-in-part of Ser. No. 10/042,141 (filed on Jan. 11, 2002; now abandoned), which is a Continuation of Ser. No. 09/726,643 (filed on Dec. 01, 2000; now abandoned), which is a Continuation-in-part of PCT/US00/15187 (filed on Jun. 02, 2000); this Application is also a Continuation-in-part of Ser. No. 09/726,643 (filed on Dec. 01, 2000; now abandoned), which is a Continuation-in-part of PCT/US00/15187 (filed on Jun. 02, 2000); this Application is also a Continuation-in-part of PCT/US00/15187 (filed on Jun. 02, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/137,725 (filed on Jun. 07, 1999); this Application is also a Continuation-in-part of Ser. No. 09/756,168 (filed on Jan. 09, 2001; now abandoned), which is a Continuation-in-part of PCT/US00/19735 (filed on Jul. 23, 1999); this Application is also a Continuation-in-part of PCT/US00/19735 (filed on Jul. 20, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/145,220 (filed on Jul. 23, 1999); this Application is also a Continuation-in-part of Ser. No. 10/060,255 (filed on Feb. 01, 2002; now abandoned), which is a Continuation of Ser. No. 09/781,417 (filed on Feb. 13, 2001; now abandoned), which is a Continuation-in-part of PCT/US00/22325 (filed on Aug. 16, 2000); this Application is also a Continuation-in-part of Ser. No. 09/781,417 (filed on Feb. 13, 2001; now abandoned), which is a Continuation-in-part of PCT/US00/22325 (filed on Aug. 16, 2000); this Application is also a Continuation-in-part of PCT/US00/22325 (filed on Aug. 16, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/149,182 (filed on Aug. 17, 1999); this Application is also a Continuation-in-part of Ser. No. 09/789,561 (filed on Feb. 22, 2001; now abandoned), which is a Continuation-in-part of PCT/US00/24008 (filed on Aug. 31, 2000); this Application is also a Continuation-in-part of PCT/US00/24008 (filed on Aug. 31, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/152,315 (filed on Sep. 03, 1999), and 60/152,317 (filed on Sep. 03, 1999); this Application is also a Continuation-in-part of Ser. No. 09/800,729 (filed on Mar. 08, 2001; issued as U.S. Pat. No. 6,605,592), which is a Continuation-in-part of PCT/US00/26013 (filed on Sep. 22, 2000); this Application is also a Continuation-in-part of PCT/US00/26013 (filed on Sep. 22, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/155,709 (filed on Sep. 24, 1999); this Application is also a Continuation-in-part of Ser. No. 09/832,129 (filed on Apr. 11, 2001), which is a Continuation-in-part of PCT/US00/28664 (filed on Oct. 17, 2000); this Application is also a Continuation-in-part of PCT/US00/28664 (filed on Oct. 17, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/163,085 (filed on Nov. 02, 1999), and, 60/172,411 (filed on Dec. 17, 1999); this Application is also a Continuation-in-part of PCT/US00/29363 (filed on Oct. 25, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/215,139 (filed on Jun. 30, 2000), and, 60/162,239 (filed on Oct. 29, 1999); this Application is also a Continuation-in-part of PCT/US00/29360 (filed on Oct. 25, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/215,138 (filed on Jun. 30, 2000), and, 60/162,211 (filed on Oct. 29, 1999); this Application is also a Continuation-in-part of PCT/US00/29362 (filed on Oct. 25, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/215,131 (filed on Jun. 30, 2000), and, 60/162,240 (filed on Oct. 29, 1999); this Application is also a Continuation-in-part of PCT/US00/29365 (filed on Oct. 25, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/219,666 (filed on Jul. 21, 2000), and, 60/162,237 (filed on Oct. 29, 1999); this Application is also a Continuation-in-part of PCT/US00/29364 (filed on Oct. 25, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/215,134 (filed on Jun. 30, 2000), and, 60/162,238 (filed on Oct. 29, 1999); this Application is also a Continuation-in-part of PCT/US00/30040 (filed on Nov. 01, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/215,130 (filed on Jun. 30, 2000), and, 60/163,580 (filed on Nov. 05, 1999); this Application is also a Continuation-in-part of PCT/US00/30037 (filed on Nov. 01, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/215,137 (filed on Jun. 30, 2000), and, 60/163,577 (filed on Nov. 05, 1999); this Application is also a Continuation-in-part of PCT/US00/30045 (filed on Nov. 01, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/215,133 (filed on Jun. 30, 2000), and, 60/163,581 (filed on Nov. 05, 1999); this Application is also a Continuation-in-part of PCT/US00/30036 (filed on Nov. 01, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/221,366 (filed on Jul. 27, 2000), and, 60/163,576 (filed on Nov. 05, 1999); this Application is also a Continuation-in-part of PCT/US00/30039 (filed on Nov. 01, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/221,367 (filed on Jul. 27, 2000), 60/195,296 (filed on Apr. 07, 2000), and, 60/164,344 (filed on Nov. 09, 1999); this Application is also a Continuation-in-part of PCT/US00/30654 (filed on Nov. 08, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/221,142 (filed on Jul. 27, 2000), and, 60/164,835 (filed on Nov. 12, 1999); this Application is also a Continuation-in-part of PCT/US00/30628 (filed on Nov. 08, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/215,140 (filed on Jun. 30, 2000), and, 60/164,744 (filed on Nov. 12, 1999); this Application is also a Continuation-in-part of PCT/US00/30653 (filed on Nov. 08, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/221,193 (filed on Jul. 27, 2000), and, 60/164,735 (filed on Nov. 12, 1999); this Application is also a Continuation-in-part of PCT/US00/30629 (filed on Nov. 08, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/222,904 (filed on Aug. 03, 2000), and, 60/164,825 (filed on Nov. 12, 1999); this Application is also a Continuation-in-part of PCT/US00/30679 (filed on Nov. 08, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/224,007 (filed on Aug. 04, 2000), and, 60/164,834 (filed on Nov. 12, 1999); this Application is also a Continuation-in-part of PCT/US00/30674 (filed on Nov. 08, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/215,128 (filed on Jun. 30, 2000), and, 60/164,750 (filed on Nov. 12, 1999); this Application is also a Continuation-in-part of PCT/US00/31162 (filed on Nov. 15, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/215,136 (filed on Jun. 30, 2000), and, 60/166,415 (filed on Nov. 19, 1999); this Application is also a Continuation-in-part of PCT/US00/31282 (filed on Nov. 15, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/219,665 (filed on Jul. 21, 2000), and, 60/166,414 (filed on Nov. 19, 1999); this Application is also a Continuation-in-part of PCT/US00/30657 (filed on Nov. 08, 2000), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/215,132 (filed on Jun. 30, 2000), and, 60/164,731 (filed on Nov. 12, 1999); this Application is also a Continuation-in-part of PCT/US01/01396 (filed on Jan. 17, 2001), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/256,968 (filed on Dec. 21, 2000), and, 60/226,280 (filed on Aug. 18, 2000); this Application is also a Continuation-in-part of PCT/US01/01387 (filed on Jan. 17, 2001), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/259,803 (filed on Jan. 05, 2001), and, 60/226,380 (filed on Aug. 18, 2000); this Application is also a Continuation-in-part of PCT/US01/01567 (filed on Jan. 17, 2001), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/228,084 (filed on Aug. 28, 2000); this Application is also a Continuation-in-part of PCT/US01/01431 (filed on Jan. 17, 2001), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/231,968 (filed on Sep. 12, 2000); PCT/US01/01431 is also a Continuation-in-part of Ser. No. 09/915,582(filed on Jul. 27, 2001; now abandoned); this Application is also a Continuation-in-part of PCT/US01/01432 (filed on Jan. 17, 2001), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/236,326 (filed on Sep. 29, 2000); this Application is also a Continuation-in-part of PCT/US01/00544 (filed on Jan. 09, 2001), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/234,211 (filed on Sep. 20, 2000); this Application is also a Continuation-in-part of PCT/US01/01435 (filed on Jan. 17, 2001), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/226,282 (filed on Aug. 18, 2000); this Application is also a Continuation-in-part of PCT/US01/01386 (filed on Jan. 17, 2001), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/232,104 (filed on Sep. 12, 2000); this Application is also a Continuation-in-part of PCT/US01/01565 (filed on Jan. 17, 2001), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/234,210 (filed on Sep. 20, 2000); this Application is also a Continuation-in-part of PCT/US01/01394 (filed on Jan. 17, 2001), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/259,805 (filed on Jan. 05, 2001), and, 60/226,278 (filed on Aug. 18, 2000); this Application is also a Continuation-in-part of PCT/US01/01434 (filed on Jan. 17, 2001), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/259,678 (filed on Jan. 05, 2001), and, 60/226,279 (filed on Aug. 18, 2000); this Application is also a Continuation-in-part of PCT/US01/01397 (filed on Jan. 17, 2001), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/226,281 (filed on Aug. 18, 2000); this Application is also a Continuation-in-part of PCT/US01/01385 (filed on Jan. 17, 2001), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/231,969 (filed on Sep. 12, 2000); this Application is also a Continuation-in-part of PCT/US01/01384 (filed on Jan. 17, 2001), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/259,516 (filed on Jan. 04, 2001), and, 60/228,086 (filed on Aug. 28, 2000); this Application is also a Continuation-in-part of PCT/US01/01383 (filed on Jan. 17, 2001), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/259,804 (filed on Jan. 05, 2001), and, 60/228,083 (filed on Aug. 28, 2000); this Application is also a Continuation-in-part of PCT/US02/05064 (filed on Feb. 21, 2002), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/304,444 (filed on Jul. 12, 2001), and, 60/270,658 (filed on Feb. 23, 2001); this Application is also a Continuation-in-part of PCT/US02/05301 (filed on Feb. 21, 2002), which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. Nos. 60/304,417 (filed on Jul. 12, 2001), and, 60/270,625 (filed on Feb. 23, 2001); this Application also claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/304,121 (filed on Jul. 11, 2001); this Application also claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/295,869 (filed on Jun. 06, 2001); this Application also claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/325,209 (filed on Sep. 28, 2001); this Application also claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/311,085 (filed on Aug. 10, 2001); this Application also claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/330,629 (filed on Oct. 26, 2001); this Application also claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/331,046 (filed on Nov. 07, 2001); this Application also claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/358,554 (filed on Feb. 22, 2002); this Application also claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Ser. No. 60/358,714 (filed on Feb. 25, 2002).

[0002] The present invention relates to human secreted proteins/polypeptides, and isolated nucleic acid molecules encoding said proteins/polypeptides, useful for detecting, preventing, diagnosing, prognosticating, treating, and/or ameliorating diseases and disorders related to said proteins/polypeptides (relatedness may be by direct or indirect association, by cause, by consequence, or by effect on said diseases and disorders). Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies. The invention further encompasses screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

[0003] Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eukaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or organelle, contains different proteins essential for the function of the organelle. The cell uses “sorting signals,” which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

[0004] One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

[0005] Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space—a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a “linker” holding the protein to the membrane.

[0006] Thus there exists a clear need for identifying and using novel secreted polynucleotides and polypeptides. Identification and sequencing of human genes is a major goal of modern scientific research. For example, by identifying genes and determining their sequences, scientists have been able to make large quantities of valuable human “gene products.” These include human insulin, interferon, Factor VIII, tumor necrosis factor, human growth hormone, tissue plasminogen activator, and numerous other compounds. Additionally, knowledge of gene sequences can provide the key to treatment or cure of genetic diseases (such as muscular dystrophy and cystic fibrosis).

[0007] The present invention relates to human secreted proteins/polypeptides, and isolated nucleic acid molecules encoding said proteins/polypeptides, useful for detecting, preventing, diagnosing, prognosticating, treating, and/or ameliorating diseases and disorders related to said proteins/polypeptides (relatedness may be by direct or indirect association, or by cause, consequence, or effect on said diseases and disorders). Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies. The invention further encompasses screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

Polynucleotides and Polypeptides of the Invention

Description of Table 1A

[0008] Table 1A summarizes information concerning certain polypnucleotides and polypeptides of the invention. The first column provides the gene number in the application for each clone identifier. The second column provides a unique clone identifier, “Clone ID:”, for a cDNA clone related to each contig sequence disclosed in Table 1A. Third column, the cDNA Clones identified in the second column were deposited as indicated in the third column (i.e. by ATCC Deposit No:Z and deposit date). Some of the deposits contain multiple different clones corresponding to the same gene. In the fourth column, “Vector” refers to the type of vector contained in the corresponding cDNA Clone identified in the second column. In the fifth column, the nucleotide sequence identified as “NT SEQ ID NO:X” was assembled from partially homologous (“overlapping”) sequences obtained from the corresponding cDNA clone identified in the second column and, in some cases, from additional related cDNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X. In the sixth column, “Total NT Seq.” refers to the total number of nucleotides in the contig sequence identified as SEQ ID NO:X.” The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as “5′ NT of Clone Seq.” (seventh column) and the “3′ NT of Clone Seq.” (eighth column) of SEQ ID NO:X. In the ninth column, the nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as “5′ NT of Start Codon.” Similarly , in column ten, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as “5′ NT of First AA of Signal Pep.” In the eleventh column, the translated amino acid sequence, beginning with the methionine, is identified as “AA SEQ ID NO:Y,” although other reading frames can also be routinely translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

[0009] In the twelfth and thirteenth columns of Table 1A, the first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as “First AA of Sig Pep” and “Last AA of Sig Pep.” In the fourteenth column, the predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as “Predicted First AA of Secreted Portion”. The amino acid position of SEQ ID NO:Y of the last amino acid encoded by the open reading frame is identified in the fifteenth column as “Last AA of ORF”.

[0010] SEQ ID NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing) and the translated SEQ ID NO:Y (where Y may be any of the polypeptide sequences disclosed in the sequence listing) are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used, for example, to generate antibodies which bind specifically to proteins containing the polypeptides and the secreted proteins encoded by the cDNA clones identified in Table 1A and/or elsewhere herein.

[0011] Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

[0012] Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X, and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1A. The nucleotide sequence of each deposited plasmid can readily be determined by sequencing the deposited plasmid in accordance with known methods

[0013] The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular plasmid can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

[0014] Also provided in Table 1A is the name of the vector which contains the cDNA plasmid. Each vector is routinely used in the art. The following additional information is provided for convenience.

[0015] Vectors Lambda Zap (U.S. Pat. Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Pat. Nos. 5,128,256 and 5,286,636), Zap Express (U.S. Pat. Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, Calif., 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Phagemid pBS may be excised from the Lambda Zap and Uni-Zap XR vectors, and phagemid pBK may be excised from the Zap Express vector. Both phagemids may be transformed into E. coli strain XL-1 Blue, also available from Stratagene

[0016] Vectors pSport1, pCMVSport 1.0, pCMVSport 2.0 and pCMVSport 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, Md. 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. See, for instance, Gruber, C. E., et al., Focus 15:59 (1993). Vector lafmid BA (Bento Soares, Columbia University, New York, N.Y.) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR®2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, Calif. 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).

[0017] The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, and/or a deposited cDNA (cDNA Clone ID). The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include, but are not limited to, preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genornic material.

[0018] Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X and SEQ ID NO:Y using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

[0019] The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X and/or a cDNA contained in ATCC Deposit No.Z. The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X, and/or a polypeptide encoded by a cDNA contained in ATCC deposit No.Z. Polynucleotides encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X and/or a polypeptide encoded by the cDNA contained in ATCC Deposit No.Z, are also encompassed by the invention. The present invention further encompasses a polynucleotide comprising, or alternatively consisting of the complement of the nucleic acid sequence of SEQ ID NO:X, and/or the complement of the coding strand of the cDNA contained in ATCC Deposit No.Z.

Description of Table 1B (Comprised of Tables 1B.1 and 1B.2)

[0020] Table 1B.1 and Table 1B.2 summarize some of the polynucleotides encompassed by the invention (including cDNA clones related to the sequences (Clone ID:), contig sequences (contig identifier (Contig ID:) and contig nucleotide sequence identifiers (SEQ ID NO:X)) and further summarizes certain characteristics of these polynucleotides and the polypeptides encoded thereby. The first column of Tables 1B.1 and 1B.2 provide the gene numbers in the application for each clone identifier. The second column of Tables 1B.1 and 1B.2 provide unique clone identifiers, “Clone ID:”, for cDNA clones related to each contig sequence disclosed in Table 1A and/or Table 1B. The third column of Tables 1B.1 and 1B.2 provide unique contig identifiers, “Contig ID:” for each of the contig sequences disclosed in these tables. The fourth column of Tables 1B.1 and 1B.2 provide the sequence identifiers, “SEQ ID NO:X”, for each of the contig sequences disclosed in Table 1A and/or 1B.

Table 1B.1

[0021] The fifth column of Table 1B.1, “ORF (From-To)”, provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence of SEQ ID NO:X that delineates the preferred open reading frame (ORF) that encodes the amino acid sequence shown in the sequence listing and referenced in Table 1B.1 as SEQ ID NO:Y (column 6). Column 7 of Table 1B.1 lists residues comprising predicted epitopes contained in the polypeptides encoded by each of the preferred ORFs (SEQ ID NO:Y). Identification of potential immunogenic regions was performed according to the method of Jameson and Wolf (CABIOS, 4; 181-186 (1988)); specifically, the Genetics Computer Group (GCG) implementation of this algorithm, embodied in the program PEPTIDESTRUCTURE (Wisconsin Package v10.0, Genetics Computer Group (GCG), Madison, Wis.). This method returns a measure of the probability that a given residue is found on the surface of the protein. Regions where the antigenic index score is greater than 0.9 over at least 6 amino acids are indicated in Table 1B.1 as “Predicted Epitopes”. In particular embodiments, polypeptides of the invention comprise, or alternatively consist of, one, two, three, four, five or more of the predicted epitopes described in Table 1B.1. It will be appreciated that depending on the analytical criteria used to predict antigenic determinants, the exact address of the determinant may vary slightly. Column 8 of Table 1B.1 (“Cytologic Band”) provides the chromosomal location of polynucleotides corresponding to SEQ ID NO:X. Chromosomal location was determined by finding exact matches to EST and cDNA sequences contained in the NCBI (National Center for Biotechnology Information) UniGene database. Given a presumptive chromosomal location, disease locus association was determined by comparison with the Morbid Map, derived from Online Mendelian Inheritance in Man (Online Mendelian Inheritance in Man, OMIM™. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, Md.) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, Md.) 2000. World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/). If the putative chromosomal location of the Query overlaps with the chromosomal location of a Morbid Map entry, an OMIM identification number is disclosed in Table 1B.1, column 9 labeled “OMIM Disease Reference(s)”. A key to the OMIM reference identification numbers is provided in Table 5.

Table 1B.2

[0022] Column 5 of Table 1B.2, “Tissue Distribution”shows the expression profile of tissue, cells, and/or cell line libraries which express the polynucleotides of the invention. The first code number shown in Table 1B.2 column 5 (preceding the colon), represents the tissue/cell source identifier code corresponding to the key provided in Table 4. Expression of these polynucleotides was not observed in the other tissues and/or cell libraries tested. The second number in column 5 (following the colon), represents the number of times a sequence corresponding to the reference polynucleotide sequence (e.g., SEQ ID NO:X) was identified in the corresponding tissue/cell source. Those tissue/cell source identifier codes in which the first two letters are “AR” designate information generated using DNA array technology. Utilizing this technology, cDNAs were amplified by PCR and then transferred, in duplicate, onto the array. Gene expression was assayed through hybridization of first strand cDNA probes to the DNA array. cDNA probes were generated from total RNA extracted from a variety of different tissues and cell lines. Probe synthesis was performed in the presence of ³³P dCTP, using oligo(dT) to prime reverse transcription. After hybridization, high stringency washing conditions were employed to remove non-specific hybrids from the array. The remaining signal, emanating from each gene target, was measured using a Phosphorimager. Gene expression was reported as Phosphor Stimulating Luminescence (PSL) which reflects the level of phosphor signal generated from the probe hybridized to each of the gene targets represented on the array. A local background signal subtraction was performed before the total signal generated from each array was used to normalize gene expression between the different hybridizations. The value presented after “[array code]:” represents the mean of the duplicate values, following background subtraction and probe normalization. One of skill in the art could routinely use this information to identify normal and/or diseased tissue(s) which show a predominant expression pattern of the corresponding polynucleotide of the invention or to identify polynucleotides which show predominant and/or specific tissue and/or cell expression.

Description of Table 1C

[0023] Table 1C summarizes additional polynucleotides encompassed by the invention (including cDNA clones related to the sequences (Clone ID:), contig sequences (contig identifier (Contig ID:) contig nucleotide sequence identifiers (SEQ ID NO:X)), and genomic sequences (SEQ ID NO:B). The first column provides a unique clone identifier, “Clone ID:”, for a cDNA clone related to each contig sequence. The second column provides the sequence identifier, “SEQ ID NO:X”, for each contig sequence. The third column provides a unique contig identifier, “Contig ID:” for each contig sequence. The fourth column, provides a BAC identifier “BAC ID NO:A” for the BAC clone referenced in the corresponding row of the table. The fifth column provides the nucleotide sequence identifier, “SEQ ID NO:B” for a fragment of the BAC clone identified in column four of the corresponding row of the table. The sixth column, “Exon From-To”, provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence of SEQ ID NO:B which delineate certain polynucleotides of the invention that are also exemplary members of polynucleotide sequences that encode polypeptides of the invention (e.g., polypeptides containing amino acid sequences encoded by the polynucleotide sequences delineated in column six, and fragments and variants thereof).

Description of Table 1D

[0024] Table 1D: In preferred embodiments, the present invention encompasses a method of detecting, preventing, treating, and/or ameliorating a disease or disorder listed as listed in the “Preferred Indications” column of Table 1D (below); comprising administering to a patient (in which such detection, prevention, treatment, and/or amelioration is desired) a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) represented by Table 1A and Table 1D (in the same row as the disease or disorder to be treated is listed in the “Preferred Indications” column of Table 1D) in an amount effective to detect, prevent, treat, or ameliorate the disease or disorder.

[0025] As indicated in Table 1D, the polynucleotides, polypeptides, agonists, or antagonists of the present invention (including antibodies) can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists thereof (including antibodies) could be used to prevent, treat, or ameliorate the associated disease.

[0026] The present invention encompasses methods of detecting, preventing, diagnosing, prognosticating, treating, and/or ameliorating a disease or disorder. In preferred embodiments, the present invention encompasses a method of detecting, diagnosing, treating, preventing, or ameliorating a disease or disorder listed in the “Preferred Indications” column of Table 1D; comprising administering to a patient in which such treatment, prevention, or amelioration is desired a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) in an amount effective to treat, prevent, or ameliorate the disease or disorder. The first and seccond columns of Table 1D show the “Gene No.” and “cDNA Clone ID No.”, respectively, indicating certain nucleic acids and proteins (or antibodies against the same) of the invention (including polynucleotide, polypeptide, and antibody fragments or variants thereof) that may be used in detecting, preventing, diagnosing, prognosticating, treating, and/or ameliorating the disease(s) or disorder(s) indicated in the corresponding row in Column 3 of Table 1D.

[0027] In another embodiment, the present invention also encompasses methods of preventing, treating, diagnosing, or ameliorating a disease or disorder listed in the “Preferred Indications” column of Table 1D; comprising administering to a patient combinations of the proteins, nucleic acids, or antibodies of the invention (or fragments or variants thereof), sharing similar indications as shown in the corresponding rows in Column 3 of Table 1D.

[0028] The “Preferred Indication” column describes diseases, disorders, and/or conditions that may be treated, prevented, diagnosed, or ameliorated by a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof).

[0029] The recitation of “Cancer” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof) may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., leukemias, cancers, and/or as described below under “Hyperproliferative Disorders”).

[0030] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Cancer” recitation in the “Preferred Indication” column of Table 1D may be used for example, to diagnose, treat, prevent, and/or ameliorate a neoplasm located in a tissue selected from the group consisting of: colon, abdomen, bone, breast, digestive system, liver, pancreas, prostate, peritoneum, lung, blood (e.g., leukemia), endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), uterus, eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

[0031] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Cancer” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a pre-neoplastic condition, selected from the group consisting of: hyperplasia (e.g., endometrial hyperplasia and/or as described in the section entitled “Hyperproliferative Disorders”), metaplasia (e.g., connective tissue metaplasia, atypical metaplasia, and/or as described in the section entitled “Hyperproliferative Disorders”), and/or dysplasia (e.g., cervical dysplasia, and bronchopulmonary dysplasia).

[0032] In another specific embodiment, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Cancer” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a benign dysproliferative disorder selected from the group consisting of: benign tumors, fibrocystic conditions, tissue hypertrophy, and/or as described in the section entitled “Hyperproliferative Disorders”.

[0033] The recitation of “Immune/Hematopoietic” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), blood disorders (e.g., as described below under “Immune Activity” “Cardiovascular Disorders” and/or “Blood-Related Disorders”), and infections (e.g., as described below under “Infectious Disease”).

[0034] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having the “Immune/Hematopoietic” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: anemia, pancytopenia, leukopenia, thrombocytopenia, leukemias, Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, asthma, AIDS, autoimmune disease, rheumatoid arthritis, granulomatous disease, immune deficiency, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, immune reactions to transplanted organs and tissues, systemic lupus erythematosis, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, and allergies.

[0035] The recitation of “Reproductive” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), and disorders of the reproductive system (e.g., as described below under “Reproductive System Disorders”).

[0036] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Reproductive” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: cryptorchism, prostatitis, inguinal hernia, varicocele, leydig cell tumors, verrucous carcinoma, prostatitis, malacoplakia, Peyronie's disease, penile carcinoma, squamous cell hyperplasia, dysmenorrhea, ovarian adenocarcinoma, Turner's syndrome, mucopurulent cervicitis, Sertoli-leydig tumors, ovarian cancer, uterine cancer, pelvic inflammatory disease, testicular cancer, prostate cancer, Klinefelter's syndrome, Young's syndrome, premature ejaculation, diabetes mellitus, cystic fibrosis, Kartagener's syndrome, testicular atrophy, testicular feminization, anorchia, ectopic testis, epididymitis, orchitis, gonorrhea, syphilis, testicular torsion, vasitis nodosa, germ cell tumors, stromal tumors, dysmenorrhea, retroverted uterus, endometriosis, fibroids, adenomyosis, anovulatory bleeding, amenorrhea, Cushing's syndrome, hydatidiform moles, Asherman's syndrome, premature menopause, precocious puberty, uterine polyps, dysfunctional uterine bleeding, cervicitis, chronic cervicitis, mucopurulent cervicitis, cervical dysplasia, cervical polyps, Nabothian cysts, cervical erosion, cervical incompetence, cervical neoplasms, pseudohermaphroditism, and premenstrual syndrome.

[0037] The recitation of “Musculoskeletal” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), and disorders of the immune system (e.g., as described below under “Immune Activity”).

[0038] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Musculoskeletal” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: bone cancers (e.g., osteochondromas, benign chondromas, chondroblastoma, chondromyxoid fibromas, osteoid osteomas, giant cell tumors, multiple myeloma, osteosarcomas), Paget's Disease, rheumatoid arthritis, systemic lupus erythematosus, osteomyelitis, Lyme Disease, gout, bursitis, tendonitis, osteoporosis, osteoarthritis, muscular dystrophy, mitochondrial myopathy, cachexia, and multiple sclerosis.

[0039] The recitation of “Cardiovascular” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), and disorders of the cardiovascular system (e.g., as described below under “Cardiovascular Disorders”).

[0040] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Cardiovascular” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: myxomas, fibromas, rhabdomyomas, cardiovascular abnormalities (e.g., congenital heart defects, cerebral arteriovenous malformations, septal defects), heart disease (e.g., heart failure, congestive heart disease, arrhythmia, tachycardia, fibrillation, pericardial Disease, endocarditis), cardiac arrest, heart valve disease (e.g., stenosis, regurgitation, prolapse), vascular disease (e.g., hypertension, coronary artery disease, angina, aneurysm, arteriosclerosis, peripheral vascular disease), hyponatremia, hypematremia, hypokalemia, and hyperkalemia.

[0041] The recitation of “Mixed Fetal” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”).

[0042] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Mixed Fetal” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: spina bifida, hydranencephaly, neurofibromatosis, fetal alcohol syndrome, diabetes mellitus, PKU, Down's syndrome, Patau syndrome, Edwards syndrome, Turner syndrome, Apert syndrome, Carpenter syndrome, Conradi syndrome, Crouzon syndrome, cutis laxa, Cornelia de Lange syndrome, Ellis-van Creveld syndrome, Holt-Oram syndrome, Kartagener syndrome, Meckel-Gruber syndrome, Noonan syndrome, Pallister-Hall syndrome, Rubinstein-Taybi syndrome, Scimitar syndrome, Smith-Lemli-Opitz syndrome, thromocytopenia-absent radius (TAR) syndrome, Treacher Collins syndrome, Williams syndrome, Hirschsprung's disease, Meckel's diverticulum, polycystic kidney disease, Turner's syndrome, and gonadal dysgenesis, Klippel-Feil syndrome, Ostogenesis imperfecta, muscular dystrophy, Tay-Sachs disease, Wilm's tumor, neuroblastoma, and retinoblastoma.

[0043] The recitation of “Excretory” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”) and renal disorders (e.g., as described below under “Renal Disorders”).

[0044] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Excretory” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: bladder cancer, prostate cancer, benign prostatic hyperplasia, bladder disorders (e.g., urinary incontinence, urinary retention, urinary obstruction, urinary tract Infections, interstitial cystitis, prostatitis, neurogenic bladder, hematuria), renal disorders (e.g., hydronephrosis, proteinuria, renal failure, pyelonephritis, urolithiasis, reflux nephropathy, and unilateral obstructive uropathy).

[0045] The recitation of “Neural/Sensory” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”) and diseases or disorders of the nervous system (e.g., as described below under “Neural Activity and Neurological Diseases”).

[0046] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Neural/Sensory” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: brain cancer (e.g., brain stem glioma, brain tumors, central nervous system (Primary) lymphoma, central nervous system lymphoma, cerebellar astrocytoma, and cerebral astrocytoma, neurodegenerative disorders (e.g., Alzheimer's Disease, Creutzfeldt-Jakob Disease, Parkinson's Disease, and Idiopathic Presenile Demcntia), encephalomyelitis, cerebral malaria, meningitis, metabolic brain diseases (e.g., phenylketonuria and pyruvate carboxylase deficiency), cerebellar ataxia, ataxia telangiectasia, and AIDS Dementia Complex, schizophrenia, attention deficit disorder, hyperactive attention deficit disorder, autism, and obsessive compulsive disorders.

[0047] The recitation of “Respiratory” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”) and diseases or disorders of the respiratory system (e.g., as described below under “Respiratory Disorders”).

[0048] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Respiratory” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: cancers of the respiratory system such as larynx cancer, pharynx cancer, trachea cancer, epiglottis cancer, lung cancer, squamous cell carcinomas, small cell (oat cell) carcinomas, large cell carcinomas, and adenocarcinomas. Allergic reactions, cystic fibrosis, sarcoidosis, histiocytosis X, infiltrative lung diseases (e.g., pulmonary fibrosis and lymphoid interstitial pneumonia), obstructive airway diseases (e.g., asthma, emphysema, chronic or acute bronchitis), occupational lung diseases (e.g., silicosis and asbestosis), pneumonia, and pleurisy.

[0049] The recitation of “Endocrine” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”) and diseases or disorders of the respiratory system (e.g., as described below under “Respiratory Disorders”), renal disorders (e.g., as described below under “Renal Disorders”), and disorders of the endocrine system (e.g., as described below under “Endocrine Disorders”.

[0050] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having an “Endocrine” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: cancers of endocrine tissues and organs (e.g., cancers of the hypothalamus, pituitary gland, thyroid gland, parathyroid glands, pancreas, adrenal glands, ovaries, and testes), diabetes (e.g., diabetes insipidus, type I and type II diabetes mellitus), obesity, disorders related to pituitary glands (e.g., hyperpituitarism, hypopituitarism, and pituitary dwarfism), hypothyroidism, hyperthyroidism, goiter, reproductive disorders (e.g. male and female infertility), disorders related to adrenal glands (e.g., Addison's Disease, corticosteroid deficiency, and Cushing's Syndrome), kidney cancer (e.g., hypemephroma, transitional cell cancer, and Wilm's tumor), diabetic nephropathy, interstitial nephritis, polycystic kidney disease, glomerulonephritis (e.g., IgM mesangial proliferative glomerulonephritis and glomerulonephritis caused by autoimmune disorders; such as Goodpasture's syndrome), and nephrocalcinosis.

[0051] The recitation of “Digestive” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders” and diseases or disorders of the gastrointestinal system (e.g., as described below under “Gastrointestinal Disorders”.

[0052] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Digestive” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: ulcerative colitis, appendicitis, Crohn's disease, hepatitis, hepatic encephalopathy, portal hypertension, cholelithiasis, cancer of the digestive system (e.g., biliary tract cancer, stomach cancer, colon cancer, gastric cancer, pancreatic cancer, cancer of the bile duct, tumors of the colon (e.g., polyps or cancers), and cirrhosis), pancreatitis, ulcerative disease, pyloric stenosis, gastroenteritis, gastritis, gastric atropy, benign tumors of the duodenum, distension, irritable bowel syndrome, malabsorption, congenital disorders of the small intestine, bacterial and parasitic infection, megacolon, Hirschsprung's disease, aganglionic megacolon, acquired megacolon, colitis, anorectal disorders (e.g., anal fistulas, hemorrhoids), congenital disorders of the liver (e.g., Wilson's disease, hemochromatosis, cystic fibrosis, biliary atresia, and alphal-antitrypsin deficiency), portal hypertension, cholelithiasis, and jaundice.

[0053] The recitation of “Connective/Epithelial” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), cellular and genetic abnormalities (e.g., as described below under “Diseases at the Cellular Level”), angiogenesis (e.g., as described below under “Anti-Angiogenesis Activity”), and or to promote or inhibit regeneration (e.g., as described below under “Regeneration”), and wound healing (e.g., as described below under “Wound Healing and Epithelial Cell Proliferation”).

[0054] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Connective/Epithelial” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: connective tissue metaplasia, mixed connective tissue disease, focal epithelial hyperplasia, epithelial metaplasia, mucoepithelial dysplasia, graft v. host disease, polymyositis, cystic hyperplasia, cerebral dysplasia, tissue hypertrophy, Alzheimer's disease, lymphoproliferative disorder, Waldenstron's macroglobulinemia, Crohn's disease, pernicious anemia, idiopathic Addison's disease, glomerulonephritis, bullous pemphigoid, Sjogren's syndrome, diabetes mellitus, cystic fibrosis, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, osteoporosis, osteocarthritis, periodontal disease, wound healing, relapsing polychondritis, vasculitis, polyarteritis nodosa, Wegener's granulomatosis, cellulitis, rheumatoid arthritis, psoriatic arthritis, discoid lupus erythematosus, systemic lupus erythematosus, scleroderma, CREST syndrome, Sjogren's syndrome, polymyositis, dermatomyositis, mixed connective tissue disease, relapsing polychondritis, vasculitis, Henoch-Schonlein syndrome, erythema nodosum, polyarteritis nodosa, temporal (giant cell) arteritis, Takayasu's arteritis, Wegener's granulomatosis, Reiter's syndrome, Behcet's syndrome, ankylosing spondylitis, cellulitis, keloids, Ehler Danlos syndrome, Marfan syndrome, pseudoxantoma elasticum, osteogenese imperfecta, chondrodysplasias, epidermolysis bullosa, Alport syndrome, and cutis laxa.

Description of Table 1E

[0055] Table 1E provides information related to biological activities and preferred indications for polynucleotides and polypeptides of the invention (including antibodies, agonists, and/or antagonists thereof). Table 1E also provides information related to assays which may be used to test polynucleotides and polypeptides of the invention (including antibodies, agonists, and/or antagonists thereof) for the corresponding biological activities. The first column (“Gene No.”) provides the gene number in the application for each clone identifier. The second column (“cDNA Clone ID:”) provides the unique clone identifier for each clone as previously described and indicated in Tables 1A, 1B, 1C, and 1D. The third column (“AA SEQ ID NO:Y”) indicates the Sequence Listing SEQ ID Number for polypeptide sequences encoded by the corresponding cDNA clones (also as indicated in Tables 1A, 1B, and 2). The fourth column (“Biological Activity”) indicates a biological activity corresponding to the indicated polypeptides (or polynucleotides encoding said polypeptides). The fifth column (“Exemplary Activity Assay”) further describes the corresponding biological activity and provides information pertaining to the various types of assays which may be performed to test, demonstrate, or quantify the corresponding biological activity. The sixth column (“Preferred Indications”) describes particular embodiments of the invention and indications (e.g. pathologies, diseases, disorders, abnormalities, etc.) for which polynucleotides and polypeptides of the invention (including antibodies, agonists, and/or antagonists thereof) may be used in detecting, preventing, diagnosing, prognosticating, treating, and/or ameliorating.

[0056] Table 1E describes the use of FMAT technology, inter alia, for testing or demonstrating various biological activities. Fluorometric microvolume assay technology (FMAT) is a fluorescence-based system which provides a means to perform nonradioactive cell- and bead-based assays to detect activation of cell signal transduction pathways. This technology was designed specifically for ligand binding and immunological assays. Using this technology, fluorescent cells or beads at the bottom of the well are detected as localized areas of concentrated fluorescence using a data processing system. Unbound flurophore comprising the background signal is ignored, allowing for a wide variety of homogeneous assays. FMAT technology may be used for peptide ligand binding assays, immunofluorescence, apoptosis, cytotoxicity, and bead-based immunocapture assays. See, Miraglia S et. al., “Homogeneous cell and bead based assays for highthroughput screening using flourometric microvolume assay technology,” Journal of Biomolecular Screening; 4:193-204 (1999). In particular, FMAT technology may be used to test, confirm, and/or identify the ability of polypeptides (including polypeptide fragments and variants) to activate signal transduction pathways. For example, FMAT technology may be used to test, confirm, and/or identify the ability of polypeptides to upregulate production of immunomodulatory proteins (such as, for example, interleukins, GM-CSF, Rantes, and Tumor Necrosis factors, as well as other cellular regulators (e.g. insulin)).

[0057] Table 1E also describes the use of kinase assays for testing, demonstrating, or quantifying biological activity. In this regard, the phosphorylation and de-phosphorylation of specific amino acid residues (e.g. Tyrosine, Serine, Threonine) on cell-signal transduction proteins provides a fast, reversible means for activation and de-activation of cellular signal transduction pathways. Moreover, cell signal transduction via phosphorylation/de-phosphorylation is crucial to the regulation of a wide variety of cellular processes (e.g. proliferation, differentiation, migration, apoptosis, etc.). Accordingly, kinase assays provide a powerful tool useful for testing, confirming, and/or identifying polypeptides (including polypeptide fragments and variants) that mediate cell signal transduction events via protein phosphorylation. See e.g., Forrer, P., Tamaskovic R., and Jaussi, R. “Enzyme-Linked Immunosorbent Assay for Measurement of JNK, ERK, and p38 Kinase Activities” Biol. Chem. 379(8-9): 1101-1110 (1998).

Description of Table 1F

[0058] Polynucleotides encoding polypeptides of the present invention can be used in assays to test for one or more biological activities. One such biological activity which may be tested includes the ability of polynucleotides and polypeptides of the invention to stimulate up-regulation or down-regulation of expression of particular genes and proteins. Hence, if polynucleotides and polypeptides of the present invention exhibit activity in altering particular gene and protein expression patterns, it is likely that these polynucleotides and polypeptides of the present invention may be involved in, or capable of effecting changes in, diseases associated with the altered gene and protein expression profiles. Hence, polynucleotides, polypeptides, or antibodies of the present invention could be used to treat said associated diseases.

[0059] TAQMAN® assays may be performed to assess the ability of polynucleotides (and polypeptides they encode) to alter the expression pattern of particular “target” genes. TAQMAN® reactions are performed to evaluate the ability of a test agent to induce or repress expression of specific genes in different cell types. TAQMAN® gene expression quantification assays (“TAQMAN® assays”) are well known to, and routinely performed by, those of ordinary skill in the art. TAQMAN® assays are performed in a two step reverse transcription/polymerase chain reaction (RT-PCR). In the first (RT) step, cDNA is reverse transcribed from total RNA samples using random hexamer primers. In the second (PCR) step, PCR products are synthesized from the cDNA using gene specific primers.

[0060] To quantify gene expression the TAQMAN® PCR reaction exploits the 5′ nuclease activity of AMPLITAQ GOLD® DNA Polymerase to cleave a TAQMAN® probe (distinct from the primers) during PCR. The TAQMAN® probe contains a reporter dye at the 5′-end of the probe and a quencher dye at the 3′ end of the probe. When the probe is intact, the proximity of the reporter dye to the quencher dye results in suppression of the reporter fluorescence. During PCR, if the target of interest is present, the probe specifically anneals between the forward and reverse primer sites. AMPLITAQ GOLD® DNA Polymerase then cleaves the probe between the reporter and quencher when the probe hybridizes to the target, resulting in increased fluorescence of the reporter (see FIG. 2). Accumulation of PCR products is detected directly by monitoring the increase in fluorescence of the reporter dye.

[0061] After the probe fragments are displaced from the target, polymerization of the strand continues. The 3′-end of the probe is blocked to prevent extension of the probe during PCR. This process occurs in every cycle and does not interfere with the exponential accumulation of product. The increase in fluorescence signal is detected only if the target sequence is complementary to the probe and is amplified during PCR. Because of these requirements, any nonspecific amplification is not detected.

[0062] For test sample preparation, vector controls or constructs containing the coding sequence for the gene of interest are transfected into cells, such as for example 293T cells, and supernatants collected after 48 hours. For cell treatment and RNA isolation, multiple primary human cells or human cell lines are used; such cells may include but are not limited to, Normal Human Dermal Fibroblasts, Aortic Smooth Muscle, Human Umbilical Vein Endothelial Cells, HepG2, Daudi, Jurkat, U937, Caco, and THP-1 cell lines. Cells are plated in growth media and growth is arrested by culturing without media change for 3 days, or by switching cells to low serum media and incubating overnight. Cells are treated for 1, 6, or 24 hours with either vector control supernatant or sample supernatant (or purified/partially purified protein preparations in buffer). Total RNA is isolated; for example, by using Trizol extraction or by using the Ambion RNAQUEOUS®-4PCR RNA isolation system. Expression levels of multiple genes are analyzed using TAQMAN®, and expression in the test sample is compared to control vector samples to identify genes induced or repressed. Each of the above described techniques are well known to, and routinely performed by, those of ordinary skill in the art.

[0063] Table 1F indicates particular disease classes and preferred indications for which polynucleotides, polypeptides, or antibodies of the present invention may be used in. detecting, diagnosing, preventing, treating and/or ameliorating said diseases and disorders based on “target” gene expression patterns which may be up- or down-regulated by polynucleotides (and the encoded polypeptides) corresponding to each indicated cDNA Clone ID (shown in Table 1F, Column 2).

[0064] Thus, in preferred embodiments, the present invention encompasses a method of detecting, diagnosing, preventing, treating, and/or ameliorating a disease or disorder listed in the “Disease Class” and/or “Preferred Indication” columns of Table 1F; comprising administering to a patient in which such detection, diagnosis, prevention, or treatment is desired a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) in an amount effective to detect, diagnose, prevent, treat, or ameliorate the disease or disorder. The first and second columns of Table 1D show the “Gene No.” and “cDNA Clone ID No.”, respectively, indicating certain nucleic acids and proteins (or antibodies against the same) of the invention (including polynucleotide, polypeptide, and antibody fragments or variants thereof) that may be used in detecting, diagnosing, preventing, treating, or ameliorating the disease(s) or disorder(s) indicated in the corresponding row in the “Disease Class” or “Preferred Indication” Columns of Table 1F.

[0065] In another embodiment, the present invention also encompasses methods of detecting, diagnosing, preventing, treating, or ameliorating a disease or disorder listed in the “Disease Class” or “Preferred Indication” Columns of Table 1F; comprising administering to a patient combinations of the proteins, nucleic acids, or antibodies of the invention (or fragments or variants thereof), sharing similar indications as shown in the corresponding rows in the “Disease Class” or “Preferred Indication” Columns of Table 1F.

[0066] The “Disease Class” Column of Table 1F provides a categorized descriptive heading for diseases, disorders, and/or conditions (more fully described below) that may be detected, diagnosed, prevented, treated, or ameliorated by a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof).

[0067] The “Preferred Indication” Column of Table 1F describes diseases, disorders, and/or conditions that may be detected, diagnosed, prevented, treated, or ameliorated by a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof).

[0068] The “Cell Line” and “Exemplary Targets” Columns of Table 1F indicate particular cell lines and target genes, respectively, which may show altered gene expression patterns (i.e., up- or down-regulation of the indicated target gene) in TAQMAN® assays, performed as described above, utilizing polynucleotides of the cDNA Clone ID shown in the corresponding row. Alteration of expression patterns of the indicated “Exemplary Target” genes is correlated with a particular “Disease Class” and/or “Preferred Indication” as shown in the corresponding row under the respective column headings.

[0069] The “Exemplary Accessions” Column indicates GenBank Accessions (available online through the National Center for Biotechnology Information (NCBI)) which correspond to the “Exemplary Targets” shown in the adjacent row.

[0070] The recitation of “Cancer” in the “Disease Class” Column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof) may be used for example, to detect, diagnose, prevent, treat, and/or ameliorate neoplastic diseases and/or disorders (e.g., leukemias, cancers, etc., as described below under “Hyperproliferative Disorders”).

[0071] The recitation of “Immune” in the “Disease Class” column indicates that the corresponding nucleic acid and protein, or antibody against the sarne, of the invention (or fragment or variant thereof), may be used for example, to detect, diagnose, prevent, treat, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), blood disorders (e.g., as described below under “Immune Activity” “Cardiovascular Disorders” and/or “Blood-Related Disorders”), and infections (e.g., as described below under “Infectious Disease”).

[0072] The recitation of “Angiogenesis” in the “Disease Class” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to detect, diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), diseases and/or disorders of the cardiovascular system (e.g., as described below under “Cardiovascular Disorders”), diseases and/or disorders involving cellular and genetic abnormalities (e.g., as described below under “Diseases at the Cellular level”), diseases and/or disorders involving angiogenesis (e.g., as described below under “Anti-Angiogenesis Activity”), to promote or inhibit cell or tissue regeneration (e.g., as described below under “Regeneration”), or to promote wound healing (e.g., as described below under “Wound Healing and Epithelial Cell Proliferation”).

[0073] The recitation of “Diabetes” in the “Disease Class” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to detect, diagnose, treat, prevent, and/or ameliorate diabetes (including diabetes mellitus types I and II), as well as diseases and/or disorders associated with, or consequential to, diabetes (e.g. as described below under “Endocrine Disorders,” “Renal Disorders,” and “Gastrointestinal Disorders”).

Description of Table 1F

[0074] Polynucleotides encoding polypeptides of the present invention can be used in assays to test for one or more biological activities. One such biological activity which may be tested includes the ability of polynucleotides and polypeptides of the invention to stimulate up-regulation or down-regulation of expression of particular genes and proteins. Hence, if polynucleotides and polypeptides of the present invention exhibit activity in altering particular gene and protein expression patterns, it is likely that these polynucleotides and polypeptides of the present invention may be involved in, or capable of effecting changes in, diseases associated with the altered gene and protein expression profiles. Hence, polynucleotides, polypeptides, or antibodies of the present invention could be used to treat said associated diseases.

[0075] TAQMAN® assays may be performed to assess the ability of polynucleotides (and polypeptides they encode) to alter the expression pattern of particular “target” genes. TAQMAN® reactions are performed to evaluate the ability of a test agent to induce or repress expression of specific genes in different cell types. TAQMAN® gene expression quantification assays (“TAQMAN® assays”) are well known to, and routinely performed by, those of ordinary skill in the art. TAQMAN® assays are performed in a two step reverse transcription/polymerase chain reaction (RT-PCR). In the first (RT) step, cDNA is reverse transcribed from total RNA samples using random hexamer primers. In the second (PCR) step, PCR products are synthesized from the cDNA using gene specific primers.

[0076] To quantify gene expression the TAQMAN® PCR reaction exploits the 5′ nuclease activity of AMPLITAQ GOLD® DNA Polymerase to cleave a TAQMAN® probe (distinct from the primers) during PCR. The TAQMAN® probe contains a reporter dye at the 5′-end of the probe and a quencher dye at the 3′ end of the probe. When the probe is intact, the proximity of the reporter dye to the quencher dye results in suppression of the reporter fluorescence. During PCR, if the target of interest is present, the probe specifically anneals between the forward and reverse primer sites. AMPLITAQ GOLD® DNA Polymerase then cleaves the probe between the reporter and quencher when the probe hybridizes to the target, resulting in increased fluorescence of the reporter (see FIG. 2). Accumulation of PCR products is detected directly by monitoring the increase in fluorescence of the reporter dye.

[0077] After the probe fragments are displaced from the target, polymerization of the strand continues. The 3′-end of the probe is blocked to prevent extension of the probe during PCR. This process occurs in every cycle and does not interfere with the exponential accumulation of product. The increase in fluorescence signal is detected only if the target sequence is complementary to the probe and is amplified during PCR. Because of these requirements, any nonspecific amplification is not detected.

[0078] For test sample preparation, vector controls or constructs containing the coding sequence for the gene of interest are transfected into cells, such as for example 293T cells, and supernatants collected after 48 hours. For cell treatment and RNA isolation, multiple primary human cells or human cell lines are used; such cells may include but are not limited to, Normal Human Dermal Fibroblasts, Aortic Smooth Muscle, Human Umbilical Vein Endothelial Cells, HepG2, Daudi, Jurkat, U937, Caco, and THP-1 cell lines. Cells are plated in growth media and growth is arrested by culturing without media change for 3 days, or by switching cells to low serum media and incubating overnight. Cells are treated for 1, 6, or 24 hours with either vector control supematant or sample supernatant (or purified/partially purified protein preparations in buffer). Total RNA is isolated; for example, by using Trizol extraction or by using the Ambion RNAQUEOUS®-4PCR RNA isolation system. Expression levels of multiple genes are analyzed using TAQMAN®, and expression in the test sample is compared to control vector samples to identify genes induced or repressed. Each of the above described techniques are well known to, and routinely performed by, those of ordinary skill in the art.

[0079] Table 1F indicates particular disease classes and preferred indications for which polynucleotides, polypeptides, or antibodies of the present invention may be used in detecting, diagnosing, preventing, treating and/or ameliorating said diseases and disorders based on “target” gene expression patterns which may be up- or down-regulated by polynucleotides (and the encoded polypeptides) corresponding to each indicated cDNA Clone ID (shown in Table 1F, Column 2).

[0080] Thus, in preferred embodiments, the present invention encompasses a method of detecting, diagnosing, preventing, treating, and/or ameliorating a disease or disorder listed in the “Disease Class” and/or “Preferred Indication” columns of Table 1F; comprising administering to a patient in which such detection, diagnosis, prevention, or treatment is desired a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) in an amount effective to detect, diagnose, prevent, treat, or ameliorate the disease or disorder. The first and second columns of Table 1D show the “Gene No.” and “cDNA Clone ID No.”, respectively, indicating certain nucleic acids and proteins (or antibodies against the same) of the invention (including polynucleotide, polypeptide, and antibody fragments or variants thereof) that may be used in detecting, diagnosing, preventing, treating, or ameliorating the disease(s) or disorder(s) indicated in the corresponding row in the “Disease Class” or “Preferred Indication” Columns of Table 1F.

[0081] In another embodiment, the present invention also encompasses methods of detecting, diagnosing, preventing, treating, or ameliorating a disease or disorder listed in the “Disease Class” or “Preferred Indication” Columns of Table 1F; comprising administering to a patient combinations of the proteins, nucleic acids, or antibodies of the invention (or fragments or variants thereof), sharing similar indications as shown in the corresponding rows in the “Disease Class” or “Preferred Indication” Columns of Table 1F.

[0082] The “Disease Class” Column of Table 1F provides a categorized descriptive heading for diseases, disorders, and/or conditions (more fully described below) that may be detected, diagnosed, prevented, treated, or ameliorated by a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof).

[0083] The “Preferred Indication” Column of Table 1F describes diseases, disorders, and/or conditions that may be detected, diagnosed, prevented, treated, or ameliorated by a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof).

[0084] The “Cell Line” and “Exemplary Targets” Columns of Table 1F indicate particular cell lines and target genes, respectively, which may show altered gene expression patterns (i.e., up- or down-regulation of the indicated target gene) in TAQMAN® assays, performed as described above, utilizing polynucleotides of the cDNA Clone ID shown in the corresponding row. Alteration of expression patterns of the indicated “Exemplary Target” genes is correlated with a particular “Disease Class” and/or “Preferred Indication” as shown in the corresponding row under the respective column headings.

[0085] The “Exemplary Accessions” Column indicates GenBank Accessions (available online through the National Center for Biotechnology Information (NCBI)) which correspond to the “Exemplary Targets” shown in the adjacent row.

[0086] The recitation of “Cancer” in the “Disease Class” Column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof) may be used for example, to detect, diagnose, prevent, treat, and/or ameliorate neoplastic diseases and/or disorders (e.g., leukemias, cancers, etc., as described below under “Hyperproliferative Disorders”).

[0087] The recitation of “Immune” in the “Disease Class” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to detect, diagnose, prevent, treat, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), blood disorders (e.g., as described below under “Immune Activity” “Cardiovascular Disorders” and/or “Blood-Related Disorders”), and infections (e.g., as described below under “Infectious Disease”).

[0088] The recitation of “Angiogenesis” in the “Disease Class” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to detect, diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), diseases and/or disorders of the cardiovascular system (e.g., as described below under “Cardiovascular Disorders”), diseases and/or disorders involving cellular and genetic abnormalities (e.g., as described below under “Diseases at the Cellular Level”), diseases and/or disorders involving angiogenesis (e.g., as described below under “Anti-Angiogenesis Activity”), to promote or inhibit cell or tissue regeneration (e.g., as described below under “Regeneration”), or to promote wound healing (e.g., as described below under “Wound Healing and Epithelial Cell Proliferation”).

[0089] The recitation of “Diabetes” in the “Disease Class” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to detect, diagnose, treat, prevent, and/or ameliorate diabetes (including diabetes mellitus types I and II), as well as diseases and/or disorders associated with, or consequential to, diabetes (e.g. as described below under “Endocrine Disorders,” “Renal Disorders,” and “Gastrointestinal Disorders”).

Description of Table 2

[0090] Table 2 summarizes homology and features of some of the polypeptides of the invention. The first column provides a unique clone identifier, “Clone ID:”, corresponding to a cDNA clone disclosed in Table 1A or 1B. The second column provides the unique contig identifier, “Contig ID:” corresponding to contigs in Table 1B and allowing for correlation with the information in Table 1B. The third column provides the sequence identifier, “SEQ ID NO:X”, for the contig polynucleotide sequence. The fourth column provides the analysis method by which the homology/identity disclosed in the Table was determined. Comparisons were made between polypeptides encoded by the polynucleotides of the invention and either a non-redundant protein database (herein referred to as “NR”), or a database of protein families (herein referred to as “PFAM”) as further described below. The fifth column provides a description of the PFAM/NR hit having a significant match to a polypeptide of the invention. Column six provides the accession number of the PFAMINR hit disclosed in the fifth column. Column seven, “Score/Percent Identity”, provides a quality score or the percent identity, of the hit disclosed in columns five and six. Columns 8 and 9, “NT From” and “NT To” respectively, delineate the polynucleotides in “SEQ ID NO:X” that encode a polypeptide having a significant match to the PFAM/NR database as disclosed in the fifth and sixth columns. In specific embodiments polypeptides of the invention comprise, or alternatively consist of, an amino acid sequence encoded by a polynucleotide in SEQ ID NO:X as delineated in columns 8 and 9, or fragments or variants thereof.

Description of Table 3

[0091] Table 3 provides polynucleotide sequences that may be disclaimed according to certain embodiments of the invention. The first column provides a unique clone identifier, “Clone ID”, for a cDNA clone related to contig sequences disclosed in Table 1B. The second column provides the sequence identifier, “SEQ ID NO:X”, for contig sequences disclosed in Table 1A and/or 1B. The third column provides the unique contig identifier, “Contig ID:”, for contigs disclosed in Table 1B. The fourth column provides a unique integer ‘a’ where ‘a’ is any integer between 1 and the final nucleotide minus 15 of SEQ ID NO:X, and the fifth column provides a unique integer ‘b’ where ‘b’ is any integer between 15 and the final nucleotide of SEQ ID NO:X, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:X, and where b is greater than or equal to a +14. For each of the polynucleotides shown as SEQ ID NO:X, the uniquely defined integers can be substituted into the general formula of a−b, and used to describe polynucleotides which may be preferably excluded from the invention. In certain embodiments, preferably excluded from the invention are at least one, two, three, four, five, ten, or more of the polynucleotide sequence(s) having the accession number(s) disclosed in the sixth column of this Table (including for example, published sequence in connection with a particular BAC clone). In further embodiments, preferably excluded from the invention are the specific polynucleotide sequence(s) contained in the clones corresponding to at least one, two, three, four, five, ten, or more of the available material having the accession numbers identified in the sixth column of this Table (including for example, the actual sequence contained in an identified BAC clone).

Description of Table 4

[0092] Table 4 provides a key to the tissue/cell source identifier code disclosed in Table 1B.2, column 5. Column 1 provides the tissue/cell source identifier code disclosed in Table 1B.2, Column 5. Columns 2-5 provide a description of the tissue or cell source. Note that “Description” and “Tissue” sources (i.e. columns 2 and 3) having the prefix “a_” indicates organs, tissues, or cells derived from “adult” sources. Codes corresponding to diseased tissues are indicated in column 6 with the word “disease.” The use of the word “disease” in column 6 is non-limiting. The tissue or cell source may be specific (e.g. a neoplasm), or may be disease-associated (e.g., a tissue sample from a normal portion of a diseased organ). Furthermore, tissues and/or cells lacking the “disease” designation may still be derived from sources directly or indirectly involved in a disease state or disorder, and therefore may have a further utility in that disease state or disorder. In numerous cases where the tissue/cell source is a library, column 7 identifies the vector used to generate the library.

Description of Table 5

[0093] Table 5 provides a key to the OMIM reference identification numbers disclosed in Table 1B.1, column 9. OMIM reference identification numbers (Table 5, Column 1) were derived from Online Mendelian Inheritance in Man (Online Mendelian Inheritance in Man, OMIM. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, Md.) and National Center for Biotechnology Information, National Library of Medicine, (Bethesda, Md.) 2000. World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/). Column 2 provides diseases associated with the cytologic band disclosed in Table 1B.1, column 8, as determined using the Morbid Map database.

Description of Table 6

[0094] Table 6 summarizes some of the ATCC Deposits, Deposit dates, and ATCC designation numbers of deposits made with the ATCC in connection with the present application. These deposits were made in addition to those described in the Table 1A.

Description of Table 7

[0095] Table 7 shows the cDNA libraries sequenced, and ATCC designation numbers and vector information relating to these cDNA libraries.

[0096] The first column shows the first four letters indicating the Library from which each library clone was derived. The second column indicates the catalogued tissue description for the corresponding libraries. The third column indicates the vector containing the corresponding clones. The fourth column shows the ATCC deposit designation for each libray clone as indicated by the deposit information in Table 6.

[0097] The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

[0098] In the present invention, “isolated” refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered “by the hand of man” from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be “isolated” because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide. The term “isolated” does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by electrophoresis and transferred onto blots), sheared whole cell genomic DNA preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotide/sequences of the present invention.

[0099] In the present invention, a “secreted” protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a “mature” protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

[0100] As used herein, a “polynucleotide” refers to a molecule having a nucleic acid sequence encoding SEQ ID NO:Y or a fragment or variant thereof (e.g., the polypeptide delinated in columns fourteen and fifteen of Table 1A); a nucleic acid sequence contained in SEQ ID NO:X (as described in column 5 of Table 1A and/or column 3 of Table 1B) or the complement thereof; a cDNA sequence contained in Clone ID: (as described in column 2 of Table 1A and/or 1B and contained within a library deposited with the ATCC); a nucleotide sequence encoding the polypeptide encoded by a nucleotidc sequence in SEQ ID NO:B as defined in column 6 (EXON From-To) of Table 1C or a fragment or variant thereof; or a nucleotide coding sequence in SEQ ID NO:B as defined in column 6 of Table 1C or the complement thereof. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5′ and 3′ untranslated sequences, the coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a “polypeptide” refers to a molecule having an amino acid sequence encoded by a polynucleotide of the invention as broadly defined (obviously excluding poly-Phenylalanine or poly-Lysine peptide sequences which result from translation of a polyA tail of a sequence corresponding to a cDNA).

[0101] In the present invention, “SEQ ID NO:X” was often generated by overlapping sequences contained in multiple clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X is deposited at Human Genome Sciences, Inc. (HGS) in a catalogued and archived library. As shown, for example, in column 2 of Table 1B, each clone is identified by a cDNA Clone ID (identifier generally referred to herein as Clone ID:). Each Clone ID is unique to an individual clone and the Clone ID is all the information needed to retrieve a given clone from the HGS library. Table 7 provides a list of the deposited cDNA libraries. One can use the Clone ID: to determine the library source by reference to Tables 6 and 7. Table 7 lists the deposited cDNA libraries by name and links each library to an ATCC Deposit. Library names contain four characters, for example, “HTWE.” The name of a cDNA clone (Clone ID) isolated from that library begins with the same four characters, for example “HTWEP07”. As mentioned below, Table 1A and/or 1B correlates the Clone ID names with SEQ ID NO:X. Thus, starting with an SEQ ID NO:X, one can use Tables 1A, 1B, 6, 7, and 9 to determine the corresponding Clone ID, which library it came from and which ATCC deposit the library is contained in. Furthermore, it is possible to retrieve a given cDNA clone from the source library by techniques known in the art and described elsewhere herein. The ATCC is located at 10801 University Boulevard, Manassas, Va. 20110-2209, USA. The ATCC deposits were made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure.

[0102] In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5 kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5′ or 3′ to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

[0103] A “polynucleotide” of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, or the complement thereof (e.g., the complement of any one, two, three, four, or more of the polynucleotide fragments described herein), the polynucleotide sequence delineated in columns 7 and 8 of Table 1A or the complement thereof, the polynucleotide sequence delineated in columns 8 and 9 of Table 2 or the complement thereof, and/or cDNA sequences contained in Clone ID: (e.g., the complement of any one, two, three, four, or more of the polynucleotide fragments, or the cDNA clone within the pool of cDNA clones deposited with the ATCC, described herein), and/or the polynucleotide sequence delineated in column 6 of Table 1C or the complement thereof. “Stringent hybridization conditions” refers to an overnight incubation at 42 degree C. in a solution comprising 50% fornamide, 5× SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5× Denhardt's solution, 10% dextran sulfate, and 20 μg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1× SSC at about 65 degree C.

[0104] Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37 degree C. in a solution comprising 6× SSPE (20× SSPE=3M NaCl; 0.2M NaH₂PO₄; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 ug/ml salmon sperm blocking DNA; followed by washes at 50 degree C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5×SSC).

[0105] Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

[0106] Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3′ terminal polyA+ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of “polynucleotide,” since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

[0107] The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. “Modified” bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, “polynucleotide” embraces chemically, enzymatically, or metabolically modified forms.

[0108] In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5 kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5′ or 3′ to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

[0109] “SEQ ID NO:X” refers to a polynucleotide sequence described in column 5 of Table 1A, while “SEQ ID NO:Y” refers to a polypeptide sequence described in column 10 of Table 1A. SEQ ID NO:X is identified by an integer specified in column 6 of Table 1A. The polypeptide sequence SEQ ID NO:Y is a translated open reading frame (ORF) encoded by polynucleotide SEQ ID NO:X. The polynucleotide sequences are shown in the sequence listing immediately followed by all of the polypeptide sequences. Thus, a polypeptide sequence corresponding to polynucleotide sequence SEQ ID NO:2 is the first polypeptide sequence shown in the sequence listing. The second polypeptide sequence corresponds to the polynucleotide sequence shown as SEQ ID NO:3, and so on.

[0110] The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS—STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth. Enzymol. 182:626-646 (1990); Rattan et al., Ann. N.Y. Acad. Sci. 663:48-62 (1992)).

[0111] “SEQ ID NO:X” refers to a polynucleotide sequence described, for example, in Tables 1A, 1B or 2, while “SEQ ID NO:Y” refers to a polypeptide sequence described in column 11 of Table 1A and or column 6 of Table 1B.1. SEQ ID NO:X is identified by an integer specified in column 4 of Table 1B.1. The polypeptide sequence SEQ ID NO:Y is a translated open reading frame (ORF) encoded by polynucleotide SEQ ID NO:X. “Clone ID:” refers to a cDNA clone described in column 2 of Table 1A and/or 1B.

[0112] “A polypeptide having functional activity” refers to a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) protein. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a polypeptide for binding) to an anti-polypeptide antibody], immunogenicity (ability to generate antibody which binds to a specific polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide.

[0113] The polypeptides of the invention can be assayed for functional activity (e.g. biological activity) using or routinely modifying assays known in the art, as well as assays described herein. Specifically, one of skill in the art may routinely assay secreted polypeptides (including fragments and variants) of the invention for activity using assays as described in the examples section below.

[0114] “A polypeptide having biological activity” refers to a polypeptide exhibiting activity similar to, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention).

Table 1A

[0115] Table 1A summarizes information concerning certain polypnucleotides and polypeptides of the invention. The first column provides the gene number in the application for each clone identifier. The second column provides a unique clone identifier, “Clone ID:”, for a cDNA clone related to each contig sequence disclosed in Table 1A. Third column, the cDNA Clones identified in the second column were deposited as indicated in the third column (i.e. by ATCC Deposit No:Z and deposit date). Some of the deposits contain multiple different clones corresponding to the same gene. In the fourth column, “Vector” refers to the type of vector contained in the corresponding cDNA Clone identified in the second column. In the fifth column, the nucleotide sequence identified as “NT SEQ ID NO:X” was assembled from partially homologous (“overlapping”) sequences obtained from the corresponding cDNA clone identified in the second column and, in some cases, from additional related cDNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X. In the sixth column, “Total NT Seq.” refers to the total number of nucleotides in the contig sequence identified as SEQ ID NO:X.” The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as “5′ NT of Clone Seq.” (seventh column) and the “3′ NT of Clone Seq.” (eighth column) of SEQ ID NO:X. In the ninth column, the nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as “5′ NT of Start Codon.” Similarly, in column ten, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as “5′ NT of First AA of Signal Pep.” In the eleventh column, the translated amino acid sequence, beginning with the methionine, is identified as “AA SEQ ID NO:Y,” although other reading frames can also be routinely translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

[0116] In the twelfth and thirteenth columns of Table 1A, the first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as “First AA of Sig Pep” and “Last AA of Sig Pep.” In the fourteenth column, the predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as “Predicted First AA of Secreted Portion”. The amino acid position of SEQ ID NO:Y of the last amino acid encoded by the open reading frame is identified in the fifteenth column as “Last AA of ORF”.

[0117] SEQ ID NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing) and the translated SEQ ID NO:Y (where Y may be any of the polypeptide sequences disclosed in the sequence listing) are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used, for example, to generate antibodies which bind specifically to proteins containing the polypeptides and the secreted proteins encoded by the cDNA clones identified in Table 1A and/or elsewhere herein.

[0118] Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

[0119] Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X, and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1A. The nucleotide sequence of each deposited plasmid can readily be determined by sequencing the deposited plasmid in accordance with known methods

[0120] The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular plasmid can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

[0121] Also provided in Table 1A is the name of the vector which contains the cDNA plasmid. Each vector is routinely used in the art. The following additional information is provided for convenience.

[0122] Vectors Lambda Zap (U.S. Pat. Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Pat. Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Pat. Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, Calif., 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Phagemid pBS may be excised from the Lambda Zap and Uni-Zap XR vectors, and phagemid pBK may be excised from the Zap Express vector. Both phagemids may be transformed into E. coli strain XL-1 Blue, also available from Stratagene

[0123] Vectors pSport1, pCMVSport 1.0, pCMVSport 2.0 and pCMVSport 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, Md. 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. See, for instance, Gruber, C. E., et al., Focus 15:59 (1993). Vector lafmid BA (Bento Soares, Columbia University, New York, N.Y.) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR®2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, Calif. 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).

[0124] The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, and/or a deposited cDNA (cDNA Clone ID). The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include, but are not limited to, preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

[0125] Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X and SEQ ID NO:Y using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

[0126] The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X and/or a cDNA contained in ATCC Deposit No.Z. The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X, and/or a polypeptide encoded by a cDNA contained in ATCC deposit No.Z. Polynucleotides encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X and/or a polypeptide encoded by the cDNA contained in ATCC Deposit No.Z, are also encompassed by the invention. The present invention further encompasses a polynucleotide comprising, or alternatively consisting of the complement of the nucleic acid sequence of SEQ ID NO:X, and/or the complement of the coding strand of the cDNA contained in ATCC Deposit No.Z.

[0127]

Lengthy table referenced here
US07368531-20080506-T00001
Please refer to the end of the specification for access instructions.

Table 1B (Comprised of Tables 1B.1 and 1B.2)

[0128] The first column in Table 1B.1 and Table 1B.2 provides the gene number in the application corresponding to the clone identifier. The second column in Table 1B.1 and Table 1B.2 provides a unique “Clone ID:” for the cDNA clone related to each contig sequence disclosed in Table 1B.I and Table 1B.2. This clone ID references the cDNA clone which contains at least the 5′ most sequence of the assembled contig and at least a portion of SEQ ID NO:X as determined by directly sequencing the referenced clone. The referenced clone may have more sequence than described in the sequence listing or the clone may have less. In the vast majority of cases, however, the clone is believed to encode a full-length polypeptide. In the case where a clone is not full-length, a full-length cDNA can be obtained by methods described elsewhere herein. The third column in Table 1B.1 and Table 1B.2 provides a unique “Contig ID” identification for each contig sequence. The fourth column in Table 1B.1 and Table 1B.2 provides the “SEQ ID NO:” identifier for each of the contig polynucleotide sequences disclosed in Table 1B.

Table 1B.1

[0129] The fifth column in Table 1B.1, “ORF (From-To)”, provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence “SEQ ID NO:X” that delineate the preferred open reading frame (ORF) shown in the sequence listing and referenced in Table 1B.1, column 6, as SEQ ID NO:Y. Where the nucleotide position number “To” is lower than the nucleotide position number “From”, the preferred ORF is the reverse complement of the referenced polynucleotide sequence. The sixth column in Table 1B.1 provides the corresponding SEQ ID NO:Y for the polypeptide sequence encoded by the preferred ORF delineated in column 5. In one embodiment, the invention provides an amino acid sequence comprising, or alternatively consisting of, a polypeptide encoded by the portion of SEQ ID NO:X delineated by “ORF (From-To)”. Also provided are polynucleotides encoding such amino acid sequences and the complementary strand thereto. Column 7 in Table 1B.1 lists residues comprising epitopes contained in the polypeptides encoded by the preferred ORF (SEQ ID NO:Y), as predicted using the algorithm of Jameson and Wolf, (1988) Comp. Appl. Biosci. 4:181-186. The Jameson-Wolf antigenic analysis was performed using the computer program PROTEAN (Version 3.11 for the Power Maclntosh, DNASTAR, Inc., 1228 South Park Street Madison, Wis.). In specific embodiments, polypeptides of the invention comprise, or altematively consist of, at least one, two, three, four, five or more of the predicted epitopes as described in Table 1B. It will be appreciated that depending on the analytical criteria used to predict antigenic determinants, the exact address of the determinant may vary slightly.

[0130] Column 8 in Table 1B.1 provides a chromosomal map location for certain polynucleotides of the invention. Chromosomal location was determined by finding exact matches to EST and cDNA sequences contained in the NCBI (National Center for Biotechnology Information) UniGene database. Each sequence in the UniGene database is assigned to a “cluster”; all of the ESTs, cDNAs, and STSs in a cluster are believed to be derived from a single gene. Chromosomal mapping data is often available for one or more sequence(s) in a UniGene cluster; this data (if consistent) is then applied to the cluster as a whole. Thus, it is possible to infer the chromosomal location of a new polynucleotide sequence by determining its identity with a mapped UniGene cluster.

[0131] A modified version of the computer program BLASTN (Altshul, et al., J. Mol. Biol. 215:403-410 (1990), and Gish, and States, Nat. Genet. 3:266-272) (1993) was used to search the UniGene database for EST or cDNA sequences that contain exact or near-exact matches to a polynucleotide sequence of the invention (the ‘Query’). A sequence from the UniGene database (the ‘Subject’) was said to be an exact match if it contained a segment of 50 nucleotides in length such that 48 of those nucleotides were in the same order as found in the Query sequence. If all of the matches that met this criteria were in the same UniGene cluster, and mapping data was available for this cluster, it is indicated in Table 1B under the heading “Cytologic Band”. Where a cluster had been further localized to a distinct cytologic band, that band is disclosed; where no banding information was available, but the gene had been localized to a single chromosome, the chromosome is disclosed.

[0132] Once a presumptive chromosomal location was determined for a polynucleotide of the invention, an associated disease locus was identified by comparison with a database of diseases which have been experimentally associated with genetic loci. The database used was the Morbid Map, derived from OMIM™ and National Center for Biotechnology Information, National Library of Medicine (Bethesda, Md.) 2000;. If the putative chromosomal location of a polynucleotide of the invention (Query sequence) was associated with a disease in the Morbid Map database, an OMIM reference identification number was noted in column 9, Table 1B.1, labelled “OMIM Disease Reference(s). Table 5 is a key to the OMIM reference identification numbers (column 1), and provides a description of the associated disease in Column 2.

Table 1B.2

[0133] Column 5, in Table 1B.2, provides an expression profile and library Code:Count for each of the contig sequences (SEQ ID NO:X) disclosed in Table 1B, which can routinely be combined with the information provided in Table 4 and used to determine the tissues, cells, and/or cell line libraries which predominantly express the polynucleotides of the invention. The first number in Table 1B.2, column 5 (preceding the colon), represents the tissue/cell source identifier code corresponding to the code and description provided in Table 4. The second number in column 5 (following the colon) represents the number of times a sequence corresponding to the reference polynucleotide sequence was identified in the corresponding tissue/cell source. Those tissue/cell source identifier codes in which the first two letters are “AR” designate information generated using DNA array technology. Utilizing this technology, cDNAs were amplified by PCR and then transferred, in duplicate, onto the array. Gene expression was assayed through hybridization of first strand cDNA probes to the DNA array. cDNA probes were generated from total RNA extracted from a variety of different tissues and cell lines. Probe synthesis was performed in the presence of ³³P dCTP, using oligo (dT) to prime reverse transcription. After hybridization, high stringency washing conditions were employed to remove non-specific hybrids from the array. The remaining signal, emanating from each gene target, was measured using a Phosphorimager. Gene expression was reported as Phosphor Stimulating Luminescence (PSL) which reflects the level of phosphor signal generated from the probe hybridized to each of the gene targets represented on the array. A local background signal subtraction was performed before the total signal generated from each array was used to normalize gene expression between the different hybridizations. The value presented after “[array code]:” represents the mean of the duplicate values, following background subtraction and probe normalization. One of skill in the art could routinely use this information to identify normal and/or diseased tissue(s) which show a predominant expression pattern of the corresponding polynucleotide of the invention or to identify polynucleotides which show predominant and/or specific tissue and/or cell expression.

[0134]

Lengthy table referenced here
US07368531-20080506-T00002
Please refer to the end of the specification for access instructions.

[0135]

Lengthy table referenced here
US07368531-20080506-T00003
Please refer to the end of the specification for access instructions.

[0136] Table 1C summarizes additional polynucleotides encompassed by the invention (including cDNA clones related to the sequences (Clone ID:), contig sequences (contig identifier (Contig ID:) contig nucleotide sequence identifiers (SEQ ID NO:X)), and genomic sequences (SEQ ID NO:B). The first column provides a unique clone identifier, “Clone ID:”, for a cDNA clone related to each contig sequence. The second column provides the sequence identifier, “SEQ ID NO:X”, for each contig sequence. The third column provides a unique contig identifier, “Contig ID:” for each contig sequence. The fourth column, provides a BAC identifier “BAC ID NO:A” for the BAC clone referenced in the corresponding row of the table. The fifth column provides the nucleotide sequence identifier, “SEQ ID NO:B” for a fragment of the BAC clone identified in column four of the corresponding row of the table. The sixth column, “Exon From-To”, provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence of SEQ ID NO:B which delineate certain polynucleotides of the invention that are also exemplary members of polynucleotide sequences that encode polypeptides of the invention (e.g., polypeptides containing amino acid sequences encoded by the polynucleotide sequences delineated in column six, and fragments and variants thereof).

[0137]

Lengthy table referenced here
US07368531-20080506-T00004
Please refer to the end of the specification for access instructions.

[0138] Tables 1D and 1E: The polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists could be used to treat the associated disease.

[0139] The present invention encompasses methods of detecting, preventing, diagnosing, prognosticating, treating, and/or ameliorating a disease or disorder. In preferred embodiments, the present invention encompasses a method of treating a disease or disorder listed in the “Preferred Indications” columns of Table 1D and Table 1E; comprising administering to a patient (in which such treatment, prevention, or amelioration is desired) a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) in an amount effective to treat, prevent, diagnose, or ameliorate the disease or disorder. The first and second columns of Table 1D show the “Gene No.” and “cDNA Clone ID No.”, respectively, indicating certain nucleic acids and proteins (or antibodies against the same) of the invention (including polynucleotide, polypeptide, and antibody fragments or variants thereof) that may be used in preventing, treating, diagnosing, or ameliorating the disease(s) or disorder(s) indicated in the corresponding row in Column 3 of Table 1D.

[0140] In another embodiment, the present invention also encompasses methods of preventing, treating, diagnosing, or ameliorating a disease or disorder listed in the “Preferred Indications” column of Table 1D and Table 1E; comprising administering to a patient combinations of the proteins, nucleic acids, or antibodies of the invention (or fragments or variants thereof), sharing similar indications as shown in the corresponding rows in Column 3 of Table 1D.

[0141] The “Preferred Indications” columns of Table 1D and Table 1E describe diseases, disorders, and/or conditions that may be treated, prevented, diagnosed, or ameliorated by a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof).

[0142] The recitation of “Cancer” in the “Preferred Indications” columns indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof) may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., leukemias, cancers, and/or as described below under “Hyperproliferative Disorders”).

[0143] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Cancer” recitation in the “Preferred Indication” column of Table 1D may be used for example, to diagnose, treat, prevent, and/or ameliorate a neoplasm located in a tissue selected from the group consisting of: colon, abdomen, bone, breast, digestive system, liver, pancreas, prostate, peritoneum, lung, blood (e.g., leukemia), endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), uterus, eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

[0144] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Cancer” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a pre-neoplastic condition, selected from the group consisting of: hyperplasia (e.g., endometrial hyperplasia and/or as described in the section entitled “Hyperproliferative Disorders”), metaplasia (e.g., connective tissue metaplasia, atypical metaplasia, and/or as described in the section entitled “Hyperproliferative Disorders”), and/or dysplasia (e.g., cervical dysplasia, and bronchopulmonary dysplasia).

[0145] In another specific embodiment, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Cancer” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a benign dysproliferative disorder selected from the group consisting of: benign tumors, fibrocystic conditions, tissue hypertrophy, and/or as described in the section entitled “Hyperproliferative Disorders”.

[0146] The recitation of “Immune/Hematopoietic” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), blood disorders (e.g., as described below under “Immune Activity” “Cardiovascular Disorders” and/or “Blood-Related Disorders”), and infections (e.g., as described below under “Infectious Disease”).

[0147] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having the “Immune/Hematopoietic” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: anemia, pancytopenia, leukopenia, thrombocytopenia, leukemias, Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, asthma, AIDS, autoimmune disease, rheumatoid arthritis, granulomatous disease, immune deficiency, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, immune reactions to transplanted organs and tissues, systemic lupus erythematosis, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, and allergies.

[0148] The recitation of “Reproductive” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), and disorders of the reproductive system (e.g., as described below under “Reproductive System Disorders”).

[0149] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Reproductive” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: cryptorchism, prostatitis, inguinal hernia, varicocele, leydig cell tumors, verrucous carcinoma, prostatitis, malacoplakia, Peyronie's disease, penile carcinoma, squamous cell hyperplasia, dysmenorrhea, ovarian adenocarcinoma, Turner's syndrome, mucopurulent cervicitis, Sertoli-leydig tumors, ovarian cancer, uterine cancer, pelvic inflammatory disease, testicular cancer, prostate cancer, Klinefelter's syndrome, Young's syndrome, premature ejaculation, diabetes mellitus, cystic fibrosis, Kartagener's syndrome, testicular atrophy, testicular feminization, anorchia, ectopic testis, epididymitis, orchitis, gonorrhea, syphilis, testicular torsion, vasitis nodosa, germ cell tumors, stromal tumors, dysmenorrhea, retroverted uterus, endometriosis, fibroids, adenomyosis, anovulatory bleeding, amenorrhea, Cushing's syndrome, hydatidiform moles, Asherman's syndrome, premature menopause, precocious puberty, uterine polyps, dysfunctional uterine bleeding, cervicitis, chronic cervicitis, mucopurulent cervicitis, cervical dysplasia, cervical polyps, Nabothian cysts, cervical erosion, cervical incompetence, cervical neoplasms, pseudohermaphroditism, and premenstrual syndrome.

[0150] The recitation of “Musculoskeletal” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), and disorders of the immune system (e.g., as described below under “Immune Activity”).

[0151] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Musculoskeletal” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: bone cancers (e.g., osteochondromas, benign chondromas, chondroblastoma, chondromyxoid fibromas, osteoid osteomas, giant cell tumors, multiple myeloma, osteosarcomas), Paget's Disease, rheumatoid arthritis, systemic lupus erythematosus, osteomyelitis, Lyme Disease, gout, bursitis, tendonitis, osteoporosis, osteoarthritis, muscular dystrophy, mitochondrial myopathy, cachexia, and multiple sclerosis.

[0152] The recitation of “Cardiovascular” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), and disorders of the cardiovascular system (e.g., as described below under “Cardiovascular Disorders”).

[0153] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Cardiovascular” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: myxomas, fibromas, rhabdomyomas, cardiovascular abnormalities (e.g., congenital heart defects, cerebral arteriovenous malformations, septal defects), heart disease (e.g., heart failure, congestive heart disease, arrhythmia, tachycardia, fibrillation, pericardial Disease, endocarditis), cardiac arrest, heart valve disease (e.g., stenosis, regurgitation, prolapse), vascular disease (e.g., hypertension, coronary artery disease, angina, aneurysm, arteriosclerosis, peripheral vascular disease), hyponatremia, hypernatremia, hypokalemia, and hyperkalemia.

[0154] The recitation of “Mixed Fetal” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”).

[0155] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Mixed Fetal” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: spina bifida, hydranencephaly, neurofibromatosis, fetal alcohol syndrome, diabetes mellitus, PKU, Down's syndrome, Patau syndrome, Edwards syndrome, Turner syndrome, Apert syndrome, Carpenter syndrome, Conradi syndrome, Crouzon syndrome, cutis laxa, Cornelia de Lange syndrome, Ellis-van Creveld syndrome, Holt-Oram syndrome, Kartagener syndrome, Meckel-Gruber syndrome, Noonan syndrome, Pallister-Hall syndrome, Rubinstein-Taybi syndrome, Scimitar syndrome, Smith-Lemli-Opitz syndrome, thromocytopenia-absent radius (TAR) syndrome, Treacher Collins syndrome, Williams syndrome, Hirschsprung's disease, Meckel's diverticulum, polycystic kidney disease, Turner's syndrome, and gonadal dysgenesis, Klippel-Feil syndrome, Ostogenesis imperfecta, muscular dystrophy, Tay-Sachs disease, Wilm's tumor, neuroblastoma, and retinoblastoma.

[0156] The recitation of “Excretory” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”) and renal disorders (e.g., as described below under “Renal Disorders”).

[0157] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Excretory” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: bladder cancer, prostate cancer, benign prostatic hyperplasia, bladder disorders (e.g., urinary incontinence, urinary retention, urinary obstruction, urinary tract Infections, interstitial cystitis, prostatitis, neurogenic bladder, hematuria), renal disorders (e.g., hydronephrosis, proteinuria, renal failure, pyelonephritis, urolithiasis, reflux nephropathy, and unilateral obstructive uropathy).

[0158] The recitation of “Neural/Sensory” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”) and diseases or disorders of the nervous system (e.g., as described below under “Neural Activity and Neurological Diseases”).

[0159] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Neural/Sensory” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: brain cancer (e.g., brain stem glioma, brain tumors, central nervous system (Primary) lymphoma, central nervous system lymphoma, cerebellar astrocytoma, and cerebral astrocytoma, neurodegenerative disorders (e.g., Alzheimer's Disease, Creutzfeldt-Jakob Disease, Parkinson's Disease, and Idiopathic Presenile Dementia), encephalomyelitis, cerebral malaria, meningitis, metabolic brain diseases (e.g., phenylketonuria and pyruvate carboxylase deficiency), cerebellar ataxia, ataxia telangiectasia, and AIDS Dementia Complex, schizophrenia, attention deficit disorder, hyperactive attention deficit disorder, autism, and obsessive compulsive disorders.

[0160] The recitation of “Respiratory” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”) and diseases or disorders of the respiratory system (e.g., as described below under “Respiratory Disorders”).

[0161] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Respiratory” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: cancers of the respiratory system such as larynx cancer, pharynx cancer, trachea cancer, epiglottis cancer, lung cancer, squamous cell carcinomas, small cell (oat cell) carcinomas, large cell carcinomas, and adenocarcinomas. Allergic reactions, cystic fibrosis, sarcoidosis, histiocytosis X, infiltrative lung diseases (e.g., pulmonary fibrosis and lymphoid interstitial pneumonia), obstructive airway diseases (e.g., asthma, emphysema, chronic or acute bronchitis), occupational lung diseases (e.g., silicosis and asbestosis), pneumonia, and pleurisy.

[0162] The recitation of “Endocrine” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”) and diseases or disorders of the respiratory system (e.g., as described below under “Respiratory Disorders”), renal disorders (e.g., as described below under “Renal Disorders”), and disorders of the endocrine system (e.g., as described below under “Endocrine Disorders”.

[0163] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having an “Endocrine” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: cancers of endocrine tissues and organs (e.g., cancers of the hypothalamus, pituitary gland, thyroid gland, parathyroid glands, pancreas, adrenal glands, ovaries, and testes), diabetes (e.g., diabetes insipidus, type I and type II diabetes mellitus), obesity, disorders related to pituitary glands (e.g., hyperpituitarism, hypopituitarism, and pituitary dwarfism), hypothyroidism, hyperthyroidism, goiter, reproductive disorders (e.g. male and female infertility), disorders related to adrenal glands (e.g., Addison's Disease, corticosteroid deficiency, and Cushing's Syndrome), kidney cancer (e.g., hypernephroma, transitional cell cancer, and Wilm's tumor), diabetic nephropathy, interstitial nephritis, polycystic kidney disease, glomerulonephritis (e.g., IgM mesangial proliferative glomerulonephritis and glomerulonephritis caused by autoimmune disorders; such as Goodpasture's syndrome), and nephrocalcinosis.

[0164] The recitation of “Digestive” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”) and diseases or disorders of the gastrointestinal system (e.g., as described below under “Gastrointestinal Disorders”.

[0165] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Digestive” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: ulcerative colitis, appendicitis, Crohn's disease, hepatitis, hepatic encephalopathy, portal hypertension, cholelithiasis, cancer of the digestive system (e.g., biliary tract cancer, stomach cancer, colon cancer, gastric cancer, pancreatic cancer, cancer of the bile duct, tumors of the colon (e.g., polyps or cancers), and cirrhosis), pancreatitis, ulcerative disease, pyloric stenosis, gastroenteritis, gastritis, gastric atropy, benign tumors of the duodenum, distension, irritable bowel syndrome, malabsorption, congenital disorders of the small intestine, bacterial and parasitic infection, megacolon, Hirschsprung's disease, aganglionic megacolon, acquired megacolon, colitis, anorectal disorders (e.g., anal fistulas, hemorrhoids), congenital disorders of the liver (e.g., Wilson's disease, hemochromatosis, cystic fibrosis, biliary atresia, and alpha1-antitrypsin deficiency), portal hypertension, cholelithiasis, and jaundice.

[0166] The recitation of “Connective/Epithelial” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), cellular and genetic abnormalities (e.g., as described below under “Diseases at the Cellular Level”), angiogenesis (e.g., as described below under “Anti-Angiogenesis Activity”), and or to promote or inhibit regeneration (e.g., as described below under “Regeneration”), and wound healing (e.g., as described below under “Wound Healing and Epithelial Cell Proliferation”).

[0167] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Connective/Epithelial” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: connective tissue metaplasia, mixed connective tissue disease, focal epithelial hyperplasia, epithelial metaplasia, mucoepithelial dysplasia, graft v. host disease, polymyositis, cystic hyperplasia, cerebral dysplasia, tissue hypertrophy, Alzheimer's disease, lymphoproliferative disorder, Waldenstron's macroglobulinemia, Crohn's disease, pernicious anemia, idiopathic Addison's disease, glomerulonephritis, bullous pemphigoid, Sjogren's syndrome, diabetes mellitus, cystic fibrosis, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, osteoporosis, osteocarthritis, periodontal disease, wound healing, relapsing polychondritis, vasculitis, polyarteritis nodosa, Wegener's granulomatosis, cellulitis, rheumatoid arthritis, psoriatic arthritis, discoid lupus erythematosus, systemic lupus erythematosus, scleroderma, CREST syndrome, Sjogren's syndrome, polymyositis, dermatomyositis, mixed connective tissue disease, relapsing polychondritis, vasculitis, Henoch-Schonlein syndrome, erythema nodosum, polyarteritis nodosa, temporal (giant cell) arteritis, Takayasu's arteritis, Wegener's granulomatosis, Reiter's syndrome, Behcet's syndrome, ankylosing spondylitis, cellulitis, keloids, Ehler Danlos syndrome, Marfan syndrome, pseudoxantoma elasticum, osteogenese imperfecta, chondrodysplasias, epidermolysis bullosa, Alport syndrome, and cutis laxa.

[0168]

TABLE 1C
Gene	cDNA
No.	Clone ID:	Preferred Indications:
1	H2CBG48	Cancer
2	H2CBU83	Cancer
3	H2MAC30	Cancer
4	H6EAB28	Musculoskeletal, Neural/Sensory
5	H6EDC19	Cancer
6	H6EDF66	Connective/Epithelial, Immune/Hematopoetic,
		Neural/Sensory
7	H6EDY30	Immune/Hematopoetic
8	HABAG37	Cancer
9	HACBD91	Cancer
10	HACCI17	Cancer
11	HADAO89	Connective/Epithelial
12	HADCP14	Connective/Epithelial, Immune/Hematopoetic
13	HAGAI85	Cancer
14	HAGAM64	Neural/Sensory
15	HAGAN21	Digestive, Immune/Hematopoetic, Neural/Sensory
16	HAGAQ26	Cancer
17	HAGBZ81	Excretory, Neural/Sensory
18	HAGDS20	Neural/Sensory, Reproductive
19	HAGDS35	Cancer
20	HAGFG51	Neural/Sensory
21	HAGFI62	Cancer
22	HAHDB16	Cardiovascular
23	HAHDR32	Cancer
24	HAIBO71	Connective/Epithelial, Digestive,
		Immune/Hematopoetic
25	HAIBP89	Cancer
26	HAIBU10	Cancer
27	HAICP19	Cancer
28	HAIFL18	Digestive, Immune/Hematopoetic
29	HAJAF57	Cancer
30	HAJAN23	Cancer
31	HAJBR69	Cancer
32	HAJBZ75	Cancer
33	HAMFE15	Cancer
34	HAMFK58	Cancer
35	HAMGG68	Cancer
36	HAMGR28	Cancer
37	HAPBS03	Cancer
38	HAPNY86	Cancer
39	HAPNY94	Cancer
40	HAPOM49	Cancer
41	HAPPW30	Cancer
42	HAPQT22	Cancer
43	HAPUC89	Cancer
44	HASAV70	Cancer
45	HASCG84	Cancer
46	HATAC53	Cancer
47	HATBR65	Cancer
48	HATCB92	Endocrine
49	HATCP77	Cancer
50	HATDM46	Cancer
51	HATEE46	Cancer
52	HAUAI83	Reproductive
53	HBAFJ33	Cancer
54	HBAFV19	Cancer
55	HBAMB15	Cardiovascular, Excretory, Reproductive
56	HBAMB34	Excretory, Reproductive
57	HBCPB32	Neural/Sensory, Reproductive
58	HBGBA69	Cancer
59	HBGNU56	Cancer
60	HBHAD12	Neural/Sensory
61	HBHMA23	Cancer
62	HBIAE26	Neural/Sensory, Reproductive
63	HBIBW67	Digestive, Neural/Sensory, Reproductive
64	HBINS58	Connective/Epithelial, Reproductive
65	HBJFU48	Immune/Hematopoetic
66	HBJIY92	Cancer
67	HBJLC01	Immune/Hematopoetic
68	HBJLF01	Cancer
69	HBJLH40	Digestive, Immune/Hematopoetic, Neural/Sensory
70	HBJNC59	Cancer
71	HBNAW17	Reproductive
72	HBOEG11	Cancer
73	HBOEG69	Cancer
74	HCACU58	Immune/Hematopoetic
75	HCACV51	Cancer
76	HCDBW86	Musculoskeletal
77	HCE1Q89	Immune/Hematopoetic, Neural/Sensory
78	HCE2F54	Cancer
79	HCE3G69	Cancer
80	HCE5F43	Cancer
81	HCEFB80	Cancer
82	HCEGR33	Cancer
83	HCEMP62	Cancer
84	HCENK38	Cancer
85	HCEWE17	Digestive, Neural/Sensory
86	HCEWE20	Endocrine, Immune/Hematopoetic, Neural/Sensory
87	HCFCU88	Immune/Hematopoetic
88	HCFMV71	Digestive, Immune/Hematopoetic
89	HCFNN01	Digestive, Immune/Hematopoetic, Neural/Sensory
90	HCFOM18	Immune/Hematopoetic
91	HCGMD59	Cancer
92	HCHNF25	Cancer
93	HCMSQ56	Cardiovascular
94	HCMST14	Cancer
95	HCMTB45	Cardiovascular, Mixed Fetal
96	HCNDR47	Digestive, Neural/Sensory, Reproductive
97	HCNSB61	Digestive, Immune/Hematopoetic
98	HCNSD93	Digestive
99	HCOOS80	Cancer
100	HCQCT05	Digestive, Endocrine, Reproductive
101	HCUBS50	Immune/Hematopoetic
102	HCUCK44	Cancer
103	HCUEO60	Immune/Hematopoetic
104	HCUGM86	Immune/Hematopoetic
105	HCUHK65	Cancer
106	HCUIM65	Cancer
107	HCWDS72	Cancer
108	HCWEB58	Cancer
109	HCWGU37	Immune/Hematopoetic, Neural/Sensory,
		Reproductive
110	HCWKC15	Immune/Hematopoetic
111	HCWLD74	Immune/Hematopoetic
112	HCWUM50	Cancer
113	HDABR72	Cancer
114	HDHEB60	Cancer
115	HDHIA94	Cancer
116	HDHMA72	Cancer
117	HDLAC10	Cancer
118	HDLAO28	Cancer
119	HDPBA28	Cancer
120	HDPBI32	Excretory, Immune/Hematopoetic, Neural/Sensory
121	HDPBQ02	Immune/Hematopoetic
122	HDPBQ71	Cancer
123	HDPCJ91	Cancer
124	HDPCL63	Cancer
125	HDPCO25	Immune/Hematopoetic
126	HDPCY37	Cancer
127	HDPFF39	Cancer
128	HDPGI49	Cancer
129	HDPGK25	Cancer
130	HDPGP94	Digestive, Immune/Hematopoetic
131	HDPGT01	Cancer
132	HDPHI51	Immune/Hematopoetic
133	HDPJF37	Cancer
134	HDPJM30	Cancer
135	HDPNC61	Immune/Hematopoetic, Reproductive
136	HDPND46	Immune/Hematopoetic
137	HDPOE32	Cancer
138	HDPOH06	Cancer
139	HDPOJ08	Cancer
140	HDPOZ56	Cancer
141	HDPPA04	Cardiovascular, Connective/Epithelial,
		Immune/Hematopoetic
142	HDPPH47	Cancer
143	HDPPN86	Cancer
144	HDPSB18	Cancer
145	HDPSH53	Immune/Hematopoetic, Reproductive
146	HDPSP01	Cancer
147	HDPSP54	Cancer
148	HDPSU13	Immune/Hematopoetic
149	HDPTD15	Immune/Hematopoetic
150	HDPTK41	Cancer
151	HDPUG50	Cancer
152	HDPUH26	Cancer
153	HDPUW68	Cancer
154	HDPVH60	Cancer
155	HDPWN93	Cancer
156	HDPWU34	Cancer
157	HDPXY01	Cancer
158	HDQHD03	Neural/Sensory
159	HDTBP04	Digestive, Immune/Hematopoetic
160	HDTBV77	Cancer
161	HDTDQ23	Cancer
162	HDTEK44	Connective/Epithelial, Immune/Hematopoetic,
		Reproductive
163	HDTEN81	Digestive, Immune/Hematopoetic
164	HDTFE17	Cancer
165	HDTGC73	Cancer
166	HDTIT10	Cancer
167	HDTMK50	Cancer
168	HE2DE47	Cancer
169	HE2DY70	Immune/Hematopoetic, Mixed Fetal,
		Musculoskeletal
170	HE2EB74	Cancer
171	HE2FV03	Cancer
172	HE2NV57	Cancer
173	HE2PD49	Cancer
174	HE2PH36	Digestive, Immune/Hematopoetic, Mixed Fetal
175	HE2PY40	Mixed Fetal
176	HE6EU50	Mixed Fetal
177	HE8DS15	Cancer
178	HE8MH91	Cancer
179	HESQV67	Cancer
180	HE9BK23	Digestive, Mixed Fetal
181	HE9CO69	Cancer
182	HE9CP41	Immune/Hematopoetic, Mixed Fetal
183	HE9DG49	Cancer
184	HE9HY07	Mixed Fetal, Reproductive
185	HE9OW20	Immune/Hematopoetic, Mixed Fetal,
		Neural/Sensory
186	HE9RM63	Cancer
187	HEAAR07	Reproductive
188	HEBAE88	Immune/Hematopoetic, Neural/Sensory
189	HEBBN36	Cancer
190	HEBCM63	Cancer
191	HEBEJ18	Cancer
192	HEEAG23	Cancer
193	HEEAJ02	Cancer
194	HEEAQ11	Reproductive
195	HEGAH43	Digestive, Reproductive
196	HEGAN94	Reproductive
197	HEGBS69	Neural/Sensory, Reproductive
198	HELGK31	Cancer
199	HELHD85	Cancer
200	HELHL48	Cancer
201	HEMAM41	Cancer
202	HEOMQ63	Digestive, Immune/Hematopoetic
203	HEPAA46	Reproductive
204	HEPAB80	Reproductive
205	HEPAD91	Connective/Epithelial, Reproductive
206	HEQAK71	Cancer
207	HEQCC55	Cancer
208	HERAD40	Connective/Epithelial
209	HERAR44	Connective/Epithelial, Reproductive
210	HESAJ10	Cancer
211	HETAB45	Cancer
212	HETBR16	Digestive, Immune/Hematopoetic, Reproductive
213	HETEU28	Cancer
214	HETLM70	Cancer
215	HFABG18	Cancer
216	HFABH95	Digestive, Neural/Sensory, Reproductive
217	HFAEF57	Neural/Sensory
218	HFAMH77	Cancer
219	HFCCQ50	Cancer
220	HFCDK17	Cancer
221	HFCEB37	Cancer
222	HFFAD59	Neural/Sensory
223	HFFAL36	Neural/Sensory
224	HFGAD82	Cancer
225	HFIIN69	Musculoskeletal, Neural/Sensory, Reproductive
226	HFKET18	Cancer
227	HFKFG02	Excretory, Immune/Hematopoetic, Neural/Sensory
228	HFLNB64	Cancer
229	HFOXB13	Musculoskeletal
230	HFPAC12	Cancer
231	HFPCX09	Mixed Fetal, Neural/Sensory
232	HFPCX36	Neural/Sensory
233	HFPCX64	Mixed Fetal, Neural/Sensory
234	HFRAN90	Neural/Sensory
235	HFTBM50	Cancer
236	HFTCU19	Cancer
237	HFTDL56	Cancer
238	HFTDZ36	Cancer
239	HFVGE32	Digestive, Immune/Hematopoetic
240	HFXAM76	Cancer
241	HFXBL33	Cancer
242	HFXDJ75	Neural/Sensory
243	HFXDN63	Neural/Sensory
244	HFXGT26	Cancer
245	HFXGV31	Neural/Sensory
246	HFXHD88	Neural/Sensory
247	HFXHK73	Neural/Sensory
248	HFXJX44	Cancer
249	HFXKJ03	Cardiovascular, Immune/Hematopoetic,
		Neural/Sensory
250	HFXKY27	Neural/Sensory
251	HGBFO79	Cancer
252	HGBHE57	Cancer
253	HGBHI35	Cancer
254	HGBIB74	Cancer
255	HGLAF75	Digestive, Immune/Hematopoetic, Reproductive
256	HGLAL82	Immune/Hematopoetic, Reproductive
257	HHAAF20	Cancer
258	HHBCS39	Cancer
259	HHEAA08	Immune/Hematopoetic
260	HHEBB10	Cancer
261	HHEMA59	Cancer
262	HHEMA75	Cancer
263	HHEMM74	Cancer
264	HHENP27	Cancer
265	HHENQ22	Immune/Hematopoetic
266	HHENV10	Immune/Hematopoetic
267	HHEPD24	Immune/Hematopoetic
268	HHEPM33	Cancer
269	HHEPT60	Cancer
270	HHEPU04	Cancer
271	HHFBY53	Cancer
272	HHFEC49	Cancer
273	HHFFJ48	Cardiovascular, Immune/Hematopoetic
274	HHFGR93	Cancer
275	HHFHJ59	Cancer
276	HHFHR32	Cancer
277	HHFOJ29	Cancer
278	HHGBO91	Digestive, Reproductive
279	HHGCG53	Cancer
280	HHGCM76	Cancer
281	HHGCQ54	Cancer
282	HHGDF16	Cancer
283	HHGDW43	Cancer
284	HHPDX20	Neural/Sensory
285	HHPEN62	Cancer
286	HHPGO40	Cancer
287	HHPTJ65	Cardiovascular, Musculoskeletal, Neural/Sensory
288	HHSDX28	Immune/Hematopoetic, Neural/Sensory
289	HHSGW69	Cancer
290	HHTLF25	Cancer
291	HILCF66	Cancer
292	HJACA79	Immune/Hematopoetic
293	HJACG30	Immune/Hematopoetic
294	HJBAV55	Cancer
295	HJBCU04	Cancer
296	HJBCY35	Cancer
297	HJMBI18	Cancer
298	HJMBM38	Cancer
299	HJMBT65	Cancer
300	HJMBW30	Cancer
301	HJPAD75	Cancer
302	HJPCP42	Cardiovascular, Immune/Hematopoetic
303	HKAAE44	Cancer
304	HKAAH36	Connective/Epithelial, Reproductive
305	HKAAK02	Cancer
306	HKABI84	Cancer
307	HKABZ65	Connective/Epithelial
308	HKACB56	Connective/Epithelial
309	HKACD58	Cancer
310	HKACH44	Cancer
311	HKACM93	Cancer
312	HKAEG43	Cancer
313	HKAEL80	Connective/Epithelial, Immune/Hematopoetic
314	HKAEV06	Cancer
315	HKAFK41	Cancer
316	HKAFT66	Connective/Epithelial, Digestive,
		Immune/Hematopoetic
317	HKB1E57	Cancer
318	HKDBF34	Cancer
319	HKFBC53	Cancer
320	HKGAT94	Digestive, Reproductive
321	HKGCO27	Cancer
322	HKGDL36	Cancer
323	HKISB57	Cancer
324	HKIYH57	Cancer
325	HKMLP68	Excretory, Reproductive
326	HKMMD13	Excretory
327	HKMMW74	Excretory
328	HKMND01	Excretory
329	HL2AG57	Immune/Hematopoetic, Reproductive
330	HLCND09	Cancer
331	HLDBE54	Digestive, Reproductive
332	HLDBX13	Digestive
333	HLDNA86	Cancer
334	HLDON23	Cancer
335	HLDOW79	Digestive
336	HLDQC46	Cancer
337	HLDQR62	Cancer
338	HLDQU79	Cancer
339	HLDRM43	Digestive, Reproductive
340	HLDRP33	Digestive, Neural/Sensory
341	HLHAL68	Respiratory
342	HLHFP03	Respiratory
343	HLIBD68	Cancer
344	HLICQ90	Cancer
345	HLJBJ61	Cancer
346	HLMBO76	Digestive, Immune/Hematopoetic, Reproductive
347	HLMCA59	Immune/Hematopoetic
348	HLQBE09	Digestive
349	HLQDR48	Digestive
350	HLQEM64	Cancer
351	HLTAU74	Cancer
352	HLTCO33	Immune/Hematopoetic, Neural/Sensory,
		Reproductive
353	HLTDV50	Immune/Hematopoetic, Respiratory
354	HLTEJ06	Digestive, Immune/Hematopoetic
355	HLTFA64	Cancer
356	HLTHG37	Cancer
357	HLTHR66	Cancer
358	HLTIP94	Immune/Hematopoetic, Mixed Fetal,
		Neural/Sensory
359	HLWAA17	Cancer
360	HLWAA88	Cancer
361	HLWAD77	Cancer
362	HLWAE11	Cardiovascular, Immune/Hematopoetic,
		Reproductive
363	HLWAO22	Cancer
364	HLWAY54	Immune/Hematopoetic, Neural/Sensory,
		Reproductive
365	HLWBH18	Reproductive
366	HLWBI63	Cancer
367	HLWBK05	Cancer
368	HLWBY76	Cancer
369	HLWCF05	Cancer
370	HLYAC95	Immune/Hematopoetic
371	HLYAF80	Immune/Hematopoetic
372	HLYAN59	Immune/Hematopoetic
373	HLYAP91	Digestive, Immune/Hematopoetic, Reproductive
374	HLYBD32	Immune/Hematopoetic
375	HLYES38	Immune/Hematopoetic, Reproductive
376	HMADK33	Cancer
377	HMADS41	Cancer
378	HMADU73	Cancer
379	HMAMI15	Cancer
380	HMCFY13	Immune/Hematopoetic, Reproductive
381	HMDAB56	Immune/Hematopoetic, Neural/Sensory
382	HMDAE65	Neural/Sensory
383	HMDAM24	Cancer
384	HMDAN54	Immune/Hematopoetic, Neural/Sensory
385	HMDAQ29	Neural/Sensory, Reproductive
386	HMEAI48	Cardiovascular
387	HMECK83	Cardiovascular
388	HMEED18	Cancer
389	HMEET96	Cancer
390	HMEFT54	Cardiovascular, Digestive, Reproductive
391	HMEGF92	Cardiovascular
392	HMIAP86	Cancer
393	HMKCG09	Digestive, Endocrine, Neural/Sensory
394	HMMAH60	Immune/Hematopoetic
395	HMQDF12	Cancer
396	HMSBX80	Immune/Hematopoetic, Reproductive
397	HMSDL37	Cancer
398	HMSFI26	Immune/Hematopoetic
399	HMSFS21	Digestive, Immune/Hematopoetic
400	HMSGB14	Immune/Hematopoetic
401	HMSGT42	Cancer
402	HMSGU01	Cancer
403	HMSHM14	Immune/Hematopoetic
404	HMSHS36	Immune/Hematopoetic
405	HMSJM65	Cancer
406	HMSJU68	Cancer
407	HMSKC04	Immune/Hematopoetic
408	HMTBI36	Cancer
409	HMUAP70	Cancer
410	HMVBN46	Immune/Hematopoetic, Neural/Sensory
411	HMVBS81	Cancer
412	HMWDC28	Cancer
413	HMWEB02	Cancer
414	HMWFO02	Immune/Hematopoetic
415	HMWFT65	Immune/Hematopoetic
416	HMWGY65	Cancer
417	HNEAC05	Immune/Hematopoetic
418	HNEEB45	Immune/Hematopoetic, Mixed Fetal
419	HNEEE24	Immune/Hematopoetic
420	HNFFC43	Cancer
421	HNFGF20	Cardiovascular, Immune/Hematopoetic
422	HNFIY77	Cancer
423	HNFJF07	Immune/Hematopoetic, Neural/Sensory
424	HNFJH45	Immune/Hematopoetic
425	HNGAK47	Immune/Hematopoetic
426	HNGAP93	Cancer
427	HNGBC07	Immune/Hematopoetic
428	HNGBT31	Immune/Hematopoetic
429	HNGDG40	Immune/Hematopoetic
430	HNGDJ72	Immune/Hematopoetic
431	HNGDU40	Immune/Hematopoetic
432	HNGEG08	Immune/Hematopoetic
433	HNGEP09	Immune/Hematopoetic
434	HNGFR31	Immune/Hematopoetic
435	HNGHR74	Immune/Hematopoetic
436	HNGIH43	Immune/Hematopoetic, Reproductive
437	HNGIJ31	Cancer
438	HNGJE50	Immune/Hematopoetic
439	HNGJO57	Immune/Hematopoetic
440	HNGJT54	Immune/Hematopoetic
441	HNGND37	Cancer
442	HNGOI12	Immune/Hematopoetic
443	HNGOM56	Immune/Hematopoetic
444	HNGOU56	Immune/Hematopoetic
445	HNGOW62	Immune/Hematopoetic
446	HNHAH01	Immune/Hematopoetic
447	HNHCX60	Immune/Hematopoetic
448	HNHCY64	Immune/Hematopoetic
449	HNHCY94	Immune/Hematopoetic
450	HNHDW38	Immune/Hematopoetic
451	HNHDW42	Immune/Hematopoetic
452	HNHED17	Immune/Hematopoetic
453	HNHEI42	Immune/Hematopoetic
454	HNHEU93	Immune/Hematopoetic
455	HNHFM14	Cancer
456	HNHFR04	Immune/Hematopoetic
457	HNHFU32	Immune/Hematopoetic
458	HNHNB29	Immune/Hematopoetic
459	HNHOD46	Immune/Hematopoetic
460	HNHOG73	Immune/Hematopoetic
461	HNTBI26	Cancer
462	HNTBL27	Cancer
463	HNTCE26	Cancer
464	HNTNC20	Cancer
465	HNTNI01	Cancer
466	HNTSY18	Cardiovascular, Reproductive
467	HOAAC90	Musculoskeletal
468	HOACB38	Musculoskeletal
469	HOCNF19	Digestive
470	HODDF13	Reproductive
471	HODDN65	Reproductive
472	HODDN92	Cancer
473	HODDO08	Cancer
474	HODDW40	Cardiovascular, Immune/Hematopoetic,
		Reproductive
475	HODEJ32	Reproductive
476	HODFN71	Mixed Fetal, Reproductive
477	HODGE68	Reproductive
478	HOEBK34	Digestive, Musculoskeletal
479	HOEBZ89	Cancer
480	HOEDB32	Cancer
481	HOEDE28	Cancer
482	HOEDH84	Cancer
483	HOFMQ33	Reproductive
484	HOFMT75	Cancer
485	HOFND85	Cancer
486	HOFNY91	Cancer
487	HOFOC33	Reproductive
488	HOGAW62	Immune/Hematopoetic, Reproductive
489	HOGCK20	Cancer
490	HOGCK63	Cancer
491	HOGCS52	Cancer
492	HOHBB49	Musculoskeletal
493	HOHBC68	Musculoskeletal, Reproductive
494	HOHBY12	Musculoskeletal
495	HOHBY44	Cancer
496	HOHCC74	Musculoskeletal
497	HOHCH55	Cancer
498	HOQBJ82	Cancer
499	HOSBY40	Digestive, Immune/Hematopoetic, Musculoskeletal
500	HOSDJ25	Cancer
501	HOSEG51	Endocrine, Immune/Hematopoetic, Musculoskeletal
502	HOSEQ49	Cancer
503	HOSFD58	Cancer
504	HOUCQ17	Cancer
505	HOUDK26	Connective/Epithelial, Digestive, Neural/Sensory
506	HOUGG12	Cancer
507	HOVCA92	Immune/Hematopoetic, Reproductive
508	HPASA81	Digestive, Endocrine, Reproductive
509	HPBCU51	Cancer
510	HPDDC77	Cancer
511	HPDWP28	Reproductive
512	HPEAD79	Reproductive
513	HPFCL43	Cancer
514	HPFDG48	Digestive, Immune/Hematopoetic, Reproductive
515	HPIAQ68	Immune/Hematopoetic, Reproductive
516	HPIBO15	Cancer
517	HPICB53	Reproductive
518	HPJB133	Reproductive
519	HPJBK12	Reproductive
520	HPJCL22	Cancer
521	HPJCW04	Reproductive
522	HPJEX20	Immune/Hematopoetic, Reproductive
523	HPMAI22	Digestive, Immune/Hematopoetic, Reproductive
524	HPMDK28	Cancer
525	HPMFP40	Reproductive
526	HPMGJ45	Cancer
527	HPQAC69	Digestive
528	HPRAL78	Cancer
529	HPRBC80	Cancer
530	HPRBF19	Cancer
531	HPTTG19	Endocrine, Immune/Hematopoetic
532	HPVAB94	Reproductive
533	HPWAY46	Cancer
534	HPWDJ42	Digestive, Reproductive
535	HPZAB47	Cancer
536	HRAAB15	Cancer
537	HRABA80	Excretory
538	HRACD15	Cancer
539	HRACD80	Digestive, Excretory
540	HRACJ35	Cancer
541	HRADL70	Excretory, Immune/Hematopoetic
542	HRDDV47	Cancer
543	HRDFD27	Immune/Hematopoetic, Musculoskeletal
544	HRGBL78	Cancer
545	HROAJ03	Cancer
546	HROAJ39	Digestive, Immune/Hematopoetic
547	HROBD68	Cancer
548	HRTAE58	Digestive
549	HSATR82	Immune/Hematopoetic
550	HSAUK57	Immune/Hematopoetic
551	HSAUL82	Immune/Hematopoetic
552	HSAVH65	Digestive, Immune/Hematopoetic, Reproductive
553	HSAVK10	Immune/Hematopoetic
554	HSAWD74	Cancer
555	HSAWZ41	Immune/Hematopoetic
556	HSAXA83	Cancer
557	HSAYB43	Immune/Hematopoetic
558	HSAYM40	Immune/Hematopoetic
559	HSDAJ46	Mixed Fetal, Neural/Sensory
560	HSDEK49	Cancer
561	HSDER95	Connective/Epithelial, Digestive, Neural/Sensory
562	HSDFJ26	Cancer
563	HSDJA15	Cancer
564	HSDJJ82	Neural/Sensory
565	HSDJM31	Digestive, Neural/Sensory
566	HSDSB09	Digestive, Excretory, Neural/Sensory
567	HSDSE75	Cancer
568	HSDZR57	Cancer
569	HSHAX21	Cancer
570	HSIAS17	Cancer
571	HSIDJ81	Digestive
572	HSIDX71	Digestive, Neural/Sensory
573	HSJBQ79	Cancer
574	HSKDA27	Cancer
575	HSKGN81	Cancer
576	HSKHZ81	Cancer
577	HSKNB56	Cancer
578	HSLCQ82	Cancer
579	HSLJG37	Cancer
580	HSNAB12	Cardiovascular
581	HSNAD72	Cancer
582	HSNMC45	Cancer
583	HSODE04	Digestive
584	HSPBF70	Cancer
585	HSQFP66	Excretory, Neural/Sensory
586	HSRFZ57	Musculoskeletal
587	HSSAJ29	Musculoskeletal, Neural/Sensory
588	HSSDX51	Cancer
589	HSSFT08	Musculoskeletal
590	HSSGD52	Cancer
591	HSSGG82	Cancer
592	HSSJC35	Cancer
593	HSTBJ86	Connective/Epithelial
594	HSUBW09	Digestive, Immune/Hematopoetic
595	HSVAM10	Cancer
596	HSVBU91	Cancer
597	HSXCG83	Cancer
598	HSXEQ06	Cancer
599	HSXGI47	Cancer
600	HSYAV50	Cancer
601	HSYAV66	Digestive, Immune/Hematopoetic
602	HSYAZ50	Cancer
603	HSYAZ63	Cancer
604	HSYBG37	Cancer
605	HT3SF53	Cancer
606	HT5GJ57	Cancer
607	HTADW91	Cancer
608	HTADX17	Immune/Hematopoetic, Reproductive
609	HTAEE28	Digestive, Immune/Hematopoetic, Mixed Fetal
610	HTDAF28	Cancer
611	HTEAF65	Excretory, Reproductive
612	HTEAM34	Reproductive
613	RTEAM34	Reproductive
614	HTEBI28	Reproductive
615	HTEBV72	Reproductive
616	HTECC05	Cancer
617	HTEDF80	Reproductive
618	HTEDY42	Reproductive
619	HTEEB42	Cancer
620	HTEFU65	Cancer
621	HTEGA76	Reproductive
622	HTEGI42	Cancer
623	HTEHR24	Cancer
624	HTEIP36	Reproductive
625	HTEIV80	Reproductive
626	HTEJN13	Neural/Sensory, Reproductive
627	HTELM16	Reproductive
628	HTELP17	Cancer
629	HTELS08	Reproductive
630	HTEPG70	Reproductive
631	HTGAU75	Immune/Hematopoetic
632	HTGEP89	Immune/Hematopoetic, Neural/Sensory
633	HTHBG43	Immune/Hematopoetic
634	HTHCA18	Immune/Hematopoetic
635	HTHDJ94	Cancer
636	HTHDS25	Endocrine, Immune/Hematopoetic
637	HTJMA95	Cancer
638	HTJML75	Cancer
639	HTLBE23	Reproductive
640	HTLEP53	Reproductive
641	HTLFE42	Cardiovascular, Digestive, Reproductive
642	HTLFE57	Cancer
643	HTLGE31	Immune/Hematopoetic, Reproductive
644	HTLHY14	Immune/Hematopoetic, Neural/Sensory,
		Reproductive
645	HTLIT32	Reproductive
646	HTLIV19	Reproductive
647	HTNBO91	Cancer
648	HTOAK16	Cancer
649	HTODK73	Cancer
650	HTODO72	Immune/Hematopoetic
651	HTOGR42	Immune/Hematopoetic
652	HTOHT18	Cancer
653	HTOIY21	Immune/Hematopoetic
654	HTOIZ02	Cancer
655	HTOJA73	Immune/Hematopoetic
656	HTOJK60	Cancer
657	HTPBW79	Cancer
658	HTPCS72	Cancer
659	HTSEW17	Immune/Hematopoetic, Reproductive
660	HTTBI76	Cancer
661	HTTBS64	Reproductive
662	HTTDB46	Digestive, Reproductive
663	HTWCT03	Cancer
664	HTWDF76	Immune/Hematopoetic
665	HTWJK32	Cancer
666	HTWKE60	Cancer
667	HTXAJ12	Immune/Hematopoetic
668	HTXCV12	Cancer
669	HTXDW56	Cancer
670	HTXFL30	Cancer
671	HTXJM03	Cancer
672	HTXKF95	Cancer
673	HTXKP61	Cancer
674	HUDBZ89	Cancer
675	HUFBY15	Digestive, Musculoskeletal, Reproductive
676	HUFCJ30	Cancer
677	HUFEF62	Digestive
678	HUKAH51	Cancer
679	HUKBT29	Cancer
680	HUSAT94	Cancer
681	HUSBA88	Cancer
682	HUSIG64	Cancer
683	HUSXS50	Cancer
684	HUVEB53	Cancer
685	HWAAD63	Endocrine, Excretory, Immune/Hematopoetic
686	HWABA81	Immune/Hematopoetic
687	HWABY10	Cancer
688	HWADJ89	Immune/Hematopoetic
689	HWBAO62	Connective/Epithelial, Immune/Hematopoetic
690	HWBAR14	Cancer
691	HWBCB89	Cancer
692	HWBCP79	Immune/Hematopoetic, Reproductive
693	HWBDP28	Cancer
694	HWBEM18	Cancer
695	HWBFE57	Connective/Epithelial, Excretory,
		Immune/Hematopoetic
696	HWBFX31	Cancer
697	HWDAC39	Connective/Epithelial
698	HWDAH38	Connective/Epithelial
699	HWHGP71	Connective/Epithelial, Immune/Hematopoetic,
		Reproductive
700	HWHGQ49	Cancer
701	HWHGU54	Connective/Epithelial
702	HWHGZ51	Cancer
703	HWHHL34	Cancer
704	HWLEV32	Cancer
705	HWLIH65	Cancer
706	HWTBK81	Cancer
707	HYAAJ71	Immune/Hematopoetic
708	HYBAR01	Musculoskeletal
709	H6EDX46	Cancer
710	HAGDG59	Cancer
711	HAMFC93	Cancer
712	HAPOB80	Immune/Hematopoetic, Musculoskeletal
713	HATDF29	Cancer
714	HBIMB51	Connective/Epithelial, Reproductive
715	HBJID05	Immune/Hematopoetic
716	HBJJU28	Immune/Hematopoetic, Neural/Sensory
717	HBXFL29	Cancer
718	HCEEA88	Cancer
719	HCEFB69	Cancer
720	HCNSM70	Cancer
721	HDHMA45	Cardiovascular, Neural/Sensory
722	HDPFP29	Cancer
723	HDTBD53	Cancer
724	HE2EN04	Cancer
725	HB8UB86	Mixed Fetal, Reproductive
726	HFAMB72	Cancer
727	HFIIZ70	Cancer
728	HFIUR10	Digestive, Immune/Hematopoetic, Musculoskeletal
729	HFOXA73	Musculoskeletal
730	HFPAO71	Cancer
731	HFVAB79	Cardiovascular, Digestive, Reproductive
732	HFXJU68	Immune/Hematopoetic, Neural/Sensory
733	HFXKT05	Cancer
734	HHENK42	Immune/Hematopoetic
735	HHPEC09	Cancer
736	HJABB94	Cancer
737	HJABT47	Cancer
738	HJABX32	Cancer
739	HJMBN89	Cancer
740	HKADQ91	Cancer
741	HKIYP40	Cancer
742	HKMLK53	Excretory/Mixed Fetal
743	HKMLM11	Cancer
744	HKMLN27	Cancer
745	HLHFR58	Cancer
746	HLQDH79	Cancer
747	HLYAZ61	Immune/Hematopoetic
748	HLYBI15	Immune/Hematopoetic
749	HMIAL37	Digestive, Neural/Sensory, Reproductive
750	HMQDT36	Cancer
751	HMTAD67	Cancer
752	HMWFY10	Cardiovascular, Immune/Hematopoetic,
		Neural/Sensory
753	HNGAJ15	Immune/Hematopoetic, Neural/Sensory
754	HNGEO29	Immune/Hematopoetic
755	HNGIQ46	Immune/Hematopoetic
756	HNGJP69	Immune/Hematopoetic
757	HNHFO29	Immune/Hematopoetic
758	HOFNC14	Reproductive
759	HOFOC73	Cancer
760	HOHCK70	Cancer
761	HPRSB76	Reproductive
762	HPWAZ95	Reproductive
763	HSABG21	Reproductive
764	HSAVD46	Immune/Hematopoetic, Mixed Fetal, Reproductive
765	HSDEZ20	Neural/Sensory
766	HSFAM31	Immune/Hematopoetic
767	HSQCM10	Cancer
768	HSXEC75	Cancer
769	HSZAF47	Mixed Fetal
770	HTEHU31	Cancer
771	HTEHU93	Reproductive
772	HTOHD42	Immune/Hematopoetic
773	HTOHM15	Cancer
774	HTPIH83	Digestive, Reproductive
775	HTXON32	Immune/Hematopoetic
776	HWBAR88	Cancer
777	HWHQS55	Cancer
778	HYABK95	Cancer
779	HYBBE75	Musculoskeletal
780	H2CAA57	Cancer
781	H2CBH03	Cancer
782	H2CBJ08	Cancer
783	H2CBK33	Cancer
784	H2CBT75	Cancer
785	H2MBB56	Cancer
786	H2MBT68	Cancer
787	H2MBY03	Cancer
788	H6BSD90	Cancer
789	H6BSG32	Cardiovascular, Immune/Hematopoetic,
		Musculoskeletal
790	H6EAA53	Cancer
791	H6EAE26	Musculoskeletal, Neural/Sensory
792	H6EEW11	Neural/Sensory, Reproductive
793	H6EEW15	Cancer
794	H7TBA62	Cancer
795	H7TMD22	Neural/Sensory
796	HA5BM53	Cancer
797	HAAAI67	Cancer
798	HACAA29	Cancer
799	HACBD86	Connective/Epithelial
800	HACBH16	Connective/Epithelial
801	HACBI61	Cancer
802	HACBS38	Cancer
803	HACBZ59	Cancer
804	HACCL63	Cancer
805	HADAE74	Cancer
806	HADCL29	Connective/Epithelial
807	HADCL55	Cancer
808	HADCL76	Cancer
809	HADCO45	Cancer
810	HADCW30	Connective/Epithelial
811	HADDH60	Connective/Epithelial, Immune/Hematopoetic,
		Neural/Sensory
812	HADDZ85	Connective/Epithelial, Immune/Hematopoetic,
		Neural/Sensory
813	HADEH21	Cancer
814	HADFF38	Cancer
815	HADFK68	Connective/Epithelial
816	HADFV30	Cancer
817	HADFY83	Cancer
818	HADGD17	Connective/Epithelial, Reproductive
819	HADGD33	Connective/Epithelial, Neural/Sensory,
		Reproductive
820	HADGG19	Connective/Epithelial, Musculoskeletal
821	HADMC21	Cancer
822	HAEAB66	Cancer
823	HAEAV45	Cardiovascular, Reproductive
824	HAFBD61	Cancer
825	HAGAI11	Cancer
826	HAGAM03	Immune/Hematopoetic, Neural/Sensory
827	HAGAO39	Digestive, Neural/Sensory, Reproductive
828	HAGBD57	Excretory, Neural/Sensory
829	HAGBP70	Cancer
830	HAGBR89	Neural/Sensory
831	HAGBX03	Neural/Sensory
832	HAGCH75	Cancer
833	HAGCT73	Cancer
834	HAGDI35	Cancer
835	HAGDO20	Cancer
836	HAGDQ42	Cancer
837	HAGDQ47	Cancer
838	HAGDU63	Cancer
839	HAGEA31	Neural/Sensory
840	HAGEB14	Cancer
841	HAGEW82	Cancer
842	HAGFB60	Neural/Sensory
843	HAGFD18	Cancer
844	HAGFE79	Immune/Hematopoetic, Neural/Sensory,
		Reproductive
845	HAGFH53	Cardiovascular, Musculoskeletal, Neural/Sensory
846	HAGFM45	Cancer
847	HAGFT48	Cancer
848	HAGFY16	Cancer
849	HAGGJ80	Cancer
850	HAGGS43	Neural/Sensory
851	HAGHD57	Cancer
852	HAGHR69	Cancer
853	HAHDZ77	Cardiovascular, Mixed Fetal
854	HAHFU44	Cardiovascular, Digestive, Musculoskeletal
855	HAIBE65	Cancer
856	HAIBO81	Neural/Sensory
857	HAIBX96	Cancer
858	HAIBZ39	Cancer
859	HAICJ23	Cancer
860	HAICJ56	Cancer
861	HAIDK60	Mixed Fetal
862	HAJAB01	Cancer
863	HAJAR23	Cancer
864	HAJAW31	Cancer
865	HAJAW93	Cancer
866	HAJAY88	Immune/Hematopoetic
867	HAJBG14	Cancer
868	HAJBV26	Cancer
869	HAJBW16	Immune/Hematopoetic, Neural/Sensory, Respiratory
870	HAJCL25	Immune/Hematopoetic
871	HALAA60	Cancer
872	HALSK07	Cancer
873	HALSQ38	Cancer
874	HAJSQ59	Cancer
875	HAMFE82	Cancer
876	HAMFL84	Cardiovascular, Digestive, Immune/Hematopoetic
877	HAMFP32	Cancer
878	HAMFT10	Cancer
879	HAMFY69	Cancer
880	HAMGG89	Immune/Hematopoetic, Neural/Sensory,
		Reproductive
881	HAMGO32	Reproductive
882	HAMGV47	Cancer
883	HAMGW29	Cancer
884	HAMHH20	Cancer
885	HANGD45	Musculoskeletal
886	HANGG89	Cancer
887	HAOAB14	Digestive, Musculoskeletal
888	HAOAB64	Musculoskeletal, Reproductive
889	HAOST94	Cancer
890	HAOTS04	Reproductive
891	HAPAT76	Cancer
892	HAPBL78	Cancer
893	HAPNJ39	Cancer
894	HAPNO80	Cancer
895	HAPNZ94	Cancer
896	HAPOC74	Excretory, Immune/Hematopoetic, Reproductive
897	HAPOD80	Cancer
898	HAPOF67	Digestive, Excretory, Musculoskeletal
899	HAPOK30	Reproductive
900	HAPOM45	Cardiovascular, Digestive
901	HAPON17	Cancer
902	HAPPS89	Cancer
903	HAPQL38	Cancer
904	HAPQQ94	Immune/Hematopoetic, Reproductive
905	HAPRJ16	Cancer
906	HAPRK85	Cancer
907	HAPSA79	Cancer
908	HAPSA79	Cancer
909	HAPSO15	Cancer
910	HAPSQ21	Reproductive, Respiratory
911	HAPSR85	Digestive, Endocrine
912	HAQAN31	Cancer
913	HAQAR23	Cancer
914	HAQBH57	Cancer
915	HAQBI01	Cancer
916	HAQBT52	Digestive, Endocrine, Reproductive
917	HAQBZ15	Cancer
918	HARAA15	Neural/Sensory
919	HARAG28	Neural/Sensory
920	HARAM05	Neural/Sensory, Respiratory
921	HARAO44	Neural/Sensory
922	HARAO51	Cancer
923	HARAY91	Immune/Hematopoetic, Mixed Fetal,
		Neural/Sensory
924	HARBA09	Cancer
925	HARMB79	Cancer
926	HARMJ38	Cancer
927	HARMS04	Connective/Epithelial, Digestive
928	HARNB17	Cancer
929	HARNB92	Connective/Epithelial, Excretory,
		Immune/Hematopoetic
930	HASAU43	Immune/Hematopoetic
931	HASAU84	Cancer
932	HASAW52	Cancer
933	HASMB80	Cancer
934	HATAA15	Cancer
935	HATCI19	Endocrine, Immune/Hematopoetic, Reproductive
936	HATCI78	Endocrine
937	HATCK44	Endocrine, Immune/Hematopoetic, Reproductive
938	HATCM08	Endocrine, Immune/Hematopoetic
939	HATCX80	Cancer
940	HATDB65	Endocrine, Reproductive, Respiratory
941	HATDL27	Endocrine
942	HATDQ62	Cancer
943	HATDZ29	Endocrine
944	HATEF60	Cancer
945	HATEI47	Endocrine
946	HAUAE83	Cancer
947	HAUAQ39	Cancer
948	HAUAU73	Cancer
949	HAVUR23	Neural/Sensory
950	HAVVG36	Cancer
951	HAWAT25	Cancer
952	HAZAD32	Cancer
953	HAZAP37	Reproductive
954	HBAFA02	Cancer
955	HBAFA04	Cancer
956	HBAFQ54	Cancer
957	HBAFZ29	Cancer
958	HBAGD39	Excretory, Reproductive
959	HBAGY25	Cancer
960	HBAHA77	Cancer
961	HBAMA40	Excretory
962	HBBBC37	Cancer
963	HBBBC71	Cancer
964	HBCAY05	Cancer
965	HBCAY27	Immune/Hematopoetic, Neural/Sensory
966	HBCQL32	Cancer
967	HBDAD07	Immune/Hematopoetic
968	HBFMA07	Cancer
969	HBFMC03	Digestive, Musculoskeletal, Reproductive
970	HBGBA14	Cancer
971	HBGNM47	Cancer
972	HBGNP63	Reproductive
973	HBGNQ12	Cancer
974	HBHME51	Reproductive, Respiratory
975	HBIAS26	Cancer
976	HBIBF16	Neural/Sensory
977	HBIBL04	Cancer
978	HBIBU30	Cancer
979	HBIBX03	Cancer
980	HBIMF63	Reproductive
981	HBIMT93	Cancer
982	HBINK72	Cancer
983	HBINU36	Connective/Epithelial, Immune/Hematopoetic,
		Musculoskeletal
984	HBIOH81	Cancer
985	HBJBQ35	Immune/Hematopoetic
986	HBJCI95	Cancer
987	HBJCK69	Cancer
988	HBJEE48	Cancer
989	HBJEL68	Immune/Hematopoetic, Neural/Sensory
990	HBJES16	Cancer
991	HBJEW84	Immune/Hematopoetic
992	HBJFA56	Cancer
993	HBJFE12	Immune/Hematopoetic
994	HBJFJ26	Cancer
995	HBJFM34	Immune/Hematopoetic
996	HBJFV28	Immune/Hematopoetic
997	HBJFX78	Cancer
998	HBJHJ80	Connective/Epithelial, Immune/Hematopoetic,
		Reproductive
999	HBJHO68	Immune/Hematopoetic
1000	HBJHP03	Immune/Hematopoetic, Reproductive
1001	HBJHZ58	Immune/Hematopoetic, Reproductive, Respiratory
1002	HBJIO81	Immune/Hematopoetic
1003	HBJIT60	Immune/Hematopoetic
1004	HBJKC04	Digestive, Immune/Hematopoetic
1005	HBJLD29	Immune/Hematopoetic
1006	HBJLR70	Immune/Hematopoetic, Neural/Sensory
1007	HBJMG49	Immune/Hematopoetic
1008	HBJMX85	Cancer
1009	HBJNB13	Immune/Hematopoetic
1010	HBKED12	Immune/Hematopoetic, Reproductive
1011	HBLKD56	Musculoskeletal
1012	HBMBB80	Digestive, Immune/Hematopoetic
1013	HBMCI50	Immune/Hematopoetic
1014	HBMCJ42	Immune/Hematopoetic, Reproductive
1015	HBMCL41	Cancer
1016	HBMCT17	Immune/Hematopoetic, Neural/Sensory
1017	HBMCU71	Immune/Hematopoetic
1018	HBMDD55	Immune/Hematopoetic
1019	HBMDK25	Immune/Hematopoetic
1020	HBMSK09	Digestive, Immune/Hematopoetic, Musculoskeletal
1021	HBMSN25	Cancer
1022	HBMSO46	Immune/Hematopoetic, Mixed Fetal, Reproductive
1023	HBMTA15	Cancer
1024	HBMTD81	Cancer
1025	HBMTV78	Digestive, Immune/Hematopoetic
1026	HBMTY28	Cancer
1027	HBMUT52	Cancer
1028	HBMVI06	Cancer
1029	HBMVI55	Immune/Hematopoetic
1030	HBMVP04	Cancer
1031	HBMWB01	Immune/Hematopoetic
1032	HBMWF85	Cancer
1033	HBMXG32	Immune/Hematopoetic
1034	HBMXN79	Cancer
1035	HBMXP84	Cancer
1036	HBNAF22	Cancer
1037	HBNAJ22	Cancer
1038	HBNAU27	Cancer
1039	HBNAV22	Digestive, Reproductive
1040	HBNBE21	Cancer
1041	HBNBG49	Cancer
1042	HBNBL77	Cancer
1043	HBNBQ61	Reproductive
1044	HBODE48	Digestive, Excretory, Immune/Hematopoetic
1045	HBODQ16	Cancer
1046	HBQAA49	Neural/Sensory
1047	HBQAB27	Endocrine, Neural/Sensory
1048	HBQAB44	Neural/Sensory, Reproductive, Respiratory
1049	HBQAE92	Cancer
1050	HBSAJ16	Connective/Epithelial, Musculoskeletal,
		Reproductive
1051	HBWBR94	Neural/Sensory
1052	HBWBX21	Immune/Hematopoetic, Neural/Sensory
1053	HBWCB95	Neural/Sensory
1054	HBWCF75	Neural/Sensory
1055	HBWCM83	Digestive, Immuno/Hematopoetic, Neural/Sensory
1056	HBXAB02	Cancer
1057	HBXAM53	Cancer
1058	HBXCF95	Cancer
1059	HBXCL50	Digestive, Excretory, Neural/Sensory
1060	HBXCL93	Neural/Sensory, Reproductive
1061	HBXCT44	Cancer
1062	HBXDC63	Neural/Sensory
1063	HBXED80	Immune/Hematopoetic, Neural/Sensory
1064	HBXFC78	Cancer
1065	HBXFG80	Cancer
1066	HBXFP23	Cancer
1067	HBXFR04	Neural/Sensory
1068	HBXFZ38	Cancer
1069	HBXGH74	Neural/Sensory
1070	HBXGI20	Cancer
1071	HBXGK12	Cancer
1072	HBXGM67	Neural/Sensory
1073	HBXGP60	Cancer
1074	HBXGP76	Immune/Hematopoetic, Neural/Sensory
1075	HBZAI19	Immune/Hematopoetic, Reproductive
1076	HBZAI90	Immune/Hematopoetic, Reproductive
1077	HBZAJ83	Reproductive
1078	HCABR41	Cancer
1079	HCABW07	Cancer
1080	HCACJ81	Cancer
1081	HCACY32	Cancer
1082	HCBND16	Digestive, Musculoskeletal, Reproductive
1083	HCCCG83	Cancer
1084	HCDAF84	Musculoskeletal
1085	HCDAN25	Cancer
1086	HCDAR68	Cancer
1087	HCDAT43	Cancer
1088	HCDBO20	Musculoskeletal, Respiratory
1089	HCDBP36	Digestive, Musculoskeletal
1090	HCDCF30	Cancer
1091	HCDDB78	Cancer
1092	HCDDP40	Immune/Hematopoetic, Musculoskeletal
1093	HCDDR90	Cancer
1094	HCDEJ37	Immune/Hematopoetic, Musculoskeletal
1095	HCDEO95	Cancer
1096	HCE1P80	Cancer
1097	HCE1Q30	Immune/Hematopoetic, Neural/Sensory
1098	HCE1X60	Neural/Sensory
1099	HCE2B33	Cancer
1100	HCE2P86	Cancer
1101	HCE2W56	Cancer
1102	HCE3C52	Cancer
1103	HCE3F11	Digestive, Neural/Sensory
1104	HCE3F70	Cancer
1105	HCE3G20	Cancer
1106	HCE3J79	Cancer
1107	HCE3L18	Neural/Sensory
1108	HCE3Q10	Cancer
1109	HCE3T57	Cancer
1110	HCE3Z39	Cancer
1111	HCE3Z61	Cancer
1112	HCE4G61	Cancer
1113	HCE4L28	Cancer
1114	HCE4Y07	Cancer
1115	HCE5B20	Mixed Petal, Neural/Sensory
1116	HCE5G23	Cancer
1117	HCE5M29	Cancer
1118	HCEAB46	Cancer
1119	HCEBA03	Neural/Sensory
1120	HCEBC76	Neural/Sensory
1121	HCEBC87	Cancer
1122	HCEBF19	Cancer
1123	HCEBN44	Neural/Sensory
1124	HCEBR71	Neural/Sensory
1125	HCECA49	Cancer
1126	HCECN54	Excretory, Neural/Sensory
1127	HCEDH38	Mixed Fetal, Neural/Sensory
1128	HCEDH81	Cancer
1129	HCEDO21	Neural/Sensory
1130	HCEDO84	Cancer
1131	HCEEC15	Cancer
1132	HCEEF50	Cardiovascular, Neural/Sensory
1133	HCEEK50	Cancer
1134	HCEEM18	Cancer
1135	HCEES64	Neural/Sensory
1136	HCEES66	Digestive, Neural/Sensory
1137	HCEFB70	Neural/Sensory
1138	HCEFE96	Cancer
1139	HCEFI77	Neural/Sensory
1140	HCEFZ05	Digestive, Mixed Fetal, Neural/Sensory
1141	HCEIA77	Cancer
1142	HCEIE80	Cancer
1143	HCEIF12	Cancer
1144	HCEJG71	Cancer
1145	HCEJP80	Neural/Sensory
1146	HCEJQ69	Cancer
1147	HCELE47	Cancer
1148	HCEMD38	Connective/Epithelial, Neural/Sensory
1149	HCEMU42	Cancer
1150	HCENE16	Cancer
1151	HCEOC41	Cancer
1152	HCEOR67	Neural/Sensory
1153	HCEPE30	Excretory, Neural/Sensory
1154	HCEPF19	Cancer
1155	HCEQA68	Neural/Sensory
1156	HCESA34	Cancer
1157	HCESF40	Immune/Hematopoetic, Neural/Sensory
1158	HCEVB07	Cancer
1159	HCEVB32	Cancer
1160	HCEVB76	Cancer
1161	HCEVF30	Cancer
1162	HCEVR60	Cancer
1163	HCEZR26	Cancer
1164	HCEZS40	Cancer
1165	HCFAD33	Cancer
1166	HCFBH15	Immune/Hematopoetic
1167	HCFBJ91	Immune/Hematopoetic
1168	HCFBL76	Cancer
1169	HCFBM53	Cancer
1170	HCFBQ81	Immune/Hematopoetic
1171	HCFCC07	Digestive, Immune/Hematopoetic
1172	HCFCE10	Cancer
1173	HCPCI07	Immune/Hematopoetic
1174	HCFDD76	Immune/Hematopoetic
1175	HCFLD84	Cancer
1176	HCFLQ84	Cancer
1177	HCFLR78	Cancer
1178	HCFLS78	Cancer
1179	HCFMJ81	Cancer
1180	HCFMM26	Immune/Hematopoetic
1181	HCFMS95	Cancer
1182	HCFMV39	Cancer
1183	HCFMX35	Immune/Hematopoetic
1184	HCFMX95	Immune/Hematopoetic
1185	HCFNC26	Immune/Hematopoetic
1186	HCFNF11	Cancer
1187	HCFNK47	Cancer
1188	HCFNN16	Cancer
1189	HCFOG45	Cancer
1190	HCGAD44	Cancer
1191	HCGBE81	Cancer
1192	HCGMF16	Cancer
1193	HCHAA63	Cancer
1194	HCHAR28	Cancer
1195	HCHAR90	Cancer
1196	HCHCF61	Reproductive
1197	HCHMX01	Cancer
1198	HCHNT03	Digestive, Reproductive
1199	HCHPF68	Cancer
1200	HCHPU32	Cancer
1201	HCLBW50	Cancer
1202	HCLCJ15	Cancer
1203	HCLCW50	Respiratory
1204	HCMSC92	Cancer
1205	HCMSS06	Cancer
1206	HCMSW93	Cancer
1207	HCMSX86	Cancer
1208	HCNAH57	Digestive
1209	HCNAP62	Cancer
1210	HCNAV36	Cancer
1211	HCNDA61	Cancer
1212	HCNDV12	Digestive, Reproductive
1213	HCNSB01	Cancer
1214	HCNSD76	Digestive
1215	HCNSP40	Cancer
1216	HCOMM91	Cancer
1217	HCOPG62	Cancer
1218	HCPAA69	Neural/Sensory
1219	HCQAI40	Digestive, Immune/Hematopoetic, Reproductive
1220	HCQAM33	Musculoskeletal, Reproductive
1221	HCQCF36	Digestive, Immune/Hematopoetic
1222	HCQDE22	Digestive
1223	HCRAF32	Neural/Sensory
1224	HCRAI47	Cancer
1225	HCRBL20	Cancer
1226	HCRBR74	Cancer
1227	HCRME12	Cancer
1228	HCRMZ90	Cancer
1229	HCRNC80	Cancer
1230	HCRNF14	Cancer
1231	HCRNO87	Cancer
1232	HCRNU76	Cancer
1233	HCRPV17	Cancer
1234	HCUAQ30	Immune/Hematopoetic
1235	HCUBF15	Immune/Hematopoetic
1236	HCUBL62	Immune/Hematopoetic
1237	HCUBN59	Immune/Hematopoetic
1238	HCUBN71	Immune/Hematopoetic, Reproductive
1239	HCUBV79	Immune/Hematopoetic, Neural/Sensory
1240	HCUBW95	Immune/Hematopoetic, Neural/Sensory
1241	HCUDB38	Immune/Hematopoetic
1242	HCUDC07	Immune/Hematopoetic
1243	HCUDD24	Digestive, Immune/Hematopoetic, Reproductive
1244	HCUDE16	Cancer
1245	HCUDK80	Immune/Hematopoetic
1246	HCUDW10	Cancer
1247	HCUEN88	Immune/Hematopoetic
1248	HCUEP91	Immune/Hematopoetic
1249	HCUFX40	Immune/Hematopoetic
1250	HCUFZ62	Immune/Hematopoetic
1251	HCUGC55	Immune/Hematopoetic
1252	HCUGE72	Cancer
1253	HCUGO12	Digestive, Immune/Hematopoetic, Mixed Fetal
1254	HCUHF89	Cancer
1255	HCUHL13	Immune/Hematopoetic
1256	HCUHQ40	Cancer
1257	HCUIN80	Immune/Hematopoetic
1258	HCUIO20	Immune/Hematopoetic
1259	HCWAG01	Cancer
1260	HCWAU23	Immune/Hematopoetic
1261	HCWBB42	Immune/Hematopoetic
1262	HCWBE20	Immune/Hematopoetic
1263	HCWBE22	Immune/Hematopoetic, Neural/Sensory
1264	HCWBP34	Immune/Hematopoetic
1265	HCWBU94	Immune/Hematopoetic
1266	HCWCH14	Immune/Hematopoetic
1267	HCWCT62	Immune/Hematopoetic
1268	HCWDE90	Immune/Hematopoetic
1269	HCWDL75	Cardiovascular, Immune/Hematopoetic
1270	HCWDV84	Immune/Hematopoetic
1271	HCWDY64	Excretory, Immune/Hematopoetic
1272	HCWEM59	Immune/Hematopoetic
1273	HCWFL55	Immune/Hematopoetic
1274	HCWFT79	Immune/Hematopoetic
1275	HCWFU77	Cancer
1276	HCWFV11	Immune/Hematopoetic
1277	HCWFZ59	Immune/Hematopoetic
1278	HCWHN10	Immune/Hematopoetic
1279	HCWHP79	Immune/Hematopoetic
1280	HCWHT35	Immune/Hematopoetic
1281	HCWHV88	Cancer
1282	HCWHX82	Immune/Hematopoetic, Neural/Sensory
1283	HCWHZ24	Immune/Hematopoetic
1284	HCWHZ93	Immune/Hematopoetic, Neural/Sensory
1285	HCWKR01	Cancer
1286	HCWUA22	Immune/Hematopoetic
1287	HCWUI05	Immune/Hematopoetic
1288	HCWUI13	Immune/Hematopoetic
1289	HCYBG92	Cancer
1290	HCYBI36	Cancer
1291	HCYBI36	Cancer
1292	HCYBI42	Digestive, Reproductive
1293	HCYBN55	Cancer
1294	HDAAC10	Cardiovascular, Digestive, Reproductive
1295	HDABU01	Neural/Sensory
1296	HDABV82	Cancer
1297	HDDMW90	Cancer
1298	HDFQB14	Immune/Hematopoetic, Neural/Sensory,
		Reproductive
1299	HDHMB42	Cancer
1300	HDLAG89	Cancer
1301	HDLAY18	Cancer
1302	HDPAE76	Cancer
1303	HDPAJ93	Cancer
1304	HDPAP35	Excretory, Immune/Hematopoetic, Neural/Sensory
1305	HDPAQ55	Digestive, Immune/Hematopoetic, Reproductive
1306	HDPAS92	Cancer
1307	HDPAU16	Cancer
1308	HDPAW44	Cancer
1309	HDPBA48	Immune/Hematopoetic
1310	HDPBN34	Immune/Hematopoetic
1311	HDPBO81	Digestive, Immune/Hematopoetic, Reproductive
1312	HDPBW68	Cancer
1313	HDPCJ43	Cancer
1314	HDPCL05	Immune/Hematopoetic
1315	HDPCM26	Cancer
1316	HDPDD03	Cancer
1317	HDPDI45	Cancer
1318	HDPDI66	Cancer
1319	HDPFB02	Cancer
1320	HDPFY41	Cancer
1321	HDPGE10	Immune/Hematopoetic
1322	HDPGT25	Cancer
1323	HDPHH40	Cancer
1324	HDPIE85	Cancer
1325	HDPIO09	Cancer
1326	HDPIO54	Immune/Hematopoetic, Reproductive
1327	HDPIW06	Digestive, Immune/Hematopoetic, Neural/Sensory
1328	HDPKB18	Immune/Hematopoetic
1329	HDPKI93	Cancer
1330	HDPLO25	Cancer
1331	HDPLV95	Immune/Hematopoetic, Reproductive
1332	HDPMA04	Immune/Hematopoetic
1333	HDPML23	Immune/Hematopoetic, Neural/Sensory
1334	HDPMM88	Cancer
1335	HDPMS12	Cancer
1336	HDPMV72	Immune/Hematopoetic
1337	HDPND68	Cancer
1338	HDPOR60	Cancer
1339	HDPOW86	Cancer
1340	HDPPJ60	Cancer
1341	HDPQN11	Cancer
1342	HDPQN12	Cancer
1343	HDPQV66	Immune/Hematopoetic
1344	HDPRH52	Cancer
1345	HDPRJ60	Cancer
1346	HDPRK33	Immune/Hematopoetic, Mixed Fetal
1347	HDPRN70	Immune/Hematopoetic
1348	HDPRX82	Cancer
1349	HDPSB01	Cancer
1350	HDPTC31	Immune/Hematopoetic
1351	HDPTM61	Digestive, Immune/Hematopoetic
1352	HDPTQ73	Cancer
1353	HDPTW24	Immune/Hematopoetic
1354	HDPTW65	Excretory
1355	HDPVW11	Cancer
1356	HDPWP69	Cancer
1357	HDPXL05	Immune/Hematopoetic, Reproductive
1358	HDPXQ54	Cardiovascular, Connective/Epithelial,
		Immune/Hematopoetic
1359	HDPXR23	Digestive, Immune/Hematopoetic
1360	HDPXY88	Cancer
1361	HDPYE41	Immune/Hematopoetic
1362	HDQFN31	Cancer
1363	HDQFN60	Cancer
1364	HDQFU27	Cancer
1365	HDQFU73	Digestive, Immune/Hematopoetic
1366	HDQGO29	Immune/Hematopoetic
1367	HDQGY41	Cancer
1368	HDQHC29	Cancer
1369	HDQHO40	Cancer
1370	HDQHQ91	Cancer
1371	HDQHY04	Cancer
1372	HDQIH54	Immune/Hematopoetic
1373	HDRMB11	Digestive
1374	HDRMF68	Digestive, Respiratory
1375	HDRMI82	Cancer
1376	HDSAG91	Immune/Hematopoetic
1377	HDSAP81	Cancer
1378	HDSAP92	Cancer
1379	HDTAB05	Cancer
1380	HDTAB58	Cancer
1381	HDTAE40	Digestive, Immune/Hematopoetic
1382	HDTAQ57	Connective/Epithelial, Immune/Hematopoetic,
		Reproductive
1383	HDTAR06	Cancer
1384	HDTAT90	Cancer
1385	HDTAV25	Cancer
1386	HDTAW95	Cancer
1387	HDTAY29	Cancer
1388	HDTBP51	Digestive, Immune/Hematopoetic, Reproductive
1389	HDTBW53	Cancer
1390	HDTDC56	Cancer
1391	HDTDM65	Cancer
1392	HDTDT55	Cancer
1393	HDTDZ50	Cancer
1394	HDTGC86	Digestive, Immune/Hematopoetic, Reproductive
1395	HDTII23	Immune/Hematopoetic
1396	HDTJG33	Cancer
1397	HDTKS69	Cancer
1398	HDTLR06	Cancer
1399	HDUAC77	Immune/Hematopoetic, Mixed Fetal,
		Neural/Sensory
1400	HE2AA26	Mixed Fetal
1401	HE2AF21	Mixed Fetal
1402	HE2AG50	Cancer
1403	HE2AT09	Cancer
1404	HE2AV74	Cancer
1405	HE2AX96	Mixed Fetal
1406	HE2AY71	Cancer
1407	HE2BX71	Cancer
1408	HE2CT29	Mixed Fetal
1409	HE2DC87	Mixed Fetal
1410	HE2EC79	Connective/Epithelial, Mixed Fetal, Neural/Sensory
1411	HE2EO70	Mixed Fetal, Neural/Sensory
1412	HE2ES51	Cancer
1413	HE2FB90	Cancer
1414	HE2FC81	Mixed Fetal
1415	HE2FE45	Cancer
1416	HE2FE69	Cancer
1417	HE2FI45	Cancer
1418	HE2FL70	Immune/Hematopoetic, Mixed Fetal,
		Neural/Sensory
1419	HE2GS36	Digestive, Mixed Fetal, Reproductive
1420	HE2GT20	Cancer
1421	HE2ID06	Cancer
1422	HE2KK74	Cancer
1423	HE2LW65	Cancer
1424	HE2NR62	Cancer
1425	HE2OF09	Cancer
1426	HE2OO64	Cancer
1427	HE2OW03	Immune/Hematopoetic, Mixed Fetal
1428	HB2PI29	Cancer
1429	HE2PO86	Cancer
1430	HE2RN91	Cancer
1431	HE2RO22	Mixed Fetal
1432	HE2SI26	Cancer
1433	HE6AJ31	Mixed Fetal
1434	HE6CL49	Mixed Fetal
1435	HE6CT22	Mixed Fetal, Reproductive
1436	HE6CT56	Mixed Fetal, Neural/Sensory
1437	HE6CY88	Mixed Fetal
1438	HE6EL90	Cancer
1439	HE6FB81	Mixed Fetal
1440	HE6GA29	Mixed Fetal
1441	HE6GE84	Mixed Fetal
1442	HE6GL64	Cardiovascular, Immune/Hematopoetic, Mixed Fetal
1443	HE6GR02	Immune/Hematopoetic, Mixed Fetal
1444	HE7TF86	Cancer
1445	HE7TM22	Mixed Fetal
1446	HE8AO36	Mixed Fetal
1447	HE8CH92	Cancer
1448	HE8CV18	Cancer
1449	HE8DG53	Cancer
1450	HE8DR25	Excretory, Mixed Fetal, Neural/Sensory
1451	HE8DX88	Mixed Fetal
1452	HE8DY08	Cancer
1453	HE8EF43	Cancer
1454	HE8EM69	Cancer
1455	HE8ER60	Cancer
1456	HE8EU04	Cancer
1457	HE8EV15	Mixed Fetal
1458	HE8EW79	Cancer
1459	HE8EY43	Cancer
1460	HE8EZ48	Cancer
1461	HE8FD93	Cancer
1462	HE8FK78	Cancer
1463	HE8MG65	Cancer
1464	HE8MG70	Mixed Fetal, Neural/Sensory
1465	HE8MH77	Immune/Hematopoetic, Mixed Fetal,
		Neural/Sensory
1466	HE8ND56	Cancer
1467	HE8NG02	Mixed Fetal, Reproductive
1468	HE8NQ42	Mixed Fetal
1469	HE8OK73	Mixed Fetal, Neural/Sensory
1470	HE8PW38	Mixed Fetal, Neural/Sensory, Reproductive
1471	HE8QD31	Digestive, Mixed Fetal, Neural/Sensory
1472	HE8QG24	Cancer
1473	HE8QO53	Cancer
1474	HE8QT72	Mixed Fetal
1475	HESQV43	Cancer
1476	HE8SE91	Cancer
1477	HE8TB68	Cancer
1478	HE8TY90	Cancer
1479	HE8UT25	Mixed Fetal
1480	HE8UY36	Cancer
1481	HE9AN21	Mixed Fetal, Neural/Sensory
1482	HE9CS37	Cancer
1483	HE9FB42	Cancer
1484	HE9FC17	Cancer
1485	HE9FE83	Immune/Hematopoetic, Mixed Fetal,
		Musculoskeletal
1486	HE9FT63	Cancer
1487	HE9HU17	Cancer
1488	HE9HW52	Cancer
1489	HE9MI43	Cancer
1490	HE9NB19	Immune/Hematopoetic, Mixed Fetal, Reproductive
1491	HE9ND27	Cancer
1492	HE9ND43	Cancer
1493	HE9ND48	Mixed Fetal
1494	HE9NH44	Cancer
1495	HE9NN84	Cancer
1496	HE9PF45	Cancer
1497	HE9PM90	Cancer
1498	HE9PR39	Digestive, Mixed Fetal, Musculoskeletal
1499	HE9QN39	Cancer
1500	HE9RJ42	Mixed Fetal
1501	HE9RO27	Connective/Epithelial, Mixed Fetal
1502	HE9RO44	Immune/Hematopoetic, Mixed Fetal
1503	HE9SE18	Digestive
1504	HE9TH18	Cancer
1505	HEAAH81	Cancer
1506	HEAAJ57	Immune/Hematopoetic, Reproductive
1507	HEAAX57	Reproductive
1508	HEBAH57	Neural/Sensory
1509	HEBAL06	Neural/Sensory, Reproductive
1510	HEBBW11	Cancer
1511	HEBCM27	Cancer
1512	HEBDF05	Neural/Sensory
1513	HEBFI91	Neural/Sensory
1514	HEBFL88	Neural/Sensory
1515	HEBFT20	Neural/Sensory
1516	HEBGF73	Cancer
1517	HEEAA16	Cancer
1518	HEEAG84	Reproductive
1519	HEEAG93	Cancer
1520	HEEAM62	Excretory, Reproductive
1521	HEEAZ65	Musculoskeletal, Reproductive
1522	HEEBB55	Cancer
1523	HEEBI05	Digestive, Reproductive
1524	HEGAI91	Reproductive
1525	HEGAK23	Cancer
1526	HEGAK44	Cancer
1527	HEGAK44	Cancer
1528	HEGAL46	Cancer
1529	HEGCL11	Cardiovascular, Immune/Hematopoetic,
		Reproductive
1530	HEIAB33	Cardiovascular, Digestive, Immune/Hematopoetic
1531	HEIAC52	Cancer
1532	HEIAU93	Immune/Hematopoetic
1533	HELAW45	Cardiovascular
1534	HELBA06	Cancer
1535	HELBC12	Cancer
1536	HELBU29	Cancer
1537	HELBW38	Cancer
1538	HELDL29	Cardiovascular
1539	HELDY05	Cancer
1540	HELDY41	Cancer
1541	HELDY74	Cancer
1542	HELDZ32	Cancer
1543	HELFQ07	Cancer
1544	HELGF34	Cancer
1545	HELHD64	Cancer
1546	HELHN47	Cancer
1547	HELHN47	Cancer
1548	HEMAE80	Cardiovascular, Musculoskeletal, Reproductive
1549	HEMCM42	Cancer
1550	HEMCV19	Cancer
1551	HEMDX17	Cardiovascular
1552	HEMFA84	Cancer
1553	HEMFQ46	Cancer
1554	HEMFS60	Cancer
1555	HEMGB12	Cancer
1556	HEMGD15	Cancer
1557	HEOMG13	Digestive/Immune/Hematopoetic, Reproductive
1558	HEOMQ62	Cancer
1559	HEOMR73	Immune/Hematopoetic
1560	HEOMW84	Connective/Epithelial, Immune/Hematopoetic
1561	HEOMX53	Digestive, Immune/Hematopoetic, Neural/Sensor
1562	HEONC95	Cancer
1563	HEONM66	Immune/Hematopoetic
1564	HEONP72	Cancer
1565	HEONX38	Cancer
1566	HEOOV79	Cancer
1567	HEOQX60	Cancer
1568	HEPBC02	Cancer
1569	HEPCE18	Cancer
1570	HEPCE37	Reproductive
1571	HEPCU48	Cancer
1572	HEQAF19	Cancer
1573	HEQAG39	Cancer
1574	HEQAO65	Cancer
1575	HEQBF32	Cardiovascular, Neural/Sensory, Reproductive
1576	HEQBH65	Immune/Hematopoetic, Reproductive
1577	HEQBR95	Cancer
1578	HEQBU15	Cancer
1579	HERAG83	Connective/Epithelial
1580	HERAH36	Connective/Epithelial
1581	HERAM05	Connective/Epithelial, Immune/Hematopoetic
1582	HERAN54	Connective/Epithelial
1583	HERAN63	Connective/Epithelial, Reproductive
1584	HESAL35	Connective/Epithelial, Mixed Fetal
1585	HETAD68	Cancer
1586	HETAM53	Cancer
1587	HETAR42	Cancer
1588	HETAR54	Cancer
1589	HETAY39	Cancer
1590	HETBA14	Cancer
1591	HETBB70	Immune/Hematopoetic, Reproductive
1592	HETBX14	Cancer
1593	HETCL11	Cancer
1594	HETCO02	Immune/Hematopoetic, Reproductive
1595	HETCP58	Reproductive
1596	HETDB76	Musculoskeletal, Reproductive
1597	HETDE26	Cancer
1598	HBTDM20	Cancer
1599	HETDT81	Digestive, Immune/Hematopoetic, Reproductive
1600	HETEQ88	Cancer
1601	HETEW02	Cancer
1602	HETFI51	Reproductive
1603	HETFJ05	Cancer
1604	HETHE81	Cancer
1605	HETHN28	Cancer
1606	HETHO95	Cancer
1607	HETHR73	Cancer
1608	HETHW90	Cancer
1609	HETIB83	Cancer
1610	HETJZ45	Cancer
1611	HETKD92	Cancer
1612	HETKL27	Cancer
1613	HETLT82	Immune/Hematopoetic, Reproductive
1614	HFAAH18	Connective/Epithelial, Neural/Sensory
1615	HFACI31	Neural/Sensory
1616	HFADD53	Cancer
1617	HFADF37	Cancer
1618	HFAME37	Neural/Sensory
1619	HFAUO78	Cancer
1620	HFCAA91	Neural/Sensory
1621	HFCAL39	Cancer
1622	HFCBD73	Cancer
1623	HFCCU63	Neural/Sensory
1624	HFCDR13	Neural/Sensory
1625	HFCDV54	Cancer
1626	HFCDW34	Cancer
1627	HFCDW42	Cancer
1628	HFCED59	Immune/Hematopoetic, Neural/Sensory
1629	HFCEP45	Neural/Sensory
1630	HFCEW05	Cardiovascular, Neural/Sensory
1631	HFCEW42	Neural/Sensory
1632	HFCFJ18	Cancer
1633	HFCFJ18	Cancer
1634	HFEAF41	Connective/Epithelial, Digestive
1635	HFEAN33	Cancer
1636	HFEAN33	Cancer
1637	HFEAT91	Connective/Epithelial, Immune/Hematopoetic
1638	HFEBA88	Cancer
1639	HFEBE12	Cancer
1640	HFEBF41	Cancer
1641	HFEBH21	Connective/Epithelial, Reproductive
1642	HFEBP27	Cancer
1643	HFEBV76	Cancer
1644	HFFAE91	Neural/Sensory
1645	HFFAK76	Neural/Sensory, Reproductive
1646	HFFAT33	Cancer
1647	HFGAB48	Digestive, Neural/Sensory
1648	HFGAB89	Cancer
1649	HFGAG96	Cancer
1650	HFGAH44	Cancer
1651	HFGAL10	Neural/Sensory
1652	HFIAB31	Cancer
1653	HFIAP16	Musculoskeletal
1654	HFIAX46	Cardiovascular, Musculoskeletal
1655	HFIBV09	Cancer
1656	HFICL62	Cancer
1657	HFICR14	Cancer
1658	HFDQ92	Cancer
1659	HFIDS78	Connective/Epithelial, Digestive, Musculoskeletal
1660	HFIHO70	Cancer
1661	HFIHQ89	Cardiovascular, Connective/Epithelial,
		Musculoskeletal
1662	HFIHZ96	Musculoskeletal
1663	HFITF82	Immune/Hematopoetic, Musculoskeletal
1664	HFIUE67	Cancer
1665	HFIUE82	Cancer
1666	HFIUM15	Cancer
1667	HFIUP37	Musculoskeletal
1668	HFIUR35	Musculoskeletal
1669	HFIUW36	Cancer
1670	HFIVA74	Musculoskeletal
1671	HFIVB57	Digestive, Musculoskeletal, Reproductive
1672	HFIXC91	Cancer
1673	HFIYI70	Cancer
1674	HFKCK85	Cancer
1675	HFKEB72	Excretory
1676	HFKEE48	Cancer
1677	HFKEM67	Excretory, Neural/Sensory, Reproductive
1678	HFKEN81	Excretory
1679	HFKET93	Excretory, Immune/Hematopoetic, Neural/Sensory
1680	HFKFF78	Excretory
1681	HFKFI40	Cancer
1682	HFKFJ07	Cancer
1683	HFKFL13	Cancer
1684	HFKFL92	Cancer
1685	HFKFN45	Cancer
1686	HFKFY69	Excretory
1687	HFKGE44	Cancer
1688	HFKHW50	Cancer
1689	HFKKS66	Cancer
1690	HFKLE15	Cancer
1691	HFKLX38	Excretory, Respiratory
1692	HFKME15	Excretory
1693	HFLSH80	Cancer
1694	HFOXB55	Cancer
1695	HFOXE30	Musculoskeletal
1696	HFOXO72	Musculoskeletal, Neural/Sensory, Reproductive
1697	HFOXV65	Immune/Hematopoetic, Musculoskeletal,
		Reproductive
1698	HFOYC02	Cancer
1699	HFOYV27	Cancer
1700	HFPAA06	Cancer
1701	HFPAE26	Neural/Sensory
1702	HFPBA88	Cancer
1703	HFPBD47	Cancer
1704	HFPBM30	Neural/Sensory
1705	HFPBW41	Neural/Sensory
1706	HFPBY77	Cancer
1707	HFPCN45	Cancer
1708	HFPCT29	Neural/Sensory
1709	HFPCY04	Neural/Sensory
1710	HFPCY39	Cancer
1711	HFPDB26	Immune/Hematopoetic, Neural/Sensory,
		Reproductive
1712	HFPDE69	Neural/Sensory
1713	HFPDE86	Neural/Sensory
1714	HFPES77	Cancer
1715	HFPFK57	Neural/Sensory, Reproductive
1716	HFPHA80	Neural/Sensory
1717	HFPHB92	Excretory, Neural/Sensory
1718	HFPHS77	Cancer
1719	HFRAC19	Neural/Sensory
1720	HFRAW86	Neural/Sensory
1721	HFRBF28	Neural/Sensory
1722	HFRBR70	Cancer
1723	HFRBU14	Neural/Sensory
1724	HFSAY85	Cancer
1725	HFSBG13	Immune/Hematopoetic
1726	HFTAB66	Digestive, Neural/Sensory
1727	HFTBE43	Cancer
1728	HFTBN23	Cancer
1729	HFTBQ52	Cancer
1730	HFTBS49	Immune/Hematopoetic, Neural/Sensory,
		Reproductive
1731	HFFBY59	Cancer
1732	HFFBY96	Immune/Hematopoetic, Neural/Sensory,
		Reproductive
1733	HFFCR15	Neural/Sensory
1734	HFTCT67	Connective/Epithelial, Digestive, Neural/Sensory
1735	HFTDJ36	Cancer
1736	HFVGM16	Cancer
1737	HFVGR41	Cancer
1738	HFVGZ42	Cancer
1739	HFVGZ79	Cancer
1740	HFVHE58	Cancer
1741	HFVHR84	Connective/Epithelial, Digestive
1742	HFVHY45	Digestive, Neural/Sensory
1743	HFVIC62	Digestive, Immune/Hematopoetic, Reproductive
1744	HFVJP07	Digestive, Immune/Hematopoetic
1745	HFVJY02	Digestive, Mixed Fetal, Neural/Sensory
1746	HFVKC95	Cancer
1747	HFXAX45	Neural/Sensory
1748	HFXBJ12	Neural/Sensory
1749	HFXBO84	Neural/Sensory
1750	HFXBS43	Neural/Sensory
1751	HFXBS68	Neural/Sensory
1752	HFXBT12	Immune/Hematopoetic, Neural/Sensory
1753	HFXBW09	Neural/Sensory
1754	HFXBW82	Neural/sensorY
1755	HFXDE67	Neural/Sensory
1756	HFXDG13	Cancer
1757	HFXDI56	Immune/Hematopoetic, Musculoskeletal,
		Neural/Sensory
1758	HFXDK20	Immune/Hematopoetic, Neural/Sensory
1759	HFXDN34	Neural/Sensory
1760	HFXDO60	Immune/Hematopoetic, Neural/Sensory
1761	HFXDT43	Neural/Sensory
1762	HFXDX75	Neural/Sensory
1763	HFXDZ79	Neural/Sensory
1764	HFXFG45	Neural/Sensory
1765	HFXFH04	Immune/Hematopoetic, Neural/Sensory
1766	HFXFZ81	Neural/Sensory
1767	HFXGT58	Neural/Sensory
1768	HFXGW52	Neural/Sensory
1769	HFXHC41	Neural/Sensory, Reproductive
1770	HFXHC85	Cancer
1771	HFXHK32	Neural/Sensory
1772	HFXHM17	Digestive, Neural/Sensory, Reproductive
1773	HFXHN31	Neural/Sensory
1774	HFXHN68	Cancer
1775	HFXHO83	Cancer
1776	HFXJC53	Neural/Sensory, Reproductive, Respiratory
1777	HFXJM91	Cancer
1778	HFXJW48	Cancer
1779	HFXJY38	Neural/Sensory
1780	HFXJZ18	Neural/Sensory
1781	HFXKD36	Digestive, Musculoskeletal, Neural/Sensory
1782	HFXKK25	Cancer
1783	HFXKL58	Cancer
1784	HFXKR54	Endocrine, Immune/Hematopoetic, Neural/Sensory
1785	HFXLL52	Neural/Sensory
1786	HGBAC11	Cancer
1787	HGBAJ60	Cancer
1788	HGBAJ93	Cancer
1789	HGBAR55	Cancer
1790	HGBBQ69	Cancer
1791	HGBCO51	Cancer
1792	HGBDH53	Cancer
1793	HGBDL30	Digestive
1794	HGBDY06	Cancer
1795	HGBGO11	Digestive, Immune/Hematopoetic
1796	HGBGV89	Digestive
1797	HGBHK46	Digestive
1798	HGBHM10	Cancer
1799	HGBHM89	Cancer
1800	HGBHR26	Digestive
1801	HGCAB62	Cancer
1802	HGCAC66	Cancer
1803	HGCNC48	Reproductive
1804	HGLAJ51	Cancer
1805	HGLAM46	Cancer
1806	HGLAM53	Immune/Hematopoetic, Neural/Sensory,
		Reproductive
1807	HGLAM56	Cancer
1808	HGLAW96	Immune/Hematopoetic, Neural/Sensory
1809	HGLDB64	Cancer
1810	HGLDE38	Cancer
1811	HGOCD38	Cancer
1812	HHAAC17	Digestive, Musculoskeletal, Neural/Sensory
1813	HHATA33	Cancer
1814	HHAUQ28	Immune/Hematopoetic
1815	HHBAG14	Cancer
1816	HHBGF77	Cancer
1817	HHEAD14	Cancer
1818	HHEAH25	Cancer
1819	HHEAH86	Cancer
1820	HHEBW54	Cancer
1821	HHEDD41	Cancer
1822	HHEDN80	Cancer
1823	HHEFO24	Cardiovascular, Immune/Hematopoetic,
		Neural/Sensory
1824	HHEMO80	Immune/Hematopoetic
1825	HHEMQ28	Digestive, Immune/Hematopoetic, Neural/Sensory
1826	HHEND31	Cancer
1827	HHENL07	Immune/Hematopoetic
1828	HHENW77	Cancer
1829	HHENZ16	Cancer
1830	HHEPF59	Cancer
1831	HHEPG23	Cancer
1832	HHEPG41	Cancer
1833	HHEPJ23	Cancer
1834	HHEPL34	Immune/Hematopoetic
1835	HHEPU32	Cancer
1836	HHEQR55	Immune/Hematopoetic
1837	HHESQ62	Immune/Hematopoetic
1838	HHEXM06	Immune/Hematopoetic
1839	HHFBY69	Cancer
1840	HHFCE59	Cancer
1841	HHFCF08	Cancer
1842	HHFCJ31	Cardiovascular, Connective/Epithelial, Reproductive
1843	HHFCP32	Cancer
1844	HHFCW75	Cardiovascular
1845	HHFCY66	Cardiovascular, Immune/Hematopoetic, Mixed Fetal
1846	HHFCZ67	Cardiovascular
1847	HHFDG44	Cardiovascular, Endocrine, Immune/Hematopoetic
1848	HHFDG51	Connective/Epithelial, Musculoskeletal
1849	HHFDH56	Cardiovascular, Immune/Hematopoetic,
		Neural/Sensory
1850	HHFDL91	Cancer
1851	HHFDM48	Cardiovascular, Neural/Sensory, Reproductive
1852	HHFDN48	Cancer
1853	HHFDN67	Cardiovascular
1854	HHFFU55	Cancer
1855	HHFGA11	Cancer
1856	HHFHD01	Cardiovascular, Musculoskeletal, Neural/Sensory
1857	HHFHD37	Cardiovascular, Immune/Hematopoetic, Respiratory
1858	HHFHD92	Cancer
1859	HHFHH34	Cardiovascular
1860	HHFHI76	Cardiovascular, Immune/Hematopoetic,
		Reproductive
1861	HHFHP90	Cardiovascular
1862	HHFHV86	Cardiovascular, Digestive
1863	HHFKM76	Cancer
1864	HHFLH45	Cardiovascular, Reproductive
1865	HHFML08	Cardiovascular, Immune/Hematopoetic, Mixed Fetal
1866	HHFOS77	Cancer
1867	HHFUC40	Cardiovascular
1868	HHGAS83	Digestive, Immune/Hematopoetic
1869	HHGAU81	Cancer
1870	HHGBC54	Cancer
1871	HHGBF89	Mixed Fetal
1872	HHGBK24	Cancer
1873	HHGBO65	Cardiovascular
1874	HHGBR15	Cancer
1875	HHGCL33	Cancer
1876	HHGCN69	Digestive, Immune/Hematopoetic, Reproductive
1877	HHGCO88	Cancer
1878	HHGCP52	Cancer
1879	HHGCU49	Cancer
1880	HHGCW91	Digestive, Immune/Hematopoetic
1881	HHGDB72	Cancer
1882	HHGDC01	Cancer
1883	HHGDE24	Cancer
1884	HHGDI71	Excretory
1885	HHGDM70	Immune/Hematopoetic
1886	HHGDO13	Cancer
1887	HHGDU58	Musculoskeletal
1888	HHLAB07	Digestive, Immune/Hematopoetic
1889	HHLAB61	Digestive
1890	HHLBA14	Cancer
1891	HHLBA89	Digestive
1892	HHNAA05	Digestive
1893	HHNAB56	Digestive
1894	HHPBI45	Cardiovascular, Neural/Sensory
1895	HHPDV90	Cancer
1896	HHPDW05	Neural/Sensory
1897	HHPFD63	Endocrine, Immune/Hematopoetic, Neural/Sensory
1898	HHPFU18	Cancer
1899	HHPSD37	Cancer
1900	HHPSF70	Cancer
1901	HHPTD20	Cancer
1902	HHSAK25	Immune/Hematopoetic, Neural/Sensory
1903	HHSBJ93	Digestive, Immune/Hematopoetic, Neural/Sensory
1904	HHSDI45	Cancer
1905	HHSDI68	Neural/Sensory
1906	HHSDR11	Neural/Sensory
1907	HHSDT26	Neural/Sensory
1908	HHSEB66	Cancer
1909	HHSEG23	Neural/Sensory
1910	HHSFB67	Neural/Sensory
1911	HHSGH19	Neural/Sensory
1912	HHTLH52	Digestive, Neural/Sensory, Reproductive
1913	HHTMM10	Immune/Hematopoetic, Neural/Sensory
1914	HHTMM30	Cancer
1915	HIABC55	Cancer
1916	HIASB53	Cancer
1917	HIBCB67	Cancer
1918	HIBCE35	Cancer
1919	HIBCO28	Cancer
1920	HIBCW32	Cancer
1921	HIBEB47	Mixed Fetal, Neural/Sensory
1922	HIBED17	Cancer
1923	HIBEU15	Excretory, Immune/Hematopoetic, Neural/Sensory
1924	HIDAF73	Cancer
1925	HILCG67	Cancer
1926	HIPAJ43	Cancer
1927	HIPBA31	Cancer
1928	HISAD54	Cancer
1929	HISAG02	Cancer
1930	HISAQ04	Digestive, Neural/Sensory, Reproductive
1931	HISBF60	Cancer
1932	HISBL03	Cancer
1933	HISBT59	Cancer
1934	HISCJ55	Digestive
1935	HISCL83	Digestive
1936	HISCN02	Digestive
1937	HISCV60	Digestive
1938	HISEN93	Cancer
1939	HISES66	Digestive, Reproductive
1940	HISET33	Digestive
1941	HJAAJ58	Immune/Hematopoetic
1942	HJAAM10	Cancer
1943	HJAAT30	Cancer
1944	HJAAU36	Cancer
1945	HJABC16	Immune/Hematopoetic
1946	HJABL02	Cancer
1947	HJABZ65	Cardiovascular, Immune/Hematopoetic,
		Musculoskeletal
1948	HJACB89	Cancer
1949	HJACE05	Cancer
1950	HJACG02	Digestive, Immune/Hematopoetic
1951	HJBAF16	Cancer
1952	HJBAR01	Cancer
1953	HJBCD89	Cancer
1954	HJBCG12	Cancer
1955	HJBCY84	Cancer
1956	HJMAG88	Cancer
1957	HJMAN03	Cancer
1958	HJMAV91	Reproductive
1959	HJMBF77	Cancer
1960	HJPAV06	Cancer
1961	HJPAY76	Cancer
1962	HJPBB39	Cancer
1963	HJPCD40	Cancer
1964	HJPCE80	Cancer
1965	HJPCR70	Cancer
1966	HJPCY06	Cancer
1967	HJPDD28	Cancer
1968	HJPDJ64	Cancer
1969	HJTAA17	Cancer
1970	HJTAD07	Cancer
1971	HKAAV61	Connective/Epithelial, Digestive, Reproductive
1972	HKABN45	Cancer
1973	HKABT24	Connective/Epithelial, Digestive,
		Immune/Hematopoetic
1974	HKABW11	Cancer
1975	HKABY55	Cancer
1976	HKACC80	Cancer
1977	HKACU58	Cancer
1978	HKADJ17	Connective/Epithelial, Immune/Hematopoetic,
		Reproductive
1979	HKADX21	Cancer
1980	HKAEA19	Cancer
1981	HKAEL28	Connective/Epithelial, Immune/Hematopoetic,
		Reproductive
1982	HKAFB88	Cancer
1983	HKAFH74	Cancer
1984	HKAHL26	Cancer
1985	HKAHN23	Connective/Epithelial, Digestive, Mixed Fetal
1986	HKAIA52	Cancer
1987	HKAJF71	Connective/Epithelial, Immune/Hematopoetic,
		Musculoskeletal
1988	HKAJK47	Cancer
1989	HKAJW28	Cancer
1990	HKAKK09	Connective/Epithelial, Digestive, Mixed Fetal
1991	HKAOS84	Connective/Epithelial
1992	HKAOV90	Cancer
1993	HKBAB11	Immune/Hematopoetic
1994	HKBAL25	Cancer
1995	HKCSO46	Cancer
1996	HKDBK22	Excretory
1997	HKFBB67	Connective/Epithelial, Immune/Hematopoetic,
		Reproductive
1998	HKFBH93	Digestive, Reproductive
1999	HKGAA73	Cancer
2000	HKGAH42	Neural/Sensory
2001	HKGAJ54	Cancer
2002	HKGAK22	Endocrine, Excretory, Neural/Sensory
2003	HKGAM07	Digestive, Endoctine
2004	HKGAM29	Digestive, Immune/Hematopoetic
2005	HKGAR66	Cancer
2006	HKGAS32	Connective/Epithelial, Neural/Sensory
2007	HKGAU45	Immune/Hematopoetic
2008	HKGAV60	Cancer
2009	HKGAX42	Digestive, Immune/Hematopoetic, Reproductive
2010	HKGAZ06	Immune/Hematopoetic
2011	HKGBF67	Cancer
2012	HKGBH24	Mixed Fetal
2013	HKGBJ74	Reproductive
2014	HKGBS01	Cancer
2015	HKGBS49	Reproductive
2016	HKGCK61	Cancer
2017	HKGCN17	Cancer
2018	HKGCR51	Immune/Hematopoetic, Mixed Fetal,
		Neural/Sensory
2019	HKGDE09	Cancer
2020	HKGDJ35	Cancer
2021	HKGDJ66	Cancer
2022	HKIAC30	Cancer
2023	HKISA27	Cancer
2024	HKIXB95	Cancer
2025	HKIXE06	Cancer
2026	HKIXI03	Excretory
2027	HKIXL73	Cancer
2028	HKIYA46	Cancer
2029	HKIYE96	Excretory
2030	HKIYI48	Cancer
2031	HKIYO61	Excretory
2032	HKIY065	Cancer
2033	HKLAB16	Cancer
2034	HKLSA57	Digestive
2035	HKMAB92	Cancer
2036	HKMLH01	Cancer
2037	HKMLM65	Excretory
2038	HKMLN51	Cancer
2039	HKMLX18	Cancer
2040	HKMMM61	Excretory
2041	HKMMU22	Excretory
2042	HKMMV77	Excretory, Reproductive
2043	HKMNC43	Excretory
2044	HKNAA95	Digestive, Excretory, Immune/Hematopoetic
2045	HKPAD05	Cancer
2046	HKPAD17	Excretory
2047	HKPMB11	Digestive, Excretory, Musculoskeletal
2048	HKTAC77	Cancer
2049	HKTAE71	Cancer
2050	HKZAH22	Reproductive
2051	HKZAO35	Reproductive
2052	HKZAS29	Cancer
2053	HKZBS01	Reproductive
2054	HKZCK47	Immune/Hematopoetic, Reproductive
2055	HL1BD22	Cancer
2056	HL2AC08	Cancer
2057	HL2AG87	Immune/Hematopoetic, Neural/Sensory,
		Reproductive
2058	HL3AA35	Reproductive
2059	HL3AB91	Immune/Hematopoetic
2060	HLCAA05	Cancer
2061	HLDAB75	Cancer
2062	HLDBB60	Digestive, Neural/Sensory, Reproductive
2063	HLDBI84	Cancer
2064	HLDBO49	Cancer
2065	HLDBQ19	Cancer
2066	HLDBS43	Cancer
2067	HLDBW08	Digestive
2068	HLDBY02	Cancer
2069	HLDCD04	Cancer
2070	HLDCE79	Digestive
2071	HLDNK64	Cancer
2072	HLDOJ66	Digestive
2073	HLDOJ68	Cancer
2074	HLDOK36	Cancer
2075	HLDQA07	Digestive
2076	HLDQZ72	Cancer
2077	HLEDB16	Cancer
2078	HLFBI27	Respiratory
2079	HLHAY19	Cancer
2080	HLHBV54	Respiratory
2081	HLHCC76	Cancer
2082	HLHCF36	Respiratory
2083	HLHCH40	Cancer
2084	HLHCI58	Cancer
2085	HLHCM89	Cancer
2086	HLHDL42	Cancer
2087	HLHDP16	Cancer
2088	HLHDP65	Cancer
2089	HLHDP83	Cancer
2090	HLHDS67	Cancer
2091	HLHDS79	Cancer
2092	HLHDT18	Cancer
2093	HLHDZ58	Respiratory
2094	HLHEB47	Cancer
2095	HLHEF26	Cancer
2096	HLHEF54	Cancer
2097	HLHEO50	Cancer
2098	HLHEY02	Endocrine, Respiratory
2099	HLHFE92	Cancer
2100	HLHFM06	Cancer
2101	HLHFP18	Cancer
2102	HLHFR19	Neural/Sensory, Reproductive, Respiratory
2103	HLHSA86	Respiratory
2104	HLHSH36	Cancer
2105	HLHSK94	Cancer
2106	HLHSV96	Respiratory
2107	HLHTC70	Digestive, Immune/Hematopoetic, Respiratory
2108	HLHTP35	Cancer
2109	HLJBF86	Cancer
2110	HLJEA01	Respiratory
2111	HLLAX19	Cancer
2112	HLMAZ95	Cancer
2113	HLMBA30	Immune/Hematopoetic
2114	HLMBP18	Immune/Hematopoetic
2115	HLMCA92	Digestive, Immune/Hematopoetic, Neural/Sensory
2116	HLMDO03	Cancer
2117	HLMFC07	Cancer
2118	HLMFC54	Immune/Hematopoetic
2119	HLMFD11	Immune/Hematopoetic
2120	HLMFD85	Immune/Hematopoetic
2121	HLMFG37	Cancer
2122	HLMIG41	Immune/Hematopoetic
2123	HLMIS23	Immune/Hematopoetic, Musculoskeletal
2124	HLMIV11	Immune/Hematopoetic
2125	HLMIW92	Cancer
2126	HLMIY86	Cancer
2127	HLMMJ13	Immune/Hematopoetic, Musculoskeletal,
		Reproductive
2128	HLMMJ78	Immune/Hematopoetic
2129	HLMMO64	Immune/Hematopoetic, Reproductive
2130	HLMMU76	Cancer
2131	HLNAB07	Immune/Hematopoetic
2132	HLQAM28	Digestive, Reproductive
2133	HLQBQ38	Cancer
2134	HLQBQ85	Cancer
2135	HLQBQ86	Cancer
2136	HLQBR11	Cancer
2137	HLQBR41	Digestive, Mixed Fetal, Neural/Sensory
2138	HLQBV04	Cancer
2139	HLQCJ74	Digestive, Immune/Hematopoetic
2140	HLQCK07	Digestive
2141	HLQCW84	Digestive
2142	HLQDY81	Cardiovascular, Digestive, Musculoskeletal
2143	HLQGP82	Cancer
2144	HLSAD65	Cancer
2145	HLSAF81	Cancer
2146	HLTAF58	Digestive, Immune/Hematopoetic
2147	HLTAI94	Immune/Hematopoetic, Reproductive
2148	HLTBF35	Cancer
2149	HLTBL58	Immune/Hematopoetic, Musculoskeletal,
		Neural/Sensory
2150	HLTBS22	Cancer
2151	HLTBU43	Immune/Hematopoetic
2152	HLTBX31	Cancer
2153	HLTCJ63	Immune/Hematopoetic, Neural/Sensory,
		Reproductive
2154	HLTCR13	Cancer
2155	HLTCS34	Cancer
2156	HLTCY93	Cancer
2157	HLTDB65	Cancer
2158	HLTDE74	Cancer
2159	HLTDW13	Cancer
2160	HLTDY51	Cancer
2161	HLTEF12	Cancer
2162	HLTEI25	Immune/Hematopoetic
2163	HLTEK17	Cancer
2164	HLTER03	Immune/Hematopoetic
2165	HLTER45	Cancer
2166	HLTEY63	Cancer
2167	HLTGX30	Immune/Hematopoetic
2168	HLTHO84	Cancer
2169	HLTIP27	Immune/Hematopoetic
2170	HLUDB47	Cancer
2171	HLWAD92	Cancer
2172	HLWAT72	Cancer
2173	HLWAX42	Reproductive
2174	HLWAX74	Cancer
2175	HLWAZ66	Cancer
2176	HLWAZ70	Cancer
2177	HLWBF94	Endocrine, Neural/Sensory, Reproductive
2178	HLWBG83	Cancer
2179	HLWBM40	Neural/Sensory, Reproductive
2180	HLWBT09	Reproductive
2181	HLWBZ21	Immune/Hematopoetic, Reproductive
2182	HLWBZ56	Immune/Hematopoetic, Reproductive
2183	HLWBZ73	Cancer
2184	HLWCP78	Cancer
2185	HLWCU38	Cancer
2186	HLWEA51	Cancer
2187	HLYAA57	Immune/Hematopoetic
2188	HLYAB80	Cancer
2189	HLYAG19	Digestive, Immune/Hematopoetic
2190	HLYAN43	Cancer
2191	HLYBA22	Immune/Hematopoetic
2192	HLYBA69	Cancer
2193	HLYBF22	Immune/Hematopoetic, Mixed Fetal
2194	HLYBI18	Immune/Hematopoetic
2195	HLYBI58	Cancer
2196	HLYBV47	Cancer
2197	HLYBY48	Immune/Hematopoetic
2198	HLYCH68	Cancer
2199	HLYCK27	Immune/Hematopoetic
2200	HLYCQ18	Immune/Hematopoetic
2201	HLYCQ48	Immune/Hematopoetic
2202	HLYCR65	Cancer
2203	HLYCT47	Digestive, Immune/Hematopoetic
2204	HLYDU25	Immune/Hematopoetic
2205	HLYDU43	Cancer
2206	HLYHA71	Cancer
2207	HMACO04	Cancer
2208	HMACS20	Cancer
2209	HMADJ14	Connective/Epithelial, Immune/Hematopoetic,
		Musculoskeletal
2210	HMADW66	Cancer
2211	HMAGA15	Cancer
2212	HMAGK93	Cancer
2213	HMAHY59	Cancer
2214	HMAJL22	Cancer
2215	HMAJR50	Cancer
2216	HMALI42	Immune/Hematopoetic, Reproductive
2217	HMCAL59	Cancer
2218	HMCAR20	Cancer
2219	HMCAV55	Immune/Hematopoetic
2220	HMCDK27	Cancer
2221	HMCDX48	Cancer
2222	HMCEH49	Cancer
2223	HMCHR48	Connective/Epithelial, Immune/Hematopoetic,
		Reproductive
2224	HMCIJ07	Immune/Hematopoetic
2225	HMDAA66	Neural/Sensory
2226	HMDAI51	Neural/Sensory
2227	HMDAK33	Neural/Sensory
2228	HMDAL04	Neural/Sensory
2229	HMDALA9	Neural/Sensory
2230	HMDAP35	Neural/Sensory
2231	HMEAI74	Cancer
2232	HMEAL02	Cardiovascular, Neural/Sensory
2233	HMEEJ79	Cardiovascular, Neural/Sensory, Reproductive
2234	HMEFS61	Cardiovascular
2235	HMEFT85	Cancer
2236	HMEIK34	Cancer
2237	HMEJE05	Cancer
2238	HMEJE13	Cancer
2239	HMEJE31	Cardiovascular
2240	HMEJJ27	Cardiovascular
2241	HMEJL08	Cancer
2242	HMEJL61	Cancer
2243	HMEJQ66	Cardiovascular
2244	HMEJQ68	Cancer
2245	HMEJY78	Cancer
2246	HMEKT48	Cancer
2247	HMEKU83	Cardiovascular, Immune/Hematopoetic,
		Reproductive
2248	HMELA16	Cardiovascular, Immune/Hematopoetic
2249	HMELR03	Cardiovascular, Immune/Hematopoetic, Mixed Fetal
2250	HMHBE18	Cancer
2251	HMHBN86	Cancer
2252	HMIAJ30	Cancer
2253	HMIALA0	Musculoskeletal, Neural/Sensory
2254	HMIAM45	Neural/Sensory
2255	HMIAS24	Immune/Hematopoetic, Neural/Sensory
2256	HMIAV27	Cancer
2257	HMIAV73	Cancer
2258	HMIAW81	Immune/Hematopoetic, Neural/Sensory,
		Reproductive
2259	HMICK94	Cancer
2260	HMICP03	Cancer
2261	HMJAG94	Neural/Sensory
2262	HMJAK50	Neural/Sensory
2263	HMJAK63	Neural/Sensory
2264	HMJAX71	Neural/Sensory
2265	HMKAH10	Neural/Sensory, Reproductive
2266	HMKAH44	Cancer
2267	HMKAI25	Cancer
2268	HMKCH52	Neural/Sensory
2269	HMKCP66	Neural/Sensory
2270	HMKCV28	Neural/Sensory
2271	HMKCW19	Cancer
2272	HMKCY17	Cardiovascular, Digestive, Neural/Sensory
2273	HMKDD07	Immune/Hematopoetic, Neural/Sensory
2274	HMKDS08	Excretory, Neural/Sensory
2275	HMMAD08	Immune/Hematopoetic
2276	HMMAS76	Endocrine, Immune/Hematopoetic
2277	HMMBD35	Cancer
2278	HMMBF71	Immune/Hematopoetic
2279	HMMCJ60	Immune/Hematopoetic, Musculoskeletal
2280	HMQAG66	Immune/Hematopoetic
2281	HMQAJ64	Connective/Epithelial, Immune/Hematopoetic,
		Reproductive
2282	HMQBO88	Cancer
2283	HMQBU44	Cancer
2284	HMQBU45	Cancer
2285	HMQCY03	Immune/Hematopoetic
2286	HMQDW19	Immune/Hematopoetic
2287	HMRAD54	Cancer
2288	HMSAC18	Cancer
2289	HMSAW68	Cancer
2290	HMSBX84	Immune/Hematopoetic
2291	HMSCD68	Cancer
2292	HMSCM88	Immune/Hematopoetic
2293	HMSCT72	Immune/Hematopoetic
2294	HMSCX69	Digestive, Immune/Hematopoetic, Neural/Sensory
2295	HMSEL55	Immune/Hematopoetic
2296	HMSFK67	Cancer
2297	HMSFP50	Digestive, Immune/Hematopoetic, Musculoskeletal
2298	HMSGK61	Cancer
2299	HMSGP80	Cancer
2300	HMSHM43	Immune/Hematopoetic
2301	HMSHQ24	Cancer
2302	HMSHY73	Cancer
2303	HMSII78	Cancer
2304	HMSIV91	Cancer
2305	HMSJJ74	Cancer
2306	HMSJO79	Cancer
2307	HMSJR08	Immune/Hematopoetic
2308	HMSJW18	Cancer
2309	HMSJX24	Immune/Hematopoetic
2310	HMSKC10	Immune/Hematopoetic
2311	HMSKH19	Cancer
2312	HMSKI86	Cancer
2313	HMSKQ35	Cancer
2314	HMSKS35	Immune/Hematopoetic
2315	HMSLC09	Immune/Hematopoetic
2316	HMSMD07	Cancer
2317	HMSOC30	Cancer
2318	HMSOW51	Cancer
2319	HMTAC69	Cancer
2320	HMTAE85	Cancer
2321	HMTAK05	Cancer
2322	HMTAL77	Cancer
2323	HMTAT59	Cancer
2324	HMTAX46	Cancer
2325	HMTBE31	Cancer
2326	HMUAI20	Cancer
2327	HMUAO21	Cancer
2328	HMUAW28	Musculoskeletal
2329	HMUBU59	Cancer
2330	HMVAM60	Cancer
2331	HMVAV54	Immune/Hematopoetic, Musculoskeletal
2332	HMVAX72	Cancer
2333	HMVBP38	Cancer
2334	HMVBR22	Cancer
2335	HMVBS69	Cardiovascular, Immune/Hematopoetic
2336	HMVCQ82	Immune/Hematopoetic
2337	HMVDF54	Cancer
2338	HMVDG26	Cancer
2339	HMVDL30	Cancer
2340	HMVDP35	Immune/Hematopoetic, Reproductive
2341	HMWAJ53	Immune/Hematopoetic
2342	HMWBC11	Immune/Hematopoetic
2343	HMWCF89	Cancer
2344	HMWDC93	Immune/Hematopoetic
2345	HMWDZ81	Immune/Hematopoetic
2346	HMWEC56	Cancer
2347	HMWEC64	Immune/Hematopoetic
2348	HMWEJ52	Cancer
2349	HMWEY26	Cancer
2350	HMWFG79	Immune/Hematopoetic
2351	HMWFT53	Immune/Hematopoetic
2352	HMWGQ73	Cancer
2353	HMWGU74	Immune/Hematopoetic
2354	HMWGY01	Immune/Hematopoetic
2355	HMWHC36	Cancer
2356	HMWHH16	Immune/Hematopoetic
2357	HMWHS73	Immune/Hematopoetic
2358	HMWHX28	Immune/Hematopoetic
2359	HMWIC78	Cancer
2360	HMWID22	Immune/Hematopoetic, Neural/Sensory
2361	HMWIG83	Cancer
2362	HMWIO93	Cancer
2363	HMZAD77	Cancer
2364	HMZME33	Digestive
2365	HMZMF54	Digestive
2366	HNAAF65	Cancer
2367	HNALC70	Cancer
2368	HNALE36	Digestive, Reproductive
2369	HNBAF49	Cancer
2370	HNBUC50	Cancer
2371	HNDAH54	Cancer
2372	HNEBN76	Immune/Hematopoetic, Reproductive, Respiratory
2373	HNEBY54	Cancer
2374	HNECF34	Immune/Hematopoetic
2375	HNECL25	Immune/Hematopoetic
2376	HNECU95	Connective/Epithelial, Immune/Hematopoetic
2377	HNEDD37	Cancer
2378	HNEDF25	Cancer
2379	HNEDJ35	Immune/Hematopoetic, Reproductive
2380	HNFAE54	Cancer
2381	HNFAH08	Cancer
2382	HNFCK41	Cancer
2383	HNFCV70	Cancer
2384	HNFDS53	Digestive, Immune/Hematopoetic, Neural/Sensory
2385	HNFED65	Excretory, Immune/Hematopoetic
2386	HNFEG11	Immune/Hematopoetic
2387	HNFEG93	Cancer
2388	HNFET17	Cancer
2389	HNFEY18	Cancer
2390	HNFFC27	Immune/Hematopoetic
2391	HNFFC39	Immune/Hematopoetic, Reproductive
2392	HNFFD47	Immune/Hematopoetic
2393	HNFFI46	Cancer
2394	HNFFY60	Cancer
2395	HNFFZ56	Cancer
2396	HNFGF45	Cancer
2397	HNFGZ45	Cardiovascular, Digestive, Immune/Hematopoetic
2398	HNFHD08	Cancer
2399	HNFHS38	Immune/Hematopoetic, Mixed Fetal
2400	HNFHY30	Immune/Hematopoetic
2401	HNFHY51	Immune/Hematopoetic, Reproductive
2402	HNFID82	Immune/Hematopoetic
2403	HNFIG36	Immune/Hematopoetic
2404	HNFIR81	Cancer
2405	HNFIS82	Digestive, Immune/Hematopoetic, Reproductive
2406	HNFIU96	Immune/Hematopoetic
2407	HNFIZ34	Cancer
2408	HNFJD91	Cardiovascular, Connective/Epithelial,
		Immune/Hematopoetic
2409	HNPJE06	Immune/Hematopoetic, Musculoskeletal
2410	HNGAC63	Immune/Hematopoetic
2411	HNGAK13	Digestive, Immune/Hematopoetic
2412	HNGAL31	Immune/Hematopoetic
2413	HNGAM20	Immune/Hematopoetic
2414	HNGAN75	Immune/Hematopoetic
2415	HNGAO10	Immune/Hematopoetic
2416	HNGAU09	Immune/Hematopoetic
2417	HNGAV42	Immune/Hematopoetic
2418	HNGAV54	Immune/Hematopoetic
2419	HNGAX58	Immune/Hematopoetic
2420	HNGAZ20	Immune/Hematopoetic
2421	HNGAZ68	Cardiovascular, Digestive, Immune/Hematopoetic
2422	HNGBB17	Excretory, Immune/Hematopoetic, Reproductive
2423	HNGBE45	Immune/Hematopoetic, Reproductive
2424	HNGBJ27	Immune/Hematopoetic
2425	HNGBO16	Immune/Hematopoetic
2426	HNGBQ56	Cancer
2427	HNGBQ90	Cancer
2428	HNGBU28	Immune/Hematopoetic
2429	HNGBV36	Cancer
2430	HNGBV72	Cancer
2431	HNGBX63	Immune/Hematopoetic
2432	HNGCF72	Immune/Hematopoetic
2433	HNGCL23	Immune/Hematopoetic
2434	HNGDD48	Immune/Hematopoetic
2435	HNGDE27	Immune/Hematopoetic
2436	HNGDP26	Immune/Hematopoetic
2437	HNGDQ28	Immune/Hematopoetic
2438	HNGDQ52	Immune/Hematopoetic
2439	HNGDS13	Immune/Hematopoetic
2440	HNGDS53	Immune/Hematopoetic
2441	HNGDU92	Immune/Hematopoetic
2442	HNGED06	Immune/Hematopoetic
2443	HNGEI34	Immune/Hematopoetic
2444	HNGEJ53	Immune/Hematopoetic
2445	HNGEM24	Immune/Hematopoetic
2446	HNGEM62	Immune/Hematopoetic
2447	HNGEN81	Immune/Hematopoetic
2448	HNGEQ48	Immune/Hematopoetic
2449	HNGEU17	Immune/Hematopoetic
2450	HNGEU90	Immune/Hematopoetic
2451	HNGEV29	Digestive, Immune/Hematopoetic
2452	HNGEW13	Immune/Hematopoetic
2453	HNGEW65	Endocrine, Immune/Hematopoetic
2454	HNGEY29	Cancer
2455	HNGEY51	Immune/Hematopoetic
2456	HNGEZ47	Immune/Hematopoetic
2457	HNGFB76	Digestive, Immune/Hematopoetic, Neural/Sensory
2458	HNGFE55	Immune/Hematopoetic
2459	HNGFI02	Immune/Hematopoetic
2460	HNGFJ67	Immune/Hematopoetic
2461	HNGFQ33	Immune/Hematopoetic
2462	HNGFR75	Immune/Hematopoetic
2463	HNGFT78	Immune/Hematopoetic
2464	HNGFU38	Immune/Hematopoetic
2465	HNGFW58	Cancer
2466	HNGGB09	Immune/Hematopoetic
2467	HNGGF85	Immune/Hematopoetic
2468	HNGGK54	Cancer
2469	HNGGR26	Immune/Hematopoetic
2470	HNGHJ73	Immune/Hematopoetic
2471	HNGHM75	Immune/Hematopoetic
2472	HNGHQ09	Immune/Hematopoetic
2473	HNGHT03	Immune/Hematopoetic
2474	HNGIC13	Immune/Hematopoetic
2475	HNGIC24	Immune/Hematopoetic
2476	HNGIC80	Immune/Hematopoetic
2477	HNGIK21	Immune/Hematopoetic
2478	HNGIK36	Immune/Hematopoetic
2479	HNGIN16	Digestive, Immune/Hematopoetic, Reproductive
2480	HNGIN60	Immune/Hematopoetic, Neural/Sensory
2481	HNGIN84	Digestive, Endocrine, Immune/Hematopoetic
2482	HNGIO50	Immune/Hematopoetic
2483	HNGIQ57	Immune/Hematopoetic
2484	HNGIR58	Immune/Hematopoetic
2485	HNGIT16	Immune/Hematopoetic
2486	HNGIX55	Immune/Hematopoetic
2487	HNGIZ06	Immune/Hematopoetic
2488	HNGJA38	Immune/Hematopoetic
2489	HNGJB81	Immune/Hematopoetic
2490	HNGJF62	Immune/Hematopoetic
2491	HNGJF70	Immune/Hematopoetic
2492	HNGJF92	Immune/Hematopoetic
2493	HNGJG84	Immune/Hematopoetic
2494	HNGJH08	Immune/Hematopoetic
2495	HNGJH63	Immune/Hematopoetic
2496	HNGJH85	Immune/Hematopoetic
2497	HNGJJ65	Immune/Hematopoetic
2498	HNGJL11	Immune/Hematopoetic, Musculoskeletal
2499	HNGJM08	Cancer
2500	HNGJM27	Immune/Hematopoetic
2501	HNGJP90	Immune/Hematopoetic
2502	HNGJR78	Immune/Hematopoetic
2503	HNGJU42	Immune/Hematopoetic
2504	HNGJU84	Immune/Hematopoetic
2505	HNGKN89	Immune/Hematopoetic
2506	HNGLH60	Immune/Hematopoetic, Musculoskeletal
2507	HNGLM62	Cancer
2508	HNGMJ91	Immune/Hematopoetic
2509	HNGNB69	Immune/Hematopoetic
2510	HNGNI25	Immune/Hematopoetic
2511	HNGNN78	Cancer
2512	HNGNS74	Cancer
2513	HNGNW50	Immune/Hematopoetic, Mixed Fetal, Reproductive
2514	HNGOD80	Cancer
2515	HNGOQ44	Immune/Hematopoetic
2516	HNGOU82	Immune/Hematopoetic, Reproductive
2517	HNGPM78	Immune/Hematopoetic, Neural/Sensory
2518	HNHAB62	Immune/Hematopoetic
2519	HNHAD65	Immune/Hematopoetic
2520	HNHAF39	Immune/Hematopoetic
2521	HNHAL34	Cancer
2522	HNHAZ16	Immune/Hematopoetic
2523	HNHBEA9	Immune/Hematopoetic
2524	HNHBI47	Immune/Hematopoetic
2525	HNHBI75	Immune/Hematopoetic
2526	HNHBL26	Immune/Hematopoetic
2527	HNHBM26	Immune/Hematopoetic, Reproductive
2528	HNHBM80	Immune/Hematopoetic, Reproductive
2529	HNHCM59	Cancer
2530	HNHCR46	Cardiovascular, Immune/Hematopoetic
2531	HNHDA78	Immune/Hematopoetic
2532	HNHDL85	Immune/Hematopoetic
2533	HNHDL95	Immune/Hematopoetic
2534	HNHDR03	Immune/Hematopoetic
2535	HNHDR64	Immune/Hematopoetic
2536	HNHDU48	Immune/Hematopoetic
2537	HNHDX07	Immune/Hematopoetic
2538	HNHDY21	Immune/Hematopoetic
2539	HNHEA64	Immune/Hematopoetic
2540	HNHEC59	Immune/Hematopoetic
2541	HNHEC63	Immune/Hematopoetic
2542	HNHED86	Immune/Hematopoetic
2543	HNHEE88	Immune/Hematopoetic
2544	HNHEI47	Immune/Hematopoetic
2545	HNHEI54	Immune/Hematopoetic, Reproductive
2546	HNHEI85	Digestive, Immune/Hematopoetic, Musculoskeletal
2547	HNHEJ88	Immune/Hematopoetic, Neural/Sensory
2548	HNHEK61	Immune/Hematopoetic
2549	HNHEK85	Immune/Hematopoetic, Mixed Fetal
2550	HNHEL19	Immune/Hematopoetic, Reproductive
2551	HNHEN68	Immune/Hematopoetic
2552	HNHEO73	Immune/Hematopoetic
2553	HNHEP59	Immune/Hematopoetic
2554	HNHER77	Immune/Hematopoetic
2555	HNHES40	Immune/Hematopoetic
2556	HNHET53	Immune/Hematopoetic
2557	HNHEU34	Immune/Hematopoetic
2558	HNHEV43	Cancer
2559	HNHEX30	Immune/Hematopoetic
2560	HHHEZ51	Immune/Hematopoetic
2561	HNNFB16	Immune/Hematopoetic
2562	HNHFB60	Immune/Hematopoetic
2563	HNHFG05	Immune/Hematopoetic
2564	HNHFH41	Immune/Hematopoetic
2565	HNHFI33	Immune/Hematopoetic
2566	HNHFI81	Immune/Hematopoetic
2567	HNHFJ25	Immune/Hematopoetic
2568	HNHFL04	Immune/Hematopoetic
2569	HNHFL46	Immune/Hematopoetic
2570	HNHFL57	Immune/Hematopoetic
2571	HNHFP80	Immune/Hematopoetic
2572	HNHFQ63	Immune/Hematopoetic
2573	HNHFS63	Digestive, Immune/Hematopoetic
2574	HNHFU59	Immune/Hematopoetic
2575	HNHFW22	Immune/Hematopoetic
2576	HNHGB09	Immune/Hematopoetic
2577	HNHGC56	Immune/Hematopoetic
2578	HNHGC82	Immune/Hematopoetic
2579	HNHGD15	Immune/Hematopoetic
2580	HNHGE28	Cancer
2581	HNHGE75	Immune/Hematopoetic
2582	HNHGN74	Immune/Hematopoetic
2583	HNHGN91	Digestive, Endocrine, Immune/Hematopoetic
2584	HNHGO09	Immune/Hematopoetic
2585	HNHHA15	Immune/Hematopoetic
2586	HNHHD42	Immune/Hematopoetic
2587	HNHIC21	Immune/Hematopoetic
2588	HNHKJ57	Immune/Hematopoetic
2589	HNHKL90	Immune/Hematopoetic
2590	HNHKS18	Immune/Hematopoetic
2591	HNHKY10	Immune/Hematopoetic
2592	HNHLA36	Immune/Hematopoetic, Reproductive
2593	HNHLB93	Immune/Hematopoetic
2594	HNHLD23	Immune/Hematopoetic
2595	HNHLY33	Immune/Hematopoetic
2596	HNHMV54	Immune/Hematopoetic
2597	HNHNE04	Immune/Hematopoetic
2598	HNHNT13	Immune/Hematopoetic, Neural/Sensory
2599	HNHNW84	Immune/Hematopoetic
2600	HNHOD23	Cancer
2601	HNHOJ75	Immune/Hematopoetic
2602	HNHOL24	Immune/Hematopoetic
2603	HNHON23	Digestive, Endocrine, Immune/Hematopoetic
2604	HNHPD10	Immune/Hematopoetic
2605	HNHPG05	Immune/Hematopoetic
2606	HNKAA41	Cancer
2607	HNKCO80	Cancer
2608	HNKELA7	Cardiovascular, Connective/Epithelial, Digestive
2609	HNNBM45	Immune/Hematopoetic, Reproductive
2610	HNSAA27	Digestive
2611	HNSAD53	Digestive
2612	HNTAC64	Cancer
2613	HNTAC73	Cancer
2614	HNTAI35	Cancer
2615	HNTAS52	Cancer
2616	HNTBI57	Cancer
2617	HNTBN41	Immune/Hematopoetic
2618	HNTBP17	Cancer
2619	HNTCH90	Cancer
2620	HNTDE84	Cancer
2621	HNTDL21	Cancer
2622	HNTDX22	Cancer
2623	HNTEF28	Cancer
2624	HNTEF53	Cancer
2625	HNTEO78	Digestive, Immune/Hematopoetic
2626	HNTEO95	Immune/Hematopoetic
2627	HNTMX29	Cancer
2628	HNTMZ90	Digestive, Reproductive
2629	HNTNB49	Cancer
2630	HNTNK95	Cancer
2631	HNTOE45	Cancer
2632	HNTPB82	Connective/Epithelial, Immune/Hematopoetic,
		Reproductive
2633	HNTRS57	Cancer
2634	RNTRW30	Digestive, Immune/Hematopoetic, Mixed Fetal
2635	HNTSJ84	Cancer
2636	HNTSL47	Cardiovascular, Digestive
2637	HNTSM04	Cancer
2638	HNTSN12	Cancer
2639	HNTSS75	Cancer
2640	HNTSW57	Cancer
2641	HOAAE80	Cancer
2642	HOAAF80	Cancer
2643	HOABG65	Musculoskeletal
2644	HOABL56	Cancer
2645	HOABP21	Cancer
2646	HOABR60	Cancer
2647	HOACG37	Digestive, Musculoskeletal
2648	HOBAF11	Cancer
2649	HOCNE30	Digestive, Musculoskeletal, Neural/Sensory
2650	HOCOO19	Cancer
2651	HOCPM23	Reproductive
2652	HODAA12	Immune/Hematopoetic, Neural/Sensory,
		Reproductive
2653	HODAE92	Cancer
2654	HODAH46	Cancer
2655	HODAH74	Connective/Epithelial, Reproductive, Respiratory
2656	HODAV86	Cancer
2657	HODAZ26	Cancer
2658	HODAZ55	Reproductive
2659	HODBF19	Cancer
2660	HODCJ90	Cancer
2661	HODCL36	Cancer
2662	HODCL50	Reproductive
2663	HODCU34	Cancer
2664	HODCV74	Cancer
2665	HODCZ09	Reproductive
2666	HODCZ16	Cancer
2667	HODDB05	Digestive, Neural/Sensory, Reproductive
2668	HODDD43	Cancer
2669	HODDF08	Reproductive
2670	HODDN60	Cancer
2671	HODEA51	Digestive, Immune/Hematopoetic, Reproductive
2672	HODEB50	Reproductive
2673	HODEE95	Digestive, Reproductive
2674	HODEI83	Reproductive
2675	HODFG71	Reproductive
2676	HODFW41	Reproductive
2677	HODGL52	Cancer
2678	HODHE60	Reproductive
2679	HODHK19	Reproductive
2680	HOEBI94	Cancer
2681	HOECN31	Cancer
2682	HOECO90	Cancer
2683	HOECU83	Cancer
2684	HOEEK12	Cancer
2685	HOEEU24	Cancer
2686	HOEFO68	Cancer
2687	HOEFV61	Cancer
2688	HOEJH89	Cancer
2689	HOFAF39	Reproductive
2690	HOFMA42	Reproductive
2691	HOFMM69	Reproductive
2692	HOFMU07	Reproductive
2693	HOFNM53	Reproductive
2694	HOFNT24	Reproductive
2695	HOFNY71	Reproductive
2696	HOFNZ45	Cancer
2697	HOFOA59	Reproductive
2698	HOFOB27	Cancer
2699	HOGAG15	Cancer
2700	HOGAR52	Cancer
2701	HOGCE48	Cancer
2702	HOGDP46	Cancer
2703	HOHBL42	Cancer
2704	HOHBP82	Musculoskeletal
2705	HOHBV89	Musculoskeletal, Reproductive
2706	HOHBY69	Cancer
2707	HOHCA35	Cancer
2708	HOHCG16	Digestive, Musculoskelelal
2709	HOHCJ90	Cancer
2710	HOHDC86	Musculoskeletal
2711	HOHDF66	Cancer
2712	HONAH29	Cancer
2713	HORBI81	Cancer
2714	HOSBI96	Cancer
2715	HOSBZ55	Cancer
2716	HOSCI83	Cancer
2717	HOSCY73	Cancer
2718	HOSCZ41	Cancer
2719	HOSDG32	Cancer
2720	HOSDI92	Cancer
2721	HOSDK95	Musculoskeletal
2722	HOSDW58	Cancer
2723	HOSEI45	Cancer
2724	HOSEK86	Cancer
2725	HOSFC36	Cancer
2726	HOSFF78	Cancer
2727	HOSFG70	Cancer
2728	HOSFM22	Cancer
2729	HOSFQ28	Cancer
2730	HOSFQ65	Cancer
2731	HOSFT61	Cancer
2732	HOSNU69	Cancer
2733	HOUAR65	Connective/Epithelial
2734	HOUBE18	Cancer
2735	HOUCT90	Connective/Epithelial
2736	HOUCW42	Connective/Epithelial
2737	HOUCZ78	Connective/Epithelial, Immune/Hematopoetic,
		Reproductive
2738	HOUDJ81	Cancer
2739	HOUDL69	Cancer
2740	HOUDU29	Cancer
2741	HOUFU35	Connective/Epithelial
2742	HOUHD63	Cancer
2743	HOUHH51	Cancer
2744	HOUHT39	Cancer
2745	HOVAF78	Cancer
2746	HOVAI58	Reproductive
2747	HOVAP06	Reproductive
2748	HOVAZ13	Cancer
2749	HOVBX78	Cancer
2750	HOVCB25	Reproductive
2751	HOVJP29	Reproductive
2752	HPAMY60	Excretory
2753	HPASD51	Digestive, Excretory, Reproductive
2754	HPBCC51	Cancer
2755	HPBCJ74	Cancer
2756	HPBDD36	Cancer
2757	HPBDH41	Immune/Hematopoetic, Musculoskeletal
2758	HPBEN24	Cancer
2759	HPBEQ12	Cancer
2760	HPCAL49	Immune/Hematopoetic, Neural/Sensory,
		Reproductive
2761	HPCAM01	Cancer
2762	HPCAO10	Cancer
2763	HPEAA33	Reproductive
2764	HPEAB57	Reproductive
2765	HPEAD48	Reproductive
2766	HPEAE34	Reproductive
2767	HPEBD85	Digestive, Reproductive
2768	HPEBE79	Reproductive
2769	HPEBT80	Immune/Hematopoetic, Reproductive
2770	HPEBT96	Cancer
2771	HPFCE63	Digestive, Musculoskeletal, Reproductive
2772	HPFCM07	Cancer
2773	HPFCR13	Cancer
2774	HPFCR15	Digestive, Mixed Fetal, Reproductive
2775	HPFCX38	Cancer
2776	HPFCX44	Cancer
2777	HPFCY51	Reproductive
2778	HPFDU90	Cancer
2779	HPHAC88	Cancer
2780	HPIAT78	Cancer
2781	HPIBO48	Cancer
2782	HPIBT55	Cancer
2783	HPIBX03	Cancer
2784	HPICC86	Reproductive
2785	HPJAP43	Cancer
2786	HPJBK03	Cancer
2787	HPJBK11	Cancer
2788	HPJBZ76	Cancer
2789	HPJCC05	Reproductive
2790	HPJCG42	Immune/Hematopoetic, Reproductive
2791	HPJCK10	Cancer
2792	HPJCL28	Neural/Sensory, Reproductive
2793	HPJCP79	Cancer
2794	HPJCT08	Connective/Epithelial, Reproductive
2795	HPJDA23	Mixed Fetal, Neural/Sensory, Reproductive
2796	HPJDM47	Reproductive
2797	HPJEC20	Connective/Epithelial, Reproductive
2798	HPJEE14	Reproductive
2799	HPJEG57	Reproductive
2800	HPJEV11	Immune/Hematopoetic, Neural/Sensory,
		Reproductive
2801	HPJEZ38	Cancer
2802	HPLAT69	Cancer
2803	HPMAG94	Cancer
2804	HPMBQ32	Neural/Sensory, Reproductive
2805	HPMBQ91	Reproductive
2806	HPMBR15	Cancer
2807	HPMBU33	Immune/Hematopoetic, Musculoskeletal,
		Reproductive
2808	HPMBY46	Cancer
2809	HPMBZ15	Cancer
2810	HPMCC16	Cancer
2811	HPMCJ92	Musculoskeletal, Reproductive
2812	HPMCU14	Cancer
2813	HPMCV08	Cancer
2814	HPMCV18	Musculoskeletal, Reproductive
2815	HPMEI44	Cancer
2816	HPMEI86	Cancer
2817	HPMFI71	Cancer
2818	HPMFS15	Reproductive
2819	HPMFY57	Immune/Hematopoetic, Reproductive
2820	HPMFY74	Reproductive
2821	HPMGD01	Cancer
2822	HPMGP24	Reproductive
2823	HPMGQ55	Digestive, Immune/Hematopoetic, Reproductive
2824	HPMGQ80	Cancer
2825	HPMGR66	Cancer
2826	HPMGT51	Immune/Hematopoetic, Musculoskeletal,
		Reproductive
2827	HPMKI40	Immune/Hematopoetic, Reproductive
2828	HPMSM14	Cancer
2829	HPQSH59	Cancer
2830	HPRCA90	Cancer
2831	HPRCE33	Cancer
2832	HPRCS53	Reproductive
2833	HPRCU95	Musculoskeletal, Reproductive
2834	HPRTG55	Cancer
2835	HPTBB03	Cancer
2836	HPTRC15	Cancer
2837	HPTRF90	Cancer
2838	HPTRH45	Digestive, Endocrine, Reproductive
2839	HPTRH57	Cancer
2840	HPTRO86	Cancer
2841	HPTTI70	Cancer
2842	HPTVX32	Cancer
2843	HPTWA66	Cancer
2844	HPTWC08	Cancer
2845	HPWAG46	Reproductive
2846	HPWAL61	Musculoskeletal, Reproductive
2847	HPWAN23	Cancer
2848	HPWAS91	Reproductive
2849	HPWCM76	Reproductive
2850	HRAAJ19	Cancer
2851	HRAAL86	Excretory
2852	HRAAM50	Excretory, Immune/Hematopoetic, Mixed Fetal
2853	HRAAN56	Excretory
2854	HRABS65	Cancer
2855	HRABV43	Cancer
2856	HRABX31	Excretory, Immune/Hematopoetic, Musculoskeletal
2857	HRACG45	Cancer
2858	HRACI26	Digestive, Excretory
2859	HRACM44	Excretory, Immune/Hematopoetic
2860	HRADO01	Excretory
2861	HRAEE45	Connective/Epithelial, Excretory,
		Immune/Hematopoetic
2862	HRAEH37	Cancer
2863	HRDAD66	Cancer
2864	HRDBT68	Cancer
2865	HRDDR94	Cancer
2866	HRDDS01	Musculoskeletal
2867	HRDEC77	Cancer
2868	HRDED19	Musculoskeletal
2869	HRDEL61	Musculoskeletal
2870	HRDEN56	Musculoskeletal
2871	HRDEP41	Cancer
2872	HRDES01	Musculoskeletal
2873	HRDEU27	Musculoskeletal
2874	HRDFB85	Cancer
2875	HRGBR18	Cancer
2876	HRGBR28	Cancer
2877	HRGCZ46	Cancer
2878	HRGDC48	Immune/Hematopoetic, Musculoskeletal
2879	HRKAB52	Cancer
2880	HRKPA09	Cancer
2881	HRLMB56	Cancer
2882	HRLMD77	Cancer
2883	HRLMF92	Cancer
2884	HROAE16	Cancer
2885	HROAE78	Digestive
2886	HROAH06	Digestive, Immune/Hematopoetic
2887	HROAN56	Digestive
2888	HROAS46	Digestive
2889	HROBM46	Connective/Epithelial, Digestive
2890	HRODZ89	Digestive, Immune/Hematopoetic
2891	HRSMC69	Cancer
2892	HRSMF51	Cancer
2893	HRSMG27	Cancer
2894	HRSMQ86	Cancer
2895	HSAAO30	Cancer
2896	HSAAO65	Cancer
2897	HSAAO65	Cancer
2898	HSAAO94	Cancer
2899	HSABI42	Immune/Hematopoetic
2900	HSATA21	Immune/Hematopoetic
2901	HSAUA82	Immune/Hematopoetic, Reproductive
2902	HSAUC38	Immune/Hematopoetic
2903	HSAUF22	Immune/Hematopoetic
2904	HSAUF49	Immune/Hematopoetic
2905	HSAUL66	Immune/Hematopoetic, Musculoskeletal
2906	HSAUM95	Digestive, Immune/Hematopoetic, Reproductive
2907	HSAUR67	Immune/Hematopoetic
2908	HSAUW44	Immune/Hematopoetic
2909	HSAVJ61	Immune/Hematopoetic
2910	HSAVP17	Immune/Hematopoetic
2911	HSAVU34	Cancer
2912	HSAWA27	Immune/Hematopoetic
2913	HSAWG42	Immune/Hematopoetic
2914	HSAWV96	Immune/Hematopoetic, Neural/Sensory
2915	HSAXB32	Immune/Hematopoetic
2916	HSAXB81	Immune/Hematopoetic
2917	HSAXF60	Immune/Hematopoetic
2918	HSAXI90	Immune/Hematopoetic
2919	HSAXI95	Immune/Hematopoetic
2920	HSAXJ29	Immune/Hematopoetic
2921	HSAXJ60	Immune/Hematopoetic
2922	HSAXM32	Cancer
2923	HSAXN46	Immune/Hematopoetic
2924	HSAXS66	Immune/Hematopoetic
2925	HSAYC21	Immune/Hematopoetic
2926	HSAYL90	Cardiovascular, Immune/Hematopoetic
2927	HSAYR13	Immune/Hematopoetic
2928	HSAYS89	Immune/Hematopoetic
2929	HSAZG33	Immune/Hematopoetic
2930	HSBBT12	Cancer
2931	HSBBT37	Cancer
2932	HSDAG05	Cancer
2933	HSDAJ53	Cancer
2934	HSDBC88	Cancer
2935	HSDDC95	Neural/Sensory
2936	HSDEG01	Cancer
2937	HSDES04	Cancer
2938	HSDEW29	Neural/Sensory
2939	HSDFA44	Neural/Sensory
2940	HSDFW45	Neural/Sensory
2941	HSDFW61	Cancer
2942	HSDGN55	Cancer
2943	HSDGP60	Immune/Hematopoetic, Musculoskeletal,
		Neural/Sensory
2944	HSDGR57	Cancer
2945	HSDGW43	Neural/Sensory
2946	HSDHC81	Neural/Sensory
2947	HSDIE16	Neural/Sensory
2948	HSDIL30	Neural/Sensory
2949	HSDIT06	Neural/Sensory, Reproductive
2950	HSDIV86	Cancer
2951	HSDJB13	Cancer
2952	HSDJE10	Cancer
2953	HSDJL42	Cancer
2954	HSDJM30	Digestive, Neural/Sensory
2955	HSDJR23	Digestive, Neural/Sensory
2956	HSDMA90	Digestive, Endocrine, Neural/Sensory
2957	HSDZM95	Cancer
2958	HSDZR95	Neural/Sensory
2959	HSFAG37	Cancer
2960	HSFAH43	Cancer
2961	HSFAL43	Cancer
2962	HSFAM39	Reproductive
2963	HSFAM73	Immune/Hematopoetic, Reproductive
2964	HSFAN12	Cardiovascular
2965	HSHAV28	Cancer
2966	HSHBQ68	Cancer
2967	HSIAC45	Digestive, Immune/Hematopoetic
2968	HSIAC80	Cancer
2969	HSICO66	Cancer
2970	HSICQ15	Cancer
2971	HSICV24	Digestive
2972	HSIDD28	Cancer
2973	HSIDD62	Cancer
2974	HSIDI15	Digestive, Immune/Hematopoetic
2975	HSIDQ18	Cancer
2976	HSIDQ93	Cancer
2977	HSIDR70	Digestive
2978	HSIDU19	Digestive, Mixed Fetal
2979	HSIDU42	Cancer
2980	HSIDY06	Cancer
2981	HSIEA14	Digestive
2982	HSIEF95	Cancer
2983	HSIFL06	Cancer
2984	HSIFO61	Cancer
2985	HSIFV30	Cancer
2986	HSIGD79	Cancer
2987	HSIGM62	Cancer
2988	HSJAQ17	Cancer
2989	HSJBB37	Cancer
2990	HSKBO20	Cancer
2991	HSKCP69	Cancer
2992	HSKCT36	Cancer
2993	HSKDD72	Cardiovascular, Digestive, Musculoskeletal
2994	HSKDI81	Cancer
2995	HSKDV92	Cancer
2996	HSKDW91	Musculoskeletal
2997	HSKEI54	Cancer
2998	HSKGO49	Cancer
2999	HSKGQ58	Cancer
3000	HSKHL65	Cancer
3001	HSKNB54	Cancer
3002	HSKND71	Cancer
3003	HSKNK73	Cancer
3004	HSKNM85	Digestive, Musculoskeletal
3005	HSKNT34	Cancer
3006	HSKXE22	Cancer
3007	HSKXJ37	Cancer
3008	HSKYU29	Cancer
3009	HSKZE52	Cancer
3010	HSLBF69	Musculoskeletal
3011	HSLCA15	Cancer
3012	HSLCK11	Cancer
3013	HSLCP57	Cancer
3014	HSLCS05	Cancer
3015	HSLCT04	Mixed Fetal, Musculoskeletal
3016	HSLCU73	Musculoskeletal
3017	HSLCX03	Cancer
3018	HSLDJ89	Cancer
3019	HSLDS06	Musculoskeletal
3020	HSLDS32	Musculoskeletal
3021	HSLEF58	Cardiovascular, Digestive, Musculoskeletal
3022	HSLFD55	Musculoskeletal
3023	HSLFM29	Cancer
3024	HSLFU05	Cancer
3025	HSLGM21	Cancer
3026	HSLGM81	Cancer
3027	HSLGU75	Cancer
3028	HSLHI86	Cancer
3029	HSLHS22	Cancer
3030	HSLIA81	Cancer
3031	HSLJW78	Musculoskeletal
3032	HSMBE69	Cancer
3033	HSNAA55	Cancer
3034	HSNAQ47	Cancer
3035	HSNAU78	Digestive, Neural/Sensory
3036	HSNAY92	Cancer
3037	HSNBG78	Connective/Epithelial, Digestive,
		Immune/Hematopoetic
3038	HSNBM49	Cancer
3039	HSNBN57	Cancer
3040	HSOAC84	Digestive
3041	HSOAH66	Cancer
3042	HSOAJ55	Cancer
3043	HSOAM40	Digestive
3044	HSOBK48	Digestive
3045	HSOBV29	Cancer
3046	HSODB85	Cancer
3047	HSPAA60	Digestive
3048	HSPAH56	Cancer
3049	HSPBY40	Cancer
3050	HSPBY63	Digestive
3051	HSPMG77	Digestive
3052	HSQAB87	Cancer
3053	HSQAC69	Cancer
3054	HSQBE28	Cancer
3055	HSQBL21	Cancer
3056	HSQEA85	Cancer
3057	HSQEH50	Cancer
3053	HSQEO84	Cancer
3059	HSQFP46	Cancer
3060	HSQFT30	Cancer
3061	HSRAL66	Cancer
3062	HSRBA90	Cancer
3063	HSRDE35	Cancer
3064	HSRDH01	Cancer
3065	HSRFB56	Cancer
3066	HSRGW16	Cancer
3067	HSSAO72	Musculoskeletal, Neural/Sensory
3068	HSSEN70	Cancer
3069	HSSEO83	Cancer
3070	HSSFZ70	Musculoskeletal
3071	HSSGJ45	Cancer
3072	HSSJF55	Musculoskeletal
3073	HSSJJ51	Cancer
3074	HSSJN64	Musculoskeletal
3075	HSSMS41	Cancer
3076	HSSMW31	Musculoskeletal, Reproductive
3077	HSTAG52	Cancer
3078	HSUMA53	Cancer
3079	HSUME76	Cancer
3080	HSVAA10	Cardiovascular
3081	HSVAC77	Cancer
3082	HSVAF16	Cancer
3083	HSVAG05	Cancer
3084	HSVAK93	Cancer
3085	HSVAM81	Mixed Fetal
3086	HSVAQ28	Cancer
3087	HSVAT02	Cancer
3088	HSVAT68	Excretory, Reproductive
3089	HSVAY16	Cancer
3090	HSVBA12	Cancer
3091	HSVBD22	Cancer
3092	HSVBF78	Cancer
3093	HSVBH58	Cancer
3094	HSVBM90	Cancer
3095	HSVBZ80	Cancer
3096	HSVCB08	Excretory, Neural/Sensory
3097	HSVCB57	Cancer
3098	HSVCF20	Cancer
3099	HSVCH32	Cancer
3100	HSWAM12	Reproductive
3101	HSWAY58	Cancer
3102	HSWBJ74	Reproductive
3103	HSXAG02	Cancer
3104	HSXAH81	Cancer
3105	HSXAM05	Cancer
3106	HSXAR64	Cancer
3107	HSXAS67	Neural/Sensory, Reproductive
3108	HSXAZ05	Neural/Sensory, Respiratory
3109	HSXBM30	Cancer
3110	HSXBO51	Cancer
3111	HSXBP68	Cancer
3112	HSXBU59	Neural/Sensory
3113	HSXBV35	Neural/Sensory
3114	HSXBX80	Cancer
3115	HSXCS62	Cancer
3116	HSXCV85	Neural/Sensory, Reproductive
3117	HSYAB05	Cancer
3118	HSYAG26	Cancer
3119	HSYBK21	Cancer
3120	HSYBL17	Cancer
3121	HSYBX48	Cancer
3122	HSYBZ44	Cancer
3123	HSYDT06	Cancer
3124	HSZAA13	Digestive, Neural/Sensory, Reproductive
3125	HT2SF14	Cancer
3126	HT2SG64	Digestive, Immune/Hematopoetic
3127	HT3BE24	Cancer
3128	HT4AI54	Cancer
3129	HT4ES80	Cancer
3130	HT4FW61	Connective/Epithelial, Immune/Hematopoetic,
		Reproductive
3131	HT5EK75	Cancer
3132	HTAAU21	Cancer
3133	HTABP30	Cancer
3134	HTACS42	Cancer
3135	HTACZ01	Immune/Hematopoetic
3136	HTADC09	Cancer
3137	HTADH39	Cancer
3138	HTADI12	Cancer
3139	HTADO22	Immune/Hematopoetic
3140	HTADV27	Immune/Hematopoetic
3141	HTAEC92	Cancer
3142	HTAGN51	Cancer
3143	HTBAA70	Connective/Epithelial, Immune/Hematopoetic,
		Reproductive
3144	HTBAB28	Immune/Hematopoetic
3145	HTDAA93	Cancer
3146	HTDAD22	Cancer
3147	HTDAG66	Digestive, Immune/Hematopoetic
3148	HTDAI54	Cancer
3149	HTEAE62	Cardiovascular, Reproductive
3150	HTEAJ18	Reproductive
3151	HTEAN76	Cancer
3152	HTEAR66	Cancer
3153	HTEAT31	Cancer
3154	HTEAV28	Reproductive
3155	HTEAX23	Reproductive
3156	HTEBC92	Cancer
3157	HTEBJ71	Cancer
3158	HTEBP77	Immune/Hematopoetic, Reproductive
3159	HTEBY11	Reproductive
3160	HTEBY84	Cancer
3161	HTECE72	Reproductive
3162	HTECE94	Cancer
3163	HTEDF42	Digestive, Reproductive
3164	HTEDJ85	Mixed Fetal, Neural/Sensory, Reproductive
3165	HTEDJ94	Cancer
3166	HTEDS39	Cancer
3167	HTEDX90	Reproductive
3168	HTEFU09	Cancer
3169	HTEFU41	Immune/Hematopoetic, Reproductive
3170	HTEGF16	Cancer
3171	HTEGQ64	Reproductive
3172	HTEGS19	Cancer
3173	HTEGT82	Digestive, Reproductive
3174	HTEHH53	Reproductive
3175	HTEHV08	Cancer
3176	HTEID16	Reproductive
3177	HTEIL66	Reproductive
3178	HTEIM65	Immune/Hematopoetic, Reproductive
3179	HTEIR61	Cancer
3180	HTEIT45	Reproductive
3181	HTEJO12	Digestive, Reproductive
3182	HTEJT39	Neural/Sensory, Reproductive
3183	HTEKE40	Cancer
3184	HTEKM35	Neural/Sensory, Reproductive
3185	HTEKS16	Connective/Epithelial, Mixed Fetal, Reproductive
3186	HTEKU58	Cancer
3187	HTELW37	Reproductive
3188	HTEMD27	Cancer
3189	HTEME02	Cancer
3190	HTEMX36	Cancer
3191	HTENO07	Reproductive
3192	HTEQI22	Cancer
3193	HTFMX90	Cancer
3194	HTFOE85	Immune/Hematopoetic
3195	HTFOS57	Cancer
3196	HTGAM78	Immune/Hematopoetic, Neural/Sensory, Respiratory
3197	HTGAW51	Immune/Hematopoetic
3198	HTGBE48	Immune/Hematopoetic, Reproductive
3199	HTGBV53	Immune/Hematopoetic
3200	HTGCH22	Immune/Hematopoetic, Mixed Fetal, Reproductive
3201	HTGCM55	Cardiovascular, Digestive, Immune/Hematopoetic
3202	HTGCQ82	Cancer
3203	HTGEU09	Immune/Hematopoetic
3204	HTGEW91	Cancer
3205	HTGGO35	Cancer
3206	HTHBH29	Immune/Hematopoetic, Mixed Fetal
3207	HTHBK35	Immune/Hematopoetic
3208	HTHBL86	Immune/Hematopoetic
3209	HTHBX95	Cancer
3210	HTHCA77	Immune/Hematopoetic
3211	HTHCB31	Immune/Hematopoetic, Mixed Fetal,
		Neural/Sensory
3212	HTHCO79	Cancer
3213	HTHCZ41	Cancer
3214	HTHDK34	Digestive, Immune/Hematopoetic
3215	HTJNX29	Cancer
3216	HTLAA40	Reproductive
3217	HTLAB25	Cancer
3218	HTLAB43	Cancer
3219	HTLAF13	Reproductive
3220	HTLAI54	Reproductive
3221	HTLAV68	Reproductive
3222	HTLBC79	Reproductive
3223	HTLBG08	Reproductive
3224	HTLCU49	Cancer
3225	HTLCX30	Rcproductive
3226	HTLDD53	Connective/Epithelial, Digestive, Reproductive
3227	HTLDP69	Cancer
3228	HTLDQ11	Reproductive
3229	HTLDQ56	Reproductive
3230	HTLDR33	Immune/Hematopoetic, Reproductive
3231	HTLDT76	Cardiovascular, Neural/Sensory, Reproductive
3232	HTLDW38	Reproductive
3233	HTLEC34	Immune/Hematopoetic, Neural/Sensory,
		Reproductive
3234	HTLEF73	Cancer
3235	HTLEK16	Cancer
3236	HTLET08	Cancer
3237	HTLEW81	Cancer
3238	HTLEX50	Cancer
3239	HTLFA90	Cancer
3240	HTLFG05	Cancer
3241	HTLFI93	Immune/Hematopoetic, Reproductive, Respiratory
3242	HTLGY87	Cancer
3243	HTLHC59	Digestive, Reproductive
3244	HTLHI35	Immune/Hematopoetic, Musculoskeletal,
		Reproductive
3245	HTLHR26	Immune/Hematopoetic
3246	HTLIO20	Immune/Hematopoetic, Neural/Sensory
3247	HTLIQ05	Reproductive
3248	HTLIT63	Reproductive
3249	HTLJC07	Cancer
3250	HTLJF15	Reproductive
3251	HTNAG39	Cancer
3252	HTNBR95	Cancer
3253	HTOAI70	Immune/Hematopoetic
3254	HTOAM21	Immune/Hematopoetic
3255	HTOAT76	Excretory, Immune/Hematopoetic
3256	HTOBX52	Cancer
3257	HTOBX69	Cancer
3258	HTODG13	Digestive, Immune/Hematopoetic, Reproductive
3259	HTODJ69	Immune/Hematopoetic
3260	HTODL90	Immune/Hematopoetic
3261	HTODL92	Cancer
3262	HTOEU03	Cancer
3263	HTOEY16	Cancer
3264	HTOFC34	Cancer
3265	HTOFD28	Immune/Hematopoetic
3266	HTOFU06	Immune/Hematopoetic, Musculoskeletal
3267	HTOHB55	Cancer
3268	HTOHG09	Cancer
3269	HT0HJ89	Immune/Hematopoetic, Reproductive
3270	HTOHV49	Immune/Hematopoetic
3271	HTOHW95	Cancer
3272	HTOIQ42	Immune/Hematopoetic
3273	HTOIW31	Immune/Hematopoetic, Reproductive
3274	HTOIZ28	Cancer
3275	HTOJP95	Immune/Hematopoetic
3276	HTOJY21	Cancer
3277	HTPAB57	Cancer
3278	HTPBG16	Digestive, Immune/Hematopoetic
3279	HTPBH21	Connective/Epithelial, Digestive, Reproductive
3280	HTPBN68	Digestive
3281	HTPBQ83	Cancer
3282	HTPBY11	Cancer
3283	HTPCN79	Digestive, Neural/Sensory
3284	HTPCS60	Cancer
3285	HTPCW21	Digestive, Neural/Sensory
3286	HTPDS14	Cancer
3287	HTPDX06	Cancer
3288	HTPFX16	Digestive, Reproductive, Respiratory
3289	HTPFX69	Digestive
3290	HTPHS66	Cancer
3291	HTPIY88	Digestive
3292	HTSAC80	Cancer
3293	HTSER67	Cancer
3294	HTSFO71	Cancer
3295	HTSGG36	Cancer
3296	HTSGM54	Cancer
3297	HTSGX80	Cancer
3298	HTSHE40	Cancer
3299	HTTBM40	Cancer
3300	HTTBR96	Immune/Hematopoetic, Reproductive
3301	HTTCN24	Cancer
3302	HTTCT79	Cancer
3303	HTTDF41	Cancer
3304	HTTDP47	Cancer
3305	HTTEA24	Digestive, Reproductive
3306	HTTEU77	Cancer
3307	HTTEU91	Cancer
3308	HTTEV40	Cancer
3309	HTTEX77	Cancer
3310	HTTFG10	Reproductive
3311	HTTIJ31	Reproductive
3312	HTTJK27	Reproductive
3313	HTTKT43	Cancer
3314	HTWAF58	Immune/Hematopoetic
3315	HTWAH05	Cancer
3316	HTWBY29	Cancer
3317	HTWBY48	Immune/Hematopoetic
3318	HTWCE16	Immune/Hematopoetic
3319	HTWCI46	Cancer
3320	HTWDC20	Immune/Hematopoetic
3321	HTWDE26	Cancer
3322	HTWEE31	Immune/Hematopoetic
3323	HTWEL91	Immune/Hematopoetic
3324	HTWEO25	Cancer
3325	HTWEV82	Immune/Hematopoetic
3326	HTWFH07	Immune/Hematopoetic
3327	HTWFK09	Immune/Hematopoetic
3328	HTWJB71	Digestive, Immune/Hematopoetic, Neural/Sensory
3329	HTWKG71	Immune/Hematopoetic
3330	HTXBK30	Cancer
3331	HTXBN56	Cancer
3332	HTXBU52	Cancer
3333	HTXBX04	Cancer
3334	HTXCS21	Cancer
3335	HTXDB52	Immune/Hematopoetic, Musculoskeletal
3336	HTXDE07	Immune/Hematopoetic
3337	HTXDG40	Immune/Hematopoetic
3338	HTXDJ88	Immune/Hematopoetic
3339	HTXDN32	Cancer
3340	HTXDO17	Immune/Hematopoetic, Neural/Sensory, Respiratory
3341	HTXDP60	Cancer
3342	HTXEB42	Cancer
3343	HTXEL29	Immune/Hematopoetic
3344	HTXEY51	Endocrine, Immune/Hematopoetic
3345	HTXFB20	Immune/Hematopoetic
3346	HTXFE73	Cancer
3347	HTXFH55	Cardiovascular, Immune/Hematopoetic
3348	HTXGG31	Cancer
3349	HTXGG45	Immune/Hematopoetic
3350	HTXGI75	Cancer
3351	HTXHB33	Immune/Hematopoetic
3352	HTXJI95	Immune/Hematopoetic, Reproductive
3353	HTXJQ11	Cancer
3354	HTXJW17	Digestive, Immune/Hematopoetic
3355	HTXJX80	Digestive, Immune/Hematopoetic
3356	HTXKB57	Cancer
3357	HTXKF10	Immune/Hematopoetic
3358	HTXKK52	Immune/Hematopoetic
3359	HTXKQ85	Immune/Hematopoetic, Musculoskeletal,
		Reproductive
3360	HTXKV29	Cancer
3361	HTXKY63	Immune/Hematopoetic
3362	HTXLE54	Immune/Hematopoetic
3363	HTXLH48	Connective/Epithelial, Immune/Hematopoetic
3364	HTXLZ79	Cancer
3365	HTXNL31	Cancer
3366	HTXNV67	Cancer
3367	HTXOZ19	Cancer
3368	HTXQM57	Immune/Hematopoetic, Mixed Fetal
3369	HTXRE15	Cancer
3370	HUCNC61	Cancer
3371	HUCNP80	Cancer
3372	HUCPD31	Cancer
3373	HUDAM89	Reproductive
3374	HUFAC36	Cancer
3375	HUFAC49	Digestive
3376	HUFAK67	Digestive, Immune/Hematopoetic, Reproductive
3377	HUFAT34	Cancer
3378	HUFBC44	Digestive, Mixed Fetal, Neural/Sensory
3379	HUFBK08	Digestive, Musculoskeletal
3380	HUFBO40	Digestive, Immune/Hematopoetic, Reproductive
3381	HUFGH53	Cancer
3382	HUJBK19	Cancer
3383	HUJCQ39	Excretory, Immune/Hematopoetic
3384	HUKAA55	Digestive, Immune/Hematopoetic, Reproductive
3385	HUKAM16	Cancer
3386	HUKBH05	Cancer
3387	HUKCD10	Cancer
3388	HUKCO64	Cancer
3389	HUKEX85	Musculoskeletal, Reproductive
3390	HUKFC71	Cancer
3391	HULAG01	Cardiovascular
3392	HUNAB18	Cancer
3393	HUNAE14	Reproductive
3394	HUNAH63	Reproductive
3395	HUSAM59	Cancer
3396	HUSAO56	Cancer
3397	HUSAQ05	Cancer
3398	HUSAQ32	Cancer
3399	HUSFE58	Cancer
3400	HUSFF19	Cancer
3401	HUSGC54	Cardiovascular, Immune/Hematopoetic, Neural/Sensory
3402	HUSGT36	Cardiovascular
3403	HUSGX69	Cancer
3404	HUSHB62	Cancer
3405	HUSHH92	Cancer
3406	HUSIB13	Cancer
3407	HUSIE23	Cancer
3408	HUSIF44	Cancer
3409	HUSIJ08	Cardiovascular, Immune/Hematopoetic
3410	HUSIR91	Cancer
3411	HUSIT18	Cancer
3412	HUSIT49	Cancer
3413	HUSIY89	Cancer
3414	HUSJM25	Cancer
3415	HUSJN32	Cardiovascular
3416	HUSXE77	Cancer
3417	HUSXJ64	Cardiovascular, Reproductive
3418	HUSXU29	Cancer
3419	HUSZS75	Cancer
3420	HUUDF48	Immune/Hematopoetic
3421	HUVDJ43	Cardiovascular, Reproductive
3422	HUVDJ43	Cardiovascular, Reproductive
3423	HUVDP63	Cancer
3424	HUVEO77	Reproductive
3425	HUVFB80	Cancer
3426	HUVFH14	Cancer
3427	HUVFY29	Cancer
3428	HUVHI35	Cancer
3429	HVAAE95	Digestive
3430	HVARW53	Digestive
3431	HVVAM64	Cancer
3432	HWAAP70	Immune/Hematopoetic
3433	HWAAW33	Cancer
3434	HWABC21	Immune/Hematopoetic
3435	HWABE12	Cancer
3436	HWABF47	Cancer
3437	HWABI12	Immune/Hematopoetic
3438	HWABU17	Cancer
3439	HWABW49	Immune/Hematopoetic
3440	HWAFG52	Immune/Hematopoetic, Reproductive, Respiratory
3441	HWAFT87	Cardiovascular, Immune/Hematopoetic
3442	HWAGJ85	Cardiovascular, Immune/Hematopoetic
3443	HWAHE17	Digestive, Immune/Hematopoetic
3444	HWBAD01	Immune/Hematopoetic
3445	HWBAO29	Immune/Hematopoetic, Reproductive
3446	HWBAS39	Cancer
3447	HWBBP10	Immune/Hematopoetic, Neural/Sensory
3448	HWBBT49	Cancer
3449	HWBCH13	Immune/Hematopoetic
3450	HWBCM79	Immune/Hematopoetic
3451	HWBCN75	Cancer
3452	HWBCV72	Cancer
3453	HWBDI30	Cancer
3454	HWBDM37	Digestive, Immune/Hematopoetic, Reproductive
3455	HWBDM62	Endocrine, Immune/Hematopoetic
3456	HWBDM68	Immune/Hematopoetic
3457	HWBDO80	Immune/Hematopoetic, Musculoskeletal,
		Reproductive
3458	HWBDV80	Cancer
3459	HWBEV57	Immune/Hematopoetic
3460	HWBFY57	Digestive, Immune/Hematopoetic
3461	HWDAD17	Cancer
3462	HWDAO37	Cancer
3463	HWDAO40	Cancer
3464	HWEAC77	Connective/Epithelial
3465	HWEAD64	Cancer
3466	HWHGZ26	Cancer
3467	HWHHD11	Cancer
3468	HWHIH10	Cancer
3469	HWHIM26	Connective/Epithelial, Immune/Hematopoetic
3470	HWHJD93	Cancer
3471	HWHKC09	Cancer
3472	HWHKR51	Cancer
3473	HWHPM16	Cancer
3474	HWHRL06	Cancer
3475	HWHSB53	Cancer
3476	HWHSK19	Cancer
3477	HWHSO13	Connective/Epithelial
3478	HWJAE49	Connective/Epithelial, Digestive, Reproductive
3479	HWLBP46	Cancer
3480	HWLEC41	Cancer
3481	HWLED11	Cancer
3482	HWLEQ37	Cancer
3483	HWLEZ82	Cancer
3484	HWLFE89	Digestive, Immune/Hematopoetic
3485	HWLFJ10	Cancer
3486	HWLFQ64	Digestive
3487	HWLFR02	Cancer
3488	HWLGV78	Digestive, Immune/Hematopoetic
3489	HWLHH15	Digestive
3490	HWLHM66	Cancer
3491	HWLHZ28	Cancer
3492	HWLJE21	Cancer
3493	HWLJQ88	Digestive
3494	HWLJX42	Cancer
3495	HWLNF33	Cancer
3496	HWLQU40	Cancer
3497	HWMAF61	Digestive
3498	HWMAH36	Immune/Hematopoetic
3499	HWMGN33	Digestive
3500	HWMKQ25	Cancer
3501	HWMLN52	Digestive, Immune/Hematopoetic
3502	HWTAD49	Cancer
3503	HWTAL40	Cancer
3504	HWTAW41	Cancer
3505	HWTAZ75	Cancer
3506	HWTBF59	Cancer
3507	HWTBL40	Cancer
3508	HWTBM18	Immune/Hematopoetic, Musculoskeletal
3509	HWTBM45	Cancer
3510	HWTCE21	Cancer
3511	HXOAC69	Cancer
3512	HYAAL70	Cancer
3513	HYAAY40	Immune/Hematopoetic
3514	HYAAY86	Immune/Hematopoetic
3515	HYABE50	Cancer
3516	HYACE88	Cancer
3517	HYACI76	Cancer
3518	HYACJ27	Immune/Hematopoetic
3519	HYASC80	Cancer
3520	HYASD09	Cancer
3521	HYBAR26	Musculoskeletal
3522	HYBAY77	Immune/Hematopoetic, Musculoskeletal
3523	HZAAE52	Cancer